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ABSTRACT 
Background: RNA processing dysfunction has been implicated in the pathology of the 
neurodegenerative disease amyotrophic lateral sclerosis (ALS), not only due to causative 
TDP-43 disease mutations (TDP-ALS), but further the characteristic mislocalisation of 
crucial RNA-binding protein TDP-43 regardless of genetic background. This implicates the 
importance of investigating the widespread TDP-43 dysfunction-mediated changes in RNA 
processing, and the need to identify differential gene expression and alternative splicing 
changes that may underlie neurodegenerative disease. 
Methods: Two mouse models of TDP-43 were investigated, each containing a single 
substitution within the coding region of the Tardbp gene: one mutation in the RNA binding 
domain (RBD), the other in the low complexity domain hotspot region for ALS-causative 
mutations. RNA sequencing was used to examine resulting differential gene expression and 
alternative splicing events, and integrated iCLIP analysis highlighted changes in RNA 
binding patterns.   
Results and discussion: We identified severe molecular dysregulation in both models. The 
RBD mutant displayed dose-dependent preferential exon inclusion, including the retention 
of cryptic exons. Alongside this was downregulation of long intron-containing genes, 
typically related to neuronal activity. These features, alongside other RNA processing 
changes, were similar to those resulting from TDP-43 loss, and thus indicated the RBD 
mutation to cause TDP-43 loss of function. Contrastingly, we found that the LCD mutation 
caused greater levels of exon skipping, including novel gain of TDP-43 function in splicing 
which resulted in mutant-specific ‘skiptic’ transcripts. A subset of these was then 
demonstrated to be conserved in a TDP-ALS mouse model, and further in human TDP-ALS 
patient settings. Importantly, this gain of function mouse model developed a 
neurodegenerative, ALS-like phenotype. This indicated that TDP-43 gain of function, even 
in the absence of loss of function effects, is sufficient to cause a neurodegenerative disease 
phenotype.  
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IMPACT STATEMENT 
Amyotrophic lateral sclerosis (ALS) is a severe, rapidly progressive and fatal disease 
that affects thousands of people worldwide. Research into the underlying biology has 
progressed quickly, however the development of resulting therapeutics remains 
inadequate. The protein TDP-43 has been heavily implicated in ALS through both 
causative mutation as well as dysregulated localisation regardless of disease aetiology. 
The aims of this study revolved around the characterisation and analysis of two disease 
models at the transcriptomic, cellular and phenotypic level in the context of ALS. The 
primary focus of this investigation was to understand how the mutations of crucial 
RNA binding protein TDP-43 disrupted RNA processing using high-throughput RNA 
sequencing analysis. Following on from this was the aim of further identifying specific 
molecular signatures which could be linked towards understanding the precise 
mechanism by which TDP-43 mutation and dysfunction could culminate in 
neurodegeneration and ALS. Alongside study of the transcriptome, other features of 
cellular dysfunction were also investigated, particularly those previously described in 
ALS settings. The results of this study have now been published in (Fratta et al. 2018 
and Sivakumar et al. 2018), answering key questions in the field on the relative 
importance of loss of function and gain of function of TDP-43 in disease pathology. 
Several patterns and specific targets of differential gene expression and alternative 
splicing have been identified, and further validated to occur in ALS patient tissues; 
therefore this work also provides a foundation for further investigation and 
development of drug and biomarker targets in ALS.   
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CHAPTER 1  
INTRODUCTION 
1.1 OVERVIEW OF TDP-43 
1.1.1 PROTEIN STRUCTURE 
TDP-43 is a ubiquitously expressed RNA binding protein (RBP) of the heterogeneous 
nuclear ribonucleoprotein (hnRNP) family. It consists of 414 amino acid residues 
(Figure 1.1), and contains an N-terminal nuclear localisation signal (NLS), an RNA 
binding domain (RBD) consisting of two RNA recognition motifs (RRMs), and a glycine-
rich, prion-like, low complexity domain (LCD). Within RRM2 lies a nuclear export 
sequence (NES) (Figure 1.2). This domain structure is conserved between humans and 
mice.  
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Figure 1.1. Amino acid sequences in human and mouse TDP-43. Central 
sequence highlights conserved residues. “+” indicates non-conserved 
residues with similar chemical properties.  
 
 
Figure 1.2. TDP-43 domains with numbered amino acid residues, accurate for 
human and mouse TDP-43 isoforms.  
The N-terminal of TDP-43 is involved in protein interaction, and enables the formation 
of TDP-43 homodimers (Xiao et al. 2011), and further the disulphide bridges that lead 
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to tetramerisation. This regulation of TDP-43 formation is likely to play roles in TDP-
43’s RNA processing functions, as well as preventing insoluble aggregation of the 
protein in the cytoplasm (Jiang et al. 2017). 
The structure of TDP-43 closely resembles other hnRNP proteins, particularly those 
linked to amyotrophic lateral sclerosis (ALS), such as FUS, hnRNP A1 and hnRNP A2B1 
(Figure 1.3) (Purice & Taylor 2018). However, while these proteins contain a proline-
tyrosine NLS (PY-NLS), which contains a proline-tyrosine pairing allowing binding to 
the transportin protein for nuclear shuttling, TDP-43 contains a classical bipartite NLS 
of K82RK84 and K95VKR98 (Winton et al. 2008). Mutation of these regions has been 
demonstrated as capable of leading to TDP-43 mislocalisation.  
 
Figure 1.3. TDP-43 domains compared to related hnRNPs and RBPs. RGG – Arg-
Gly-Gly box, ZnF – Zinc finger, PRI – Polypyrimidine tract binding RRM 
interaction domain, MSP – Multisystem proteinopathy (Purice & Taylor 2018).  
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TDP-43 further contains two RRMs, both involved in controlling TDP-43 DNA and RNA 
binding function (Kuo et al. 2009). TDP-43 was first discovered as a possible 
transcriptional repressor binding to the transactivation response element of HIV-1 
DNA, hence it’s full name: transactive response DNA binding protein 43 kDa (Ou et al. 
1995). However, due to its interaction with a large number of transcript targets 
(Polymenidou et al. 2011), a strong focus on its role in RNA processing control has 
developed. The role of both RRMs in controlling aspects of RNA regulation is not 
equally distributed; RRM1 is known to be both necessary and sufficient for nucleic acid 
binding in TDP-43 (Buratti & Baralle 2001). For RNA binding in particular, mutation of 
just two amino acid residues – F147L and F149L – is enough to completely abolish 
TDP-43 binding, and remove control of splicing in target transcripts (Buratti & Baralle 
2001; D’Ambrogio et al. 2009). RRM2 has an unusual structure in comparison to typical 
RRM sequences –it contains an additional β strand which would imply roles in protein 
interaction (Kuo et al. 2009). This structure is thought to lead to self-association, and 
results in a high level of stability of the RRM2 to act as the ‘stability core’ of TDP-43 
(Morgan et al. 2017). However, its role in RNA binding is reduced relative to RRM1, 
with its affinity for RNA two orders of magnitude lower (Kuo et al. 2009). Nonetheless, 
it partially controls overall binding ability of TDP-43 to RNA, likely performing a more 
regulatory role (Furukawa et al. 2016).  
The LCD of TDP-43 contains a central hydrophobic element surrounded on either side 
by two prion-like domains. This means it is intrinsically disordered, but possesses the 
ability to form β-rich dynamic oligomers at high concentrations, resulting in dynamic 
self-assembly and formation of intracellular, membrane-less organelles such as stress 
granules, a behaviour known as liquid-liquid phase separation (LLPS) (Kato et al. 2012; 
Nott et al. 2015; Mitrea & Kriwacki 2016; Lim et al. 2016). The LCD is primarily 
involved in protein interaction, and contains the residues 321-366 which are required 
for recruitment of a variety of other hnRNPs (D’Ambrogio et al. 2009). Tied to this, the 
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LCD of TDP-43 is necessary for its control of RNA splicing, and this function is 
conserved across several species (Ayala et al. 2005). Each of the domains of TDP-43 are 
also involved in overall inter-domain interaction within the protein, modulating its 
activity by causing conformational changes which result in the protein forming open 
and closed states. This altering of overall protein folding is primarily controlled by the 
LCD (Wei et al. 2016).  
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TDP-43 FUNCTIONS IN RNA PROCESSING 
 
Figure 1.4. Schematic overview of TDP-43 cellular functions in RNA processing 
and regulation (Lagier-Tourenne et al. 2010). 
Outside of regulating its own transcript levels, TDP-43 functions to control several 
aspects of RNA processing, such as alternative splicing (Buratti et al. 2001; Buratti & 
Baralle 2001), turnover (Ayala et al. 2008; Fiesel et al. 2010; Godena et al. 2011), 
stability (Strong et al. 2007; Colombrita et al. 2009), transport (Dewey et al. 2011; 
Fallini et al. 2012) and translation (Wang et al. 2008) in target transcripts (Figure 1.4). 
These functions are not limited to mRNA, with roles in ncRNA regulation also reported 
(Kawahara & Mieda-Sato 2012). Several RBPs exist, but TDP-43 is thought to be 
particularly vital given that it is reported to bind to 30 % of the mouse transcriptome 
(Polymenidou et al. 2011), and its RBD is notably conserved across species ranging 
from C. elegans all the way to humans (Ayala et al. 2005). In particular, TDP-43 is 
known to have high affinity for UG repeat motifs in RNA targets (Buratti & Baralle 
2001), whether in the form of long stretches of UG repeats or as short clusters of UG 
7 
 
interspersed with other sequences. In determining this affinity, RRM1 plays a primary 
role, with a low dissociation constant of 14.2 nM for RNA sequences containing at least 
six UG repeats (Kuo et al. 2009). RRM2 affinity for UG repeats is markedly lower, but 
the affinity for this motif is highest with the RRMs in conjunction as the total RBD of 
TDP-43 (Kuo et al. 2009).   
The role of TDP-43 in alternative splicing of target transcripts has been especially well 
documented. It was initially attributed to repression of exon inclusion, such as of exon 
9 of the CFTR gene (Buratti et al. 2001; Mercado et al. 2005), but contrary events 
describing TDP-43-mediated exon skipping have also now been established (Fiesel et 
al. 2012). Currently, several strongly TDP-43-mediated splicing events have been 
identified, including in POLDIP3, SORT1, EIF4H and MADD (Fiesel et al. 2012; Prudencio 
et al. 2012; Yang et al. 2014; De Conti et al. 2015), and these provide a subset of 
primary targets for investigating presence of TDP-43 dysfunction. TDP-43 functions by 
interacting with nascent pre-RNA transcripts and co-ordinates the processing of these 
targets via interaction with other RBPs, hnRNPs and the spliceosome. Importantly, this 
regulatory splicing control is also likely to be conserved across several species (Ayala 
et al. 2005). The changes in TDP-43-RNA processing in various diseases has been 
investigated in several models, further discussed in 1.3 Models of TDP-43 dysfunction,, 
and reviewed in Nussbacher, Batra, Lagier-Tourenne, & Yeo (2015). 
The structure of TDP-43 enables LLPS, and the formation of transient membrane-less 
stress granules designed to protect RNA transcripts from degradation as part of the 
cellular stress response (Liu-Yesucevitz et al. 2010; Kato et al. 2012). It has been 
hypothesised that these structures may be dysfunctional in disease, with protein 
mutations causing unwanted stability of the organelles to form toxic aggregates (Ratti 
& Buratti 2016).  
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1.1.3 TARDBP ISOFORMS AND AUTOREGULATION 
 
Figure 1.5. Human TARDBP transcript. UTR sequences represented by white 
boxes, exons represented by black boxes. Key introns and alternative 
polyadenylation sites annotated. Adapted from Koyama et al. (2016).  
TDP-43 is coded for by the TARDBP gene, found on chromosome 1 in humans and 
chromosome 4 in mice. In both species, several isoforms of the transcript exist to 
enable regulation of TDP-43 protein levels. TDP-43 is tightly autoregulated in a 
mechanism involving the alternative splicing and polyadenylation of TARDBP 
transcripts in response to changes in TDP-43 binding. Figure 1.5 illustrates the most 
common TARDBP transcript isoforms and the alternative introns which can be spliced 
to result in usage of different polyadenylation sites (pAs).  
TDP-43 is known to directly bind to its own transcripts to influence processing of the 
RNA, and the integral region of binding for this control lies within intron 7, 5’ of 
polyadenylation site pA1 (Ayala et al. 2011). This 34 nt region, termed the TDP-43 
Binding Region (TDPBR), contains UG repeats but, unlike the archetypal TDP-43 target 
sequences, this sequence consists of short interspersed UG motifs as opposed to long 
stretches of UG. Despite the resulting lower affinity for TDP-43 to the TDBPR in 
comparison to long UG sequences,  TDP-43 binding to this region was confirmed by the 
presence of high cluster density in TDP-43 CLIP studies (Ayala et al. 2011).  
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TDP-43 binding to the TDPBR has been shown to be crucial to autoregulation through 
transfection studies of the TARDBP 3’UTR isoforms into HeLa cell lines by Polymenidou 
et al. (2011). Either the long, unspliced TARDBP 3’UTR form containing the TDPBR, or 
the short spliced 3’UTR form lacking the TDPBR, was cloned adjacent to a Renilla 
luciferase gene and transfected into HeLa cells. Upon TDP-43 overexpression, cells 
transfected with the unspliced 3’UTR isoform (containing the TDPBR) showed 
significantly less Relative Fluorescence Units (RFUs) produced relative to the spliced 
isoform with no TDPBR, suggesting that TDP-43 was able to restrict expression of the 
unspliced 3’UTR isoform but not the spliced isoform lacking the TDPBR.  
There has been a great deal of debate surrounding the precise splicing and 
polyadenylation processes undergone by TARDBP transcripts and their respective 
consequences on TARDBP transcript fate. Specifically how the splicing of introns 6 and 
7, and the binding of TDP-43 throughout the TDPBR, influence the choice of 
polyadenylation sites pA1, pA2 and pA4 is not fully understood.  
In early studies, computational analysis predicted the presence of four possible 
polyadenylation signals in the TARDBP gene. However, Expressed Sequence Tag (EST) 
evidence from the UCSC Genome Browser database suggested two sites, pA1 and pA4, 
accounted for the vast majority of transcript polyadenylation sites (Ayala et al. 2011). 
Current consensus is that TARDBP transcripts with pA1 are stable, can be exported into 
the cytoplasm, and translated into protein. Transcripts with pA4, a polyadenylation site 
1.5 kb further 3’, are instead retained in the nucleus and are unavailable for translation 
(Koyama et al. 2016). In HEK293 cells, the ratio of transcripts using pA1:pA4 was 
approximated to be 3:1 (Ayala et al. 2011). Alongside these polyadenylation sites is 
another, pA2, and TARDBP transcripts with pA2 were identified using Rapid 
Amplification of cDNA Ends (RACE) (Eréndira Avendaño-Vázquez et al. 2012). Like 
pA4-containing transcripts, TARDBP transcripts using pA2 are also not translated into 
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protein. However, whether they are exported from the nucleus into the cytoplasm and 
degraded (Koyama et al. 2016), or whether they are retained in the nucleus (Eréndira 
Avendaño-Vázquez et al. 2012), is still a topic of debate. Importantly, all three of the 
aforementioned polyadenylation sites are conserved between mice and humans, 
showing near identical arrangement (Eréndira Avendaño-Vázquez et al. 2012).  
The polyadenylation site to be used is partly dependent on the splicing of the TARDBP 
transcript, particularly the retention or splicing of introns 6 and 7. Intron 7 is known to 
be critical to the autoregulation mechanism as it contains pA1, the polyadenylation site 
typical required for TARDBP transcripts to undergo translation, as well as the TDPBR.  
Typically, both intron 6 and intron 7 are retained, leading to use of pA1 and a stable 
isoform to be exported and translated. However, some transcripts can retain both 
introns but as a result of TDP-43 binding around the pA1 region, do not use pA1 but 
instead pA4 and are therefore not exported. 
Upon TDP-43 overexpression, intron 7 splicing is enhanced. This removes the pA1 site, 
leading instead to a switch to the next polyadenylation site, pA2. As transcripts with pA2 
are not translated, this means that TDP-43 overexpression would reduce the level of 
TARDBP transcripts to be translated and behave as the required feedback mechanism. 
Concordantly, nullification of intron 7 splice sites can prevent the autoregulatory 
mechanism from functioning (Eréndira Avendaño-Vázquez et al. 2012).  
Intron 6 is of interest as it contains ALS-causative mutations in TDP-43 (Koyama et al. 
2016). It has also recently been identified as possibly important in TDP-43 
autoregulation, as retention of intron 6 alongside splicing of intron 7 reduces the 
severity of autoregulation in comparison to splicing of both introns (Koyama et al. 
2016). Studies disagree on the importance of this transcript, with some stating that it is 
very rarely seen under basal conditions (Koyama et al. 2016), whereas others state that 
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it is the primary transcript that displays pA2 usage (Eréndira Avendaño-Vázquez et al. 
2012).  
More simply, there is unanimous agreement on the non-existence of TARDBP 
transcripts with spliced intron 6 and retained intron 7 (Eréndira Avendaño-Vázquez et 
al. 2012; Koyama et al. 2016). Indeed, Koyama et al. (2016) state that intron 7 splicing 
is necessary for, and precedes, intron 6 splicing.  
The final combination, splicing of both intron 6 and intron 7, leads to a pA2-utilising 
transcript (Koyama et al. 2016), which was also the transcript described to originally 
be involved in autoregulation by Polymenidou et al. (2011). As it contains the pA2 
polyadenylation site, this transcript is not translated. This isoform is also detected, 
albeit at low levels and termed “V2”, in Ayala et al. (2011), however they determine 
that as it does not change in expression levels upon either TDP-43 overexpression or 
nonsense-mediated decay (NMD) inhibition, it is not involved in autoregulation. 
Further disagreement in the field exists on whether the autoregulatory mechanism 
results in a reduction in TARDBP transcript translation through NMD (Polymenidou et 
al. 2011; Koyama et al. 2016), or another pathway (Ayala et al. 2011; Eréndira 
Avendaño-Vázquez et al. 2012).  
From the aforementioned Polymenidou et al. (2011) investigation of TARDBP 3’UTR 
isoforms fused with the luciferase gene and transfected into HEK293 cells, the role of 
NMD was tested through concomitant treatment with siRNA targeting UPF1, a 
component required for NMD. They found that inhibition of NMD resulted in increased 
RFU produced by the unspliced 3’UTR isoform, suggesting that NMD played a role in 
the degradation of the mRNA. Further experiments revealed that blocking NMD in this 
manner caused increased expression of the TARDBP isoform with both introns 6 and 7 
spliced out in HeLa cells; a similar effect to the transient overexpression of TDP-43 in 
the same model. Koyama et al. (2016) also report the involvement of NMD in TDP-43 
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autoregulation, with pA2-containing transcripts with both introns spliced out showing 
an increase upon cyclohexamide treatment (CHX) and UPF1 phosphorylation inhibition 
in HEK293 cells. 
Conversely, Ayala et al. (2011) found that upon CHX treatment of HEK293 cells, there 
was no change in the autoregulation mechanism. However, in this case they report no 
difference in TARDBP isoforms containing pA1 or pA4, both of which result from 
retention of introns 6 and 7. They do suggest that the isoform with both intron 6 and 7 
spliced out (“V2”) would undergo NMD, having ruled that it was not involved in 
autoregulation. Eréndira Avendaño-Vázquez et al. (2012) look into pA2 isoforms and 
maintain that CHX treatment in HEK293 cells had no effect on pA2 isoform abundance. 
Instead, these studies propose alternative methods by which translation is prevented, 
including a nuclear retention of the transcripts (since contradicted in  Koyama et al. 
[2016]) or exosome-mediated degradation.  
The precise mechanism by which TDP-43 binding to the TDPBR leads to intron splicing 
is also unclear. One likely possibility is that TDP-43 binding to this region is required in 
order to recruit other hnRNPs and splicing factors to enable the splicing of the intron, 
but the identity of these factors is not yet known. The importance of spliceosome 
assembly in intron 7 in particular has been suggested to be the key feature for 
subsequent polyadenylation site selection, over and above other factors such as the 
intrinsic quality of the polyadenylation sites themselves (Bembich et al. 2014). Another 
mechanism posits that TDP-43 binding causes stalling of RNA polymerase II (Pol II). It 
has previously been suggested that stalling of Pol II can lead to favouring of suboptimal 
splicing (Kornblihtt 2007). Furthermore, ChIP analysis has revealed that TDP-43 
overexpression results in increased Pol II signals throughout the TARDBP 3’UTR, 
stretching from the TDPBR to pA4 (Eréndira Avendaño-Vázquez et al. 2012). Therefore, 
overexpression of TDP-43 may lead to sufficient stalling of Pol II to enable recognition 
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of the suboptimal splice sites, resulting in intron removal. Additionally, CstF-64, a 
cleavage factor involved in 3’ end cleavage and polyadenylation, targets a similar 
consensus motif to TDP-43, GU3-5U2-4 (Takagaki & Manley 1997). It is possible that 
TDP-43 overexpression results in it outcompeting CstF-64, blocking the latter 
recognising pA1 and therefore resulting in the nascent transcript forming an isoform 
with a polyadenylation site that will not be translated. Evidence for this hypothesis was 
provided from RNA immunoprecipitation (RIP) experiments which showed that when 
TDP-43 and CstF-64 were in competition, TDP-43 overexpression caused increased pA1 
RNA binding and reduced CstF-64-pA1 RNA binding as a result (Eréndira Avendaño-
Vázquez et al. 2012).  
The autoregulation of TDP-43 may be yet more complicated. One possibility was that 
the length of the 3’UTR itself may play a role in TARDBP transcript instability, but 
results from Koyama et al. (2016) suggest that this is not the case. Intriguingly, the 
entire ~3 kb TARDBP 3’UTR long isoform is well conserved between mice and humans, 
despite TDP-43 itself only binding to a relatively small region. This raises the 
possibility that TDP-43 is not alone in regulating TARDBP levels, and other proteins 
possess their own conserved regulatory binding sites in the TARDBP 3’UTR to control 
TARDBP transcript fate (Ayala et al. 2011). Post-translational control may also be 
involved, as TDP-43 protein half-life results have been described as highly variable 
depending on the cell line used (Ling et al. 2010). The presence of changes in TDP-43 
autoregulation in disease settings is also unclear, and so identifying the precise 
intricate measures by which TDP-43 synthesis is modulated is crucial for 
understanding how otherwise tightly-controlled expression levels may be heavily 
disrupted in ALS.  
 
  
14 
 
1.2 AMYOTROPHIC LATERAL SCLEROSIS 
1.2.1 DISEASE OVERVIEW 
First described in 1869 by Jean-Martin Charcot, amyotrophic lateral sclerosis (ALS) is a 
rapidly progressive neurodegenerative disease characterised by the degeneration of 
both the upper motor neurons in the motor cortex and the lower motor neurons of the 
brainstem and spinal cord. The degeneration of the latter leads to inactivity and 
atrophy of no longer-stimulated voluntary muscles, resulting in muscle weakness and 
eventual paralysis. ALS is typically lethal within 2-3 years of onset, often through 
respiratory failure (Rowland & Shneider 2001).  It is often a late-onset disease, and 
region of onset is variable, but early-onset and even juvenile forms of ALS have been 
described (Orban et al. 2007). It has an incidence rate of 2.16 in 100,000 in Europe 
(Logroscino et al. 2010), and is 20 % more common in men than women (Manjaly et al. 
2010).  
It is also strongly related to another neurodegenerative disease, frontotemporal 
dementia (FTD), and the two are now thought to coexist on an ALS/FTD spectrum 
(Mackenzie et al. 2010). FTD is a form of dementia that results in behavioural and 
personality changes, as well as impairment of brain functions such as attention and 
memory through neurodegeneration of the frontal and temporal brain lobes. 50 % of 
ALS patients are additionally diagnosed with additional cognitive impairment (Gordon 
et al. 2010). The precise mechanisms by which mutation in these genes leads to either 
of these diseases is unclear, with research suggesting the presence of overlap but also 
distinct pathways disrupted in each disease (Hardy & Rogaeva 2014). One broad 
distinction of the summary is that RNA processing genes such as TDP-43 are typically 
more associated with the ALS variant of the ALS/FTD spectrum. 
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ALS has no cure, and development of therapeutics has been poor, with only two drugs 
approved by the FDA in the US – Riluzole and Edaravone – following over two decades 
of translational research. Even then, the latter is not yet approved in the UK, and the 
former has only modest effects on extended lifespan (Miller et al. 2002).  
1.2.2 GENETICS OF ALS 
ALS is a primarily sporadic disease, with only 5-20 % of cases classified as familial 
(fALS) (Byrne et al. 2011; He et al. 2015). Phenotypes resulting from either cause of the 
disease are difficult to distinguish, and substantial overlap exists (Turner et al. 2017). 
In fALS, the majority of mutations are classed as autosomal dominant, and primary 
cause is mutation of C9ORF72, thought to be pathologically mutated in 40 % of cases 
(Figure 1.6). Mutations in SOD1 were the first identified cause of ALS, and these 
underlie approximately 20 % of fALS. Causative variants in TARDBP and FUS further 
account for 4 % of fALS cases each. Genes with even rarer ALS-causative mutations 
include OPTN, VCP, p62/SQSTM1, PFN1, UBQLN2 and NEK1 (Renton et al. 2013). 
Roughly 70 % of fALS can be attributed to these known ALS genes, and 10 % of 
sporadic ALS cases can also be traced back to these. Clinical symptoms resulting from 
mutation in each of these genes are also variable, but broad patterns have emerged 
linking mutation of each of the most common ALS genes to the ALS/FTD spectrum of 
disease phenotype (Ling et al. 2013).  
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Figure 1.6. Left: Progression of ALS-causative gene identification with cumulative 
tally of percentage of explained fALS and sALS cases. Right: ALS-causative genes 
in fALS and sALS represented by proportion of respective cases explained by 
gene mutation. Central number represents total number of cases explained by 
known ALS-causative gene mutations (Renton et al. 2013). 
Intriguingly, several environmental risk factors have also been posited, including 
smoking, alcohol consumption, military service, lead exposure and traumatic brain 
injury (reviewed in Martin et al. 2017). However, these effectors in general have been 
poorly studied, and even where correlation to disease onset exists it is typically weak 
and highly variable. Therefore, currently these risk factors do not substantially add to 
the existing knowledge on causes of ALS.  
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1.2.3 TDP-43 IN ALS 
 
Figure 1.7. TDP-43 domains with all TDP-ALS mutations annotated, adapted from 
Emanuele Buratti (2015).  
Mutations in TARDBP are known to cause ALS (Sreedharan et al. 2008), and as of 2015, 
52 different mutations have been identified as ALS-causative in TARDBP (TDP-ALS) 
(Buratti 2015). Intriguingly, all but three of these mutations are found in the LCD of 
TDP-43 (Figure 1.7), implicating dysfunction of protein interaction as key to TDP-ALS 
(Pesiridis et al. 2009). Importantly, however, although TARDBP mutation is responsible 
for a minority of ALS cases, almost all ALS patients exhibit dysregulation of the TDP-43 
protein regardless of genetic cause. This dysregulation is in the form of nuclear 
depletion of TDP-43, and its subsequent mislocalisation and aggregation juxtaposed to 
the nucleus, in the cytoplasm (Figure 1.8) (Arai et al. 2006; Neumann et al. 2006). This 
TDP-43 pathology is a hallmark of ALS, occurring in approximately 97 % of all cases; 
absent in only SOD1- and FUS-caused ALS (Ling et al. 2013). 50 % of FTD cases also 
show similar TDP-43 mislocalisation, and interestingly, other diseases can also exhibit 
this type of pathology, such as Alzheimer’s disease (Amador-Ortiz et al. 2007; Higashi 
et al. 2007; Uryu et al. 2008; Josephs et al. 2014). Together, these diseases can be 
described as TDP-43 proteinopathies (Geser et al. 2010). Alongside pathology, elevated 
TARDBP transcript and TDP-43 protein levels have been detected in ALS patients, 
further suggesting TDP-43 dysfunction (Mishra et al. 2007; Gitcho et al. 2009; Kasai et 
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al. 2009; Swarup, Phaneuf, Dupré, et al. 2011; Verstraete et al. 2012; Iguchi et al. 2016; 
Koyama et al. 2016).  
 
Figure 1.8. Example TDP-43-DAB staining of TDP-43 proteinopathy. TDP-43 is 
primarily nuclear, however some cells show nuclear depletion and cytoplasmic 
aggregation of TDP-43, indicated by arrows. Adapted from Vatsavayi et al. 
(2014).  
The TDP-43 aggregates formed in ALS have been heavily studied, given the strong link 
between pathology and disease. The nuclear depletion and cytoplasmic mislocalisation 
precede the formation of eventual aggregates (Giordana et al. 2010). Rather than the 
full length form, these aggregates often consist of C-terminal fragments of TDP-43. A 35 
kDa fragment exists, containing all but the N-terminal region, whereas the 25 kDa 
fragment lacks any of the RRM1 and consists of a truncated RRM2 as well as the LCD. 
Both of these forms have been linked to enhanced aggregation propensity and toxicity 
of the protein (Johnson et al. 2008), and in particular the 25 kDa fragment is thought to 
recapitulate the pathological features of TDP-43 proteinopathy (Zhang et al. 2009; Wei 
et al. 2017). Whether these aggregates display amyloid negative or positive staining 
properties is still debated, however (Chen et al. 2010; Guo et al. 2011; Wang et al. 
2013).  
It has been hypothesised that the reason the 25 kDa fragment is enriched in TDP-43 
aggregates is that the cleavage of the RRM2 at R208 drastically reduces its solubility, 
and further eliminates its folding structure, resulting in increased risk of aggregation  
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(Zhang et al. 2009; Wei et al. 2016). Concomitant with this, the loss of the N-terminal in 
both TDP-43 fragment forms also prevents dimerisation, leaving unassembled RRM2 β 
strands exposed and prone to oligomerisation into high-order inclusions (Wang et al. 
2013). The initial seed inclusions are also capable of sequestering wildtype full-length 
TDP-43, propagating the aggregation (Furukawa et al. 2011). Degradation of these 
cytoplasmic aggregates is also markedly slow, one-fifth of the speed of nuclear TDP-43 
clearance, enabling their persistence (Sugai et al. 2018).  
Importantly, these TDP-43 aggregates in ALS are also hyperphosphorylated (Arai et al. 
2006). This phosphorylation is linked to enhance formation of the aggregates, as well 
as the resulting toxicity, in vivo (Igaz et al. 2009; Zhang et al. 2009), but this notion has 
been contradicted by in vitro study (Wei et al. 2016). Specifically, the phosphorylation 
of serine residues S409 and S410 have been pinpointed as signs of pathological TDP-43 
aggregation (Neumann et al. 2009). The phosphorylation itself may not be the cause of 
aggregation however; rather it could demarcate attempts by the cell to degrade the 
inclusions (Mompeán et al. 2016). Acetylation of TDP-43 aggregates has also been 
reported in ALS patient spinal cords but not in FTD-TDP brain, suggesting a degree of 
variability in this feature (Cohen et al. 2015). Oxidative stress may also play a role in 
the formation of TDP-43 inclusions (Rabdano et al. 2017), displayed by cysteine 
oxidation, and markers of oxidative stress can be found elevated in ALS patient spinal 
cords (Pedersen et al. 1998), but a concrete link has not yet been established. TDP-43 
aggregates are also often ubiquitinated, and show p62 co-localisation in ALS patient 
CNS tissue (Arai et al. 2006; Tanji et al. 2012). These are factors involved in protein 
degradation and so they further demonstrate cellular mechanisms attempting to clear 
the TDP-43 proteinaceous aggregates.  
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1.3 MODELS OF TDP-43 DYSFUNCTION 
1.3.1 LOSS OF FUNCTION MODELS 
To fully understand the role of TDP-43 in cellular homeostasis, and the subsequent 
effects of mutation or dysfunction that could underlie ALS phenotype, several cellular 
and animal models have been created. Due to the joint presence of nuclear TDP-43 
depletion alongside cytoplasmic increase and aggregation, it is not clear whether the 
pathological effects of TDP-43 result from a loss of its normal function or a gain of 
function, either its normal function to excessive levels or a toxic gain of function with 
novel effects in the cytoplasm.  
To understand the effects of TDP-43 loss of function, primary method of study has 
involved knock-out (KO) or knock-down (KD) of Tardbp, reducing the levels of TDP-43 
and investigation the consequential effects. KO of TDP-43 homologue TBPH in 
Drosophila melanogaster resulted in severe motor phenotype, with the neuromuscular 
junction in particular regarded to be malformed (Feiguin et al. 2009). These flies also 
exhibited semi-lethality, and a reduced lifespan, and further these effects could be 
reversed using ectopic expression of a human wildtype TDP-43 construct.  In zebrafish, 
two forms of Tardbp exist, Tardbp and Tardbpl. KD of Tardbp alone in zebrafish was 
sufficient to cause motor phenotype in one investigation (Kabashi et al. 2009), and 
while KD of Tardbpl did not result in a phenotype, KD of both culminated in a more 
severe motor phenotype than KD of Tardbp alone (Hewamadduma et al. 2013). 
However, another study determined that Tardbp loss alone did not result in motor 
phenotype (Schmid et al. 2013). 
Three mouse models were also simultaneously developed with TDP-43 KO, and in all 
cases homozygosity resulted in early embryonic lethality with substantial growth 
deficiency (Wu et al. 2009; Kraemer et al. 2010; Sephton et al. 2010). Inducible KO 
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developmental models showed similar rapidly lethal results, highlighting the 
importance of TDP-43 function throughout development (Chiang et al. 2010). 
Heterozygous KO of TDP-43 instead resulted in viable mice, however, likely due to the 
autoregulation mechanism of TDP-43 compensating for the loss of one allele as 
outlined in 1.1.2 TARDBP isoforms and autoregulation. Importantly, these adult 
heterozygous KO models did eventually develop variable motor phenotype, but no 
neurodegeneration (Kraemer et al. 2010), suggesting TDP-43 was important even in 
mature models, and also implied a reduction in the capabilities of the TDP-43 
autoregulatory mechanism in adult mice. This was further supported by TDP-43 KO in 
adult mouse motor neurons resulting in axonal and muscular atrophy alongside 
progressive motor neuron dysfunction (Iguchi et al. 2013). TDP-43 KD in the adult 
mouse striatum was further revealed to cause mass RNA dysregulation (Polymenidou 
et al. 2011), further discussed in Chapter 3 F210I model transcriptome dysregulation.  
Finally, cell death has also been shown to result in human HeLa cells as a result of TDP-
43 loss, as well as in neuron-like Neuro-2a cells, in which neurite growth was 
diminished (Iguchi et al. 2009). 
1.3.2 OVEREXPRESSION MODELS 
Given the elevated TARDBP and TDP-43 levels detected in ALS patients, alongside the 
increased proportion of protein localised in the cytoplasm, the effects of TDP-43 
overexpression have also been similarly studied in several models. In C. elegans, 
overexpression of TDP-43 orthologue Tdp-1 was not found to be toxic (Ash et al. 2010). 
However, highlighting the differences between C. elegans and human systems, 
complete Tdp-1 loss was also not described as toxic in C. elegans, and bizarrely even 
associated with a slight increase in lifespan (Vaccaro et al. 2012). Overexpression of 
TBPH in Drosophila melanogaster lead to axonopathy (Lu et al. 2009), whereas 
22 
 
overexpression of wildtype human TDP-43 in Drosophila melanogaster resulted in 
motor neuron degeneration, with neuromuscular junction formation again pinpointed 
(Li et al. 2010; Hanson et al. 2010). However, despite the overexpression, 
mislocalisation of TDP-43 was not triggered. Interestingly, overexpression of the C-
terminal TDP-43 fragments alone were found to cause reduced phenotype in 
comparison to the full length TDP-43 (Li et al. 2010; Voigt et al. 2010).  
In mice, transgenic overexpression of either mouse or human wildtype TDP-43 is toxic, 
and results in motor phenotype in the form of gait abnormalities. Mouse lifespan is also 
typically reduced (Shan et al. 2010; Wils et al. 2010; Xu et al. 2010). Wils et al. (2010) 
also reported neuronal inclusion formation and subsequent muscle paralysis in their 
model, while Xu et al. (2010) described mitochondrial aggregation alongside motor 
deficits. FTD-like symptoms of progressive learning and memory defects have also 
been reported, in conjunction with degeneration of the frontal cortex and hippocampus 
(Tsai et al. 2010; Igaz et al. 2011). However, lower motor neuron degeneration is often 
not seen in these models (Joyce et al. 2011). TDP-43 overexpression phenotype and 
lifespan reduction has also been reported as dose-dependent (McGoldrick et al. 2013). 
It is thought that overexpression of TDP-43 leads to incomplete oligomeric complexes 
(Xu 2012), but whether this replicates the outcome of TDP-ALS mutation is not clear.  
1.3.3 TDP-ALS MODELS 
Although the TDP-43 KD, KO and transgenic wildtype overexpression models all 
provide insight into the varying roles of TDP-43 mislocalisation in subsequent 
molecular, cellular and model phenotype, it is not clear precisely how these changes 
relate to those caused by TDP-ALS mutations. To examine this further, several mouse 
models have now been developed expressing transgenic TDP-ALS mutated human 
TARDBP constructs under the control of various promoters. These include models with 
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the A315T mutation from Wegorzewska, Bell, Cairns, Miller, & Baloh, (2009), Stallings, 
Puttaparthi, Luther, Burns, & Elliott, (2010), Swarup, Phaneuf, Bareil, et al. (2011) and 
Stribl et al. (2014), the M337V from Stallings et al. (2010), Y.-F. Xu et al. (2011), Arnold 
et al. (2013), Janssens et al. (2013), and the Q331K from Arnold et al. (2013), and 
Mitchell et al. (2015). Phenotypes across these models vary, and between them several 
features of the typical ALS phenotype are covered, including TDP-43 mislocalisation 
and aggregation, gliosis, mitochondrial defects, behavioural changes, motor neuron 
degeneration and loss, and neuromuscular junction loss.  
However, a key drawback of all of these models is the use of transgenic TARDBP 
construct expression for study of TDP-ALS mutation effects. This results in TDP-43 
overexpression, and as outlined earlier, overexpression of even wildtype TDP-43 can 
cause severe motor phenotype. Therefore, it is not possible to distinguish the 
phenotype that results from mutation of the protein rather than overexpression. 
Furthermore, in several of these models, the effect of mutation on RNA processing is 
also not studied for the same reason. TDP-43 overexpression, and subsequent 
autoregulation, would likely have an impact on its control of target transcript 
processing, again preventing investigation of how the TDP-ALS mutation specifically 
affects TDP-43 functions. Overcoming the shortcomings of these ALS mouse models is 
vital for downstream therapeutic development, as RNA dysregulation may be a key 
area of impairment to be targeted (Ferraiuolo et al. 2011). In one study, noted to have 
Tardbp expression levels comparable to wildtype animals despite transgenic 
expression, RNA splicing dysfunction was studied (Arnold et al. 2013). This 
investigation reported some splicing changes resembling TDP-43 loss of function, and 
others following the pattern expected of TDP-43 gain of function.  
The work documented in this thesis is based on two mouse models with single point 
mutations inside the endogenous Tardbp gene through N-ethyl-N-nitrosurea (ENU) 
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mutagenesis (Acevedo-Arozena et al. 2008; Georgel et al. 2008), developed in order to 
study the effect of TDP-43 mutations without the drawback of transgenic TDP-43 
overexpression. These mutations were selected upon testing of several mutated TDP-
43 constructs using the CFTR minigene assay (detailed in Chapter 3 – F210I model 
transcriptome dysregulation) which revealed notable changes in TDP-43 splicing 
activity. In this method, the mutagen was administered to adult male mice via a series 
of intraperitoneal injections and allowed to spread throughout the body, including to 
the testes, where it caused mutations in sperm cells as they were formed from the 
spermatagonial stem cells. Approximately 6 weeks after ENU injection, male mice were 
mated to wildtype females. In the sperm of mice from the MRC Harwell programme, the 
result of mutagen exposure was a point mutation per million base pairs of genomic 
DNA. The ENU treated male mice were bred to produce F1 progeny, culled and two 
storage banks, of DNA and sperm from the same animal, were created, ready for 
multiplex analysis. The DNA bank was screened in a high-throughput manner for 
mutations in genes of interest, and the gametes of models containing desired mutations 
were revived and used, via in vitro fertilisation of female mice of the desired 
background, to create a mouse model containing the mutation of interest. These 
models were further crossed in order to eliminate other undesired mutations as a 
result of the ENU mutagen, eventually resulting in a mouse model with a wildtype 
background aside from the mutation of interest.  
Using this method, two mouse models of mutant TDP-43 have been developed, each 
containing a single A>T missense mutation in the Tardbp gene resulting in a single 
amino acid change in either RRM2 (F210I) or LCD (M323K) of TDP-43 (Figure 1.9). 
Both models have been extensively studied for molecular, cellular and developmental 
phenotype to further elucidate the early molecular mechanisms underlying pathology 
as a consequence of TDP-43 dysfunction and the findings have been recently been 
published (Fratta et al. 2018; Sivakumar et al. 2018). 
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Figure 1.9. Mouse TDP-43 domains with the two ENU mutagenesis-derived 
mutations primarily investigated in this thesis annotated, F210I and M323K. 
1.3.4 TDP-43 LOSS VERSUS GAIN OF FUNCTION 
Distinguishing the loss and gain of function mechanisms that result from TDP-43 
mutation, dysfunction, and mislocalisation is made difficult due to the processes 
occurring simultaneously in models with TDP-43 proteinopathy. Therefore, it has so 
far been difficult to attribute the molecular dysregulation that results from TDP-43 
change in activity to one specific mechanism, although previous investigations provide 
evidence for the importance of both loss and gain of function.  
One hypothesis is that loss of function of basal TDP-43 activity is primarily responsible 
for the RNA processing dysregulation upon TDP-ALS mutation, and possibly the 
phenotype that results. This hypothesis posits that the key event is the nuclear 
depletion of TDP-43. As it is lost from the nucleus, its roles in the transcription, 
splicing, and transport of pre-mRNA and mRNA transcripts are compromised. This 
leads to the failure to process transcripts for a large number of different genes, some of 
which may be of particular importance to motor neuron function. The loss of the 
subsequent mRNA translation, and therefore protein, leads to disturbance in cellular 
homeostasis that proves toxic to the cell. Alongside this, the theory infers that nuclear 
TDP-43 depletion is also the key trigger for TDP-43 protein aggregation. As nuclear 
TDP-43 is lost, the synthesis of TDP-43 is increased via the autoregulatory mechanism 
of TARDBP transcripts, increasing TARDBP transcript and TDP-43 protein levels. 
However, TDP-43 continues to be mislocalised towards the cytoplasm, with the 
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excessive concentration forming aggregates, while the continued nuclear depletion 
maintains the upregulation of TDP-43 production, causing a continuous cycle of 
increased aggregation.  
Several lines of evidence exist for the role of loss of function of TDP-43 in cellular 
toxicity. Study of TDP-43 KO and KD models, as previously outlined, are often lethal, 
and even when not can result in several variations of developmental and motor 
phenotype, showing that standard TDP-43 function is vital at the cellular level. TDP-43 
is also known to be an RBP that interacts with an exceptionally high number of 
transcripts (Polymenidou et al. 2011), therefore its loss is likely to affect many 
different pathways and a number of key genes. Previous study of TDP-43 loss of 
function has also revealed widespread RNA misregulation, including mass changes in 
RNA expression and splicing patterns (Polymenidou et al. 2011; Ling et al. 2015). In 
regards to ALS, the detection of nuclear depletion is widespread and evident in more 
than 97 % of all ALS patients (Ling et al. 2013), providing a strong link between the 
loss of function of TDP-43 that would result and the possibly consequent phenotype. 
Although the patients show cytoplasmic mislocalisation and TDP-43 aggregation, tying 
this to gain of function of the protein is more difficult to infer.  
Gain of function effects of TDP-43 have also been previously investigated, both in terms 
of excessive levels of normal function and possible toxic gain of new function. These 
hypotheses also suggest that cytoplasmic TDP-43 is the key driver of TDP-43 
pathology; perhaps the mutant toxic TDP-43 protein seeds aggregate formation, 
sequestering wildtype TDP-43 protein too. This toxic effect may reduce the synthesis of 
stable TARDBP transcripts and TDP-43 protein further and further until it is completely 
depleted in the nucleus and remains only in the form of aggregates in the cytoplasm. 
Like TDP-43 KD and KO models, models of TDP-43 overexpression are also typically 
toxic and documented to cause motor phenotype. Specifically, overexpression of 
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wildtype TDP-43 was found to enable TDP-43 pathology and neurological symptoms in 
mice, and the cessation of the overexpression reversed both the TDP-43 aggregate 
formation and the concomitant phenotype (Walker et al. 2015). Overexpression of 
transgenic human TDP-43 with the NLS removed was also found to cause 
neurodegeneration in mouse models despite the presence of endogenous TDP-43 in 
the nucleus, suggesting loss of function effects were not taking place (Igaz et al. 2011).  
One study developed mouse models with human TDP-43 constructs harbouring either 
the M337V or Q331K mutation and showed TDP-43 expression levels comparable to 
wildtype animals (Arnold et al. 2013). In these models, the nuclear depletion and 
subsequent TDP-43 mislocalisation and pathology were not detected, suggesting no 
loss of function or toxic gain of new function. However, the mouse models did show 
substantial RNA dysregulation with several examples of excessive TDP-43-mediated 
exon repression, and developed progressive motor axon degeneration and motor 
neuron death, and this phenotype was not detected upon transgenic expression of 
wildtype human TDP-43 in a similar manner. Therefore, this study would strongly 
suggest the excessive gain of normal TDP-43 function as a result of TDP-43 mutation as 
a primary mechanism. Further evidence for this method is the knowledge that TDP-43 
overexpression toxicity is well-documented to rely on the presence of the RBD (Ash et 
al. 2010; Voigt et al. 2010; Ihara et al. 2013), and several other RBPs have also been 
implicated in both ALS and a variety of other diseases, implying that the typical 
protein-RNA interaction is crucial and its alteration is central to toxic effects (Kapeli et 
al. 2017).  
In simple organisms, the study of TDP-43 loss vs overexpression has been investigated 
by controlled dysregulation of the protein specifically in either the nuclear or 
cytoplasmic compartments. In flies, using the TBPH homologue, studies have 
contrastingly found that either both the nuclear depletion and cytoplasmic 
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overexpression are toxic (Miguel et al. 2011), or that only the cytoplasmic 
overexpression alone is harmful (Ritson et al. 2010). Other studies examining both 
mechanisms have reported both as detrimental, and further that both result in a 
similar phenotype (Diaper et al. 2013), even at the transcriptome level (Vanden Broeck 
et al. 2013). It seems likely that loss of normal function and gain of function are both 
likely to prove inimical to normal TDP-43 activities; further work is required to 
understand precisely how each mechanism contributes to the overall pathogenicity 
that results.  
1.3 STUDY OF RNA 
The work in this thesis primarily focuses on the RNA dysregulation that results from 
the F210I and M323K TDP-43 mutations in mouse models. In order to study this in a 
high-throughput manner, RNA sequencing (RNA-Seq) of these models was utilised. 
RNA-Seq is an example of an application of next-generation sequencing (NGS), a 
technology which uses the sequencing-by-synthesis method. First notably utilised by 
Margulies et al. in 2005, NGS enables the investigation of a substantial and sizeable 
number of target genetic or genomic features in parallel, providing large scale datasets 
for downstream analysis and enabling focus on features of interest in the context of the 
complete genetic setting. As a result, several ambitious projects detailing complete 
analysis of features such as transcription and chromatin structure across the entire 
genome (ENCODE Project Consortium 2012), and in tissue-specific settings (Melé et al. 
2015), have been conducted.  
Previous high-throughput methodology, such as hybridisation-based microarrays, still 
required the prior selection of targets, introducing selection bias, and further needed 
post-experiment removal of background hybridisation levels where RNA-Seq enables 
accurate identification of expression levels. Drawbacks with RNA-Seq exist, including 
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batch effects, but these mostly result from prior sample processing and library 
preparation and methods exist to incorporate this variation into downstream analysis. 
The use of RNA-Seq is particularly important in the context of ALS, for which focus on 
transcriptomics is not new (Malaspina et al. 2001), given the growing understanding of 
the importance of RBPs and subsequent mass RNA processing changes that result from 
their mutation and dysregulation.  
1.5 AIMS 
The aims of this study revolved around the characterisation and analysis of the F210I 
and M323K TDP-43 mutant models at the transcriptomic, cellular and phenotypic level 
in the context of ALS. The primary focus of this investigation was to understand how 
the mutations of TDP-43 disrupted RNA processing resulting from mutation of either 
the RBD or LCD of TDP-43 using high-throughput RNA-Seq analysis. Following on from 
this was the aim of further identifying specific molecular signatures which could be 
linked towards understanding the precise mechanism by which TDP-43 mutation and 
dysfunction could culminate in neurodegeneration and ALS. Alongside study of the 
transcriptome, overall phenotypes was also investigated, particularly those previously 
described in ALS. Initiated at the MRC Mammalian Genetics Unit, Harwell, by Abraham 
Acevedo-Arozena, the complete characterisation of the models was completed by me 
and several others across a number of institutions. The results of this study have now 
been published in (Fratta et al. 2018; Sivakumar et al. 2018). Summarised aims 
involved: 
 RNA sequencing and bioinformatics analysis of the F210I and M323K mouse 
models at multiple time points to form complete picture of RNA dysregulation. 
 Identification of molecular signatures that provide clues as to how the two 
mutations disrupt TDP-43 activity, and how they may link to ALS. 
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 Study of phenotype developed by the TDP-43 mutant models, with a particular 
focus on ALS or neurodegeneration-linked symptoms. 
 Incorporation of previously published transcriptomic analysis to provide a 
more complete understanding of TDP-43 dysfunction in ALS.  
 Validation of key RNA disruption events in these models that remain conserved 
in TDP-ALS patient settings.  
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CHAPTER 2     
MATERIALS AND METHODS 
2.1  TRANSCRIPTOMICS 
2.1.1 RNA ISOLATION 
Dissected tissues were homogenised using the TissueRuptor (Qiagen) in 1 ml QIAzol 
(Qiagen) until uniformly homogenous. 350 µl of the lysate was transferred to LoBind 
microcentrifuge tubes (Sigma-Aldrich) for each RNA extraction and left to rest at room 
temperature for 5 min to allow dissociation of nucleoprotein complexes. After addition 
of 70 µl 1-bromo-3-chloropropane (BCP), the tubes were shaken vigorously for 15 s to 
mix, and from this stage the miRNeasy Mini Kit (Qiagen) was used according to the 
manufacturer’s protocol. The mix was incubated at room temperature for 3 min, and 
then centrifuged at 4 °C at 12,000 xg for 15 min. The upper aqueous phase was then 
transferred to a new LoBind tube and the RNA was precipitated with 1.5 volumes of 
absolute ethanol. The samples were then transferred to RNeasy Mini spin columns and 
centrifuged at 8,500 xg for 15 s. 350 µl Buffer RWT was then added to the columns and 
they were further centrifuged at 8,500 xg for 15 s. RNase-free DNase (Qiagen) was 
made by adding 70 µl Buffer RDD to 10 µl DNase I stock solution (solubilised in ddH2O), 
and 80 µl of this solution was added to the spin columns to remove DNA contaminants. 
The columns were incubated with the DNase solution for 15 min, before being washed 
with 350 µl Buffer RWT at 8,500 xg for 15 s. The columns were then washed twice with 
500 µl Buffer RPE, first at 8,500 xg for 15 s and then at 8,500 xg for 2 min.  Final RNA 
extract was eluted in 30 µl RNase-free water by centrifugation at 8,500 xg for 1 min. 
RNA concentrations were measured using the NanoDrop ND-1000 spectrophotometer 
(Thermo Fisher Scientific) at absorption wavelengths of 260 nm and 280 nm.    
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2.1.2 RNA QUALITY CONTROL 
RNA integrity was tested by electrophoresing RNA samples through RNA ScreenTape 
(Agilent Technologies) using the Agilent 2200 Tapestation System (Agilent 
Technologies). The electrophoretic trace of the RNA was used to determine the RNA 
Integrity Number (RIN), which enabled quantification of RNA integrity. In order to 
conduct these measures, the RNA ScreenTape, RNA ScreenTape Sample Buffer and RNA 
ScreenTape Ladder (all Agilent Technologies) were allowed to equilibrate to room 
temperature for 30 min. Then, 1 µl of each RNA sample, and also 1 µl RNA ScreenTape 
Ladder, was added to 5 µl RNA ScreenTape Sample Buffer. Each mix was vortexed 
using the IKA vortexer and adaptor (Agilent Technologies) at 2,000 rpm for 1 min. The 
samples were then heated to 72 °C for 3 min, immediately cooled on ice for 2 min, and 
loaded into the Agilent 2200 Tapestation System alongside the RNA ScreenTape. Gel 
electrophoresis was performed using the RNA ScreenTape programme. Completion of 
the programme provided the RIN score for each RNA sample, and RNA samples with 
scores of 8 or higher were used for experiments.  
2.1.3 REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION 
Reverse transcription polymerase chain reaction (RT-PCR) of the RNA to 
complementary DNA (cDNA) was achieved using the SuperScript III Reverse 
Transcriptase kit (Thermo Fisher Scientific) following the manufacturer's instructions. 
Typically, the desired volume of RNA was diluted in ddH2O to give a volume of 13 µl. To 
this, 1 µl oligo dT20 (50 µM) and 1 µl dNTP Mix (10 mM each of dATP, dGTP, dCTP and 
dTTP, all Thermo Fisher Scientific) were added. The samples were heated at 65 °C for 5 
min and then incubated on ice for 2 min. To the cooled samples, 4 µl 5X First-Strand 
Buffer, 1 µl 0.1 M DTT, 1 µl RNaseOUT and 1 µl SuperScript III RT (all Thermo Fisher 
Scientific) were added. The samples were then incubated at 50 °C for 1 h, and the 
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reaction was inactivated by heating at 70 °C for 15 min, as in Table 2.1. The cDNA was 
further diluted between 1:1 and 1:5 with ddH₂O as required to give the final working 
concentration of cDNA. For post-mortem tissue-derived RNA, the desired volume of 
RNA was diluted in ddH2O to give a lesser volume of 12 µl. To this, 1 µl oligo dT20 (50 
µM) and 1 µl random hexamers were added, alongside the 1 µl dNTP Mix. The heating 
to 65 °C, cooling and addition of further reagents were carried out as above. Before the 
50 °C heating step, the samples were heated to 37 °C for 10 min. Further steps were 
carried out as above, also outlined in Table 2.1.  
 RT-PCR RT-PCR post-mortem tissue 
Step Temp Time Temp Time 
1 65 °C 5 min 65 °C 5 min 
2 Further addition 
of reagents 
Further addition 
of reagents 
3 37 °C 10 min 
4 50 °C 1 h 50 °C 1 h 
5 70 °C 15 min 70 °C 15 min 
Table 2.1. PCR programmes for RT-PCR. 
2.1.4 POLYMERASE CHAIN REACTION 
Polymerase chain reactions (PCRs) were performed using the 2X PCR Master Mix 
(Thermo Fisher Scientific). A 10 µl reaction was set up, consisting of 5 µl 2X PCR Master 
Mix, 1 µl of the appropriate forward and reverse primers (10 µM), and the remaining 
volume of cDNA diluted in ddH₂O.  For certain alternative splicing events, an 
alternative reaction mix was set up consisting of three primers – either two forward 
primers and one reverse, or one forward primer and two reverse. In this case the total 
primer volume constituted 3 µl, but the total reaction volume was maintained at 10 µl. 
PCR cycling conditions for each experiment are described in Table 2.2, Table 2.3. 
Typically, the PCR consisted of an initial heating step to 95 °C for 3 min, and then 
cycling repeats between 35-40 times as required for final product volume. In each 
cycling step, DNA denaturation was conducted at 95 °C for 20 s, primer annealing at 
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between 58-62 °C for 30 s as recommended for specific primer pairs, and primer 
extension at 72 °C for 30 s. Following the PCR, samples were allowed to cool prior to 
further experiments or analysis.  
 Cryptic exon PCR Skiptic exon PCR 
Skiptic exon human 
PCR 
Step Temp Time Temp Time Temp Time 
1 95 °C 3 min 95 °C 3 min 95 °C 3 min 
2 95 °C 20 s 95 °C 20 s 95 °C 20 s 
3 60 °C 30 s 58-62 °C 30 s 60 °C 30 s 
4 72 °C 30 s 72 °C 30 s 72 °C 30 s 
 Steps 2-4 repeated 37X 
Steps 3-4 repeated 35-
37X 
Steps 3-4 repeated 
40X 
Table 2.2. PCR programmes used in this thesis (1/2). 
 
Skiptic exon human 3 
primer PCR 
3 primer 3’UTR PCR 
Long gene qPCR 
primer test 
Step Temp Time Temp Time Temp Time 
1 95 °C 3 min 95 °C 3 min 95 °C 3 min 
2 95 °C 20 s 95 °C 20 s 95 °C 20 s 
3 60 °C 30 s 58 °C 30 s 60 °C 30 s 
4 72 °C 30 s 72 °C 30 s 72 °C 30 s 
 
Steps 3-4 repeated 35-
40X 
Steps 2-4 repeated 35X 
Steps 3-4 repeated 
40X 
Table 2.3. PCR programmes used in this thesis (2/2). 
To visualise the PCR results, the product was electrophoresed on either the Agilent 
2200 Tapestation System or on 1.5 % agarose gels. The agarose gels were made by 
dissolving agarose (Thermo Fisher Scientific) in 1X Tris-borate-EDTA (TBE) buffer 
(National Diagnostics) in a microwave for 3 min. The solution was then cooled and 0.05 
µl/ml ethidium bromide (Sigma-Aldrich) was added. The solution was then poured into 
a gel cast and left to set for 20 min. Samples were loaded into the wells, with 
HyperLadder 100 bp (Bioline) used as the molecular weight marker. Gel 
electrophoresis was conducted in 1X TBE buffer at 120 V for 45 min, and the gel was 
visualised with UV light to acquire the resulting images.  
To visualise using the Agilent 2200 Tapestation System, the PCR products were 
electrophoresed on D1000 ScreenTape (Agilent Technologies). The D1000 ScreenTape, 
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D1000 Ladder and D1000 Sample Buffer (all Agilent Technologies) were allowed to 
equilibrate to room temperature for 30 min. 3 µl D1000 Sample Buffer was then added 
to 1 µl of each PCR product sample, and also 1 µl D1000 Ladder. All samples were then 
mixed using the IKA vortexer and adaptor at 2,000 rpm for 1 min, and then loaded into 
the Agilent 2200 Tapestation System along with the D1000 ScreenTape. The D1000 
ScreenTape programme was executed, and the results of the gel electrophoresis were 
visualised to analyse the size and quantity of the PCR product samples.  
2.1.5 QUANTITATIVE PCR  
Quantitative PCR (qPCR) was used to investigate mRNA expression. Primers were 
tested for dimer formation or non-specific products by electrophoresing the products 
of the qPCR programme on an agarose gel (see 'Polymerase Chain Reaction: Long gene 
qPCR primer test’). The 15 µl qPCR mix consisted of 7.5 µl PowerUp SYBR Green Master 
Mix (Thermo Fisher Scientific), 1 µl appropriate forward and reverse primers (10 µM), 
and the remaining volume of cDNA in ddH₂O. The qPCR was performed on a 7500 Fast 
Real-Time PCR System (Thermo Fisher Scientific) to be quantified via the comparative 
CT method. The reaction involved heating to 50 °C for 20 s, 95 °C for 10 min, and then 
40 cycles of 95 °C for 15 s followed by 60 °C for 1 min, as outlined in Table 2.4. An 
optional melting curve was also subsequently used as described in steps 5-8 of Table 
2.4. 7500 software was used to calculate the baseline and Ct values of each sample. 
Relative gene expression was calculated by subtracting the mean Ct value of reference 
genes from the Ct value of the gene of interest, to give ΔCt. The ΔCt for one sample of 
interest was then subtracted from the ΔCt of a control to give the ΔΔCt value, and by 
using the calculation 2-ΔΔCt, the relative gene expression change between two samples 
was determined. 
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  40 cycles Optional melting curve 
Temp 50 °C 95 °C 95 °C 60 °C 95 °C 60 °C 95 °C 60 °C 
Time 20 s 10 min 15 s 1 min 15 s 1 min 30 s 15 s 
Table 2.4. QPCR programme with optional melting curve step. 
2.1.6 RNA-SEQUENCING 
Following RNA quality control, RNA samples to be sequenced were normalised to the 
desired concentration, typically consisting of 500-1500ng of RNA diluted into 30 µl 
ddH₂O. For standard poly-A-purified or ribo-depleted RNA sequencing libraries, the 
library preparation and sequencing stages were outsourced to the Wellcome Trust 
Centre for Human Genetics, Oxford (WTCHG). Library preparation was conducted 
using the TruSeq Stranded mRNA HT Sample Prep Kit (Illumina) with poly-A 
purification or ribo-depletion as required. Paired-end multiplex sequencing of the 
cDNA libraries was conducted on either the HiSeq 2500 or HiSeq 4000 Sequencing 
System (both Illumina). 
Model Tissue 
Genotypes and 
sample sizes 
Read 
length (bp) 
Average reads 
per sample 
(~millions) 
F210I 
E14.5 head 
3 WT, 3 HET, 3 
HOM 
35 x2 20 
E14.5 forebrain 4 WT, 4 HOM 150 x2 60 
Adult spinal 
cord 
5 WT, 7 HET 75 x2 45 
MEFs 
3 WT, 3 HET, 3 
HOM 
50 x2 10 
M323K 
E14.5 head 
3 WT, 3 HET, 3 
HOM 
35 x2 20 
Adult spinal 
cord 
4 WT, 4 HET, 5 
HOM 
75 x2 45 
MEFs 
3 WT, 3 HET, 3 
HOM 
50 x2 10 
F210I / M323K 
compound HET 
E14.5 head 
3 WT, 3 
COMPOUND 
HET 
35 x2 20 
TDP-43-KD MEFs 3 WT, 3 KD 50 x2 10 
TDP-ALS patient Fibroblasts 4 WT, 4 HET 35 x2 25 
Table 2.5. RNA-Seq experiments conducted for this thesis. Read lengths given x2 
in paired-end datasets.  
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2.1.7 BIOINFORMATICS ANALYSIS 
RNA-Seq results were provided from the WTCHG in the FASTQ format and data 
processing was conducted by me or a member of Dr. Vincent Plagnol’s lab. All samples 
were first examined using FastQC (Andrews 2010) to check read quality and for the 
presence of adapters. Any reads determined to contain base calls of low quality (phred 
score < 20), or adaptor sequences, were trimmed with Trim Galore! 0.4.1 (Krueger 
2012). Reads were then aligned to the mouse genome mm10 or human genome hg38 
as appropriate with STAR aligner v2.4.2a using the two-pass alignment method (Dobin 
et al. 2013). The aligned reads were sorted and duplicate reads marked with NovoSort 
1.03.09 (Novocraft).  
For gene expression analysis, reads were grouped by gene to form a count matrix using 
HTSeq (Anders et al. 2015). Differential gene expression was determined using DESeq2 
(Love et al. 2014). Briefly, sample library sizes were normalised for sequencing depth 
and library composition using scaling factors calculated from the median of gene count 
ratios between each sample and the average across all samples. Genes with low 
adjusted counts were filtered from the analysis.  Variability of each gene was estimated 
using maximum likelihood estimate, and a curve was fitted to the distribution to 
provide an approximate value of dispersion across the range of normalised counts. The 
gene-wise dispersion estimates were then shrunk towards the curve using an empirical 
Bayes approach. A negative binomial generalised linear model was used to derive 
maximum likelihood estimates for the log2 fold change across two conditions and 
another empirical Bayes approach was used to shrink the log2 fold changes towards 0. 
The Wald test was used to test the shrunken log2 fold changes for statistical 
significance of differential gene expression. P-values were corrected for multiple-
testing using the Benjamini-Hochberg method with a false discovery rate of 10% as 
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suggested by the authors of DESeq2 for exploratory differential gene expression 
analysis (Love et al. 2014).  
Alternative splicing analysis was conducted using SGSeq (Goldstein et al. 2016). Briefly, 
SGSeq identifies exons and splice junctions present across all samples from spliced 
reads, and forms a splice graph which contains this information in the form of splicing 
events. Novel splicing events were included in downstream analysis. Events were 
classified appropriately as cassette exons, retained introns, alternative 5’ junctions, 
alternative 3’ junctions, alternative first exons, alternative last exons, mutually 
exclusive exons or some combination of the above. Quantification and differential use 
of these splice sites were conducted with DEXSeq (Anders et al. 2012). Normalisation 
and dispersion estimation was carried out as outlined above in differential gene 
expression analysis. Statistical analysis was conducted by fitting a generalised linear 
model accounting for the condition of interest and using chi-squared distribution to 
test whether the usage of each splicing event was statistically significant. P-values were 
corrected for multiple-testing using the Benjamini-Hochberg method with a false 
discovery rate of 1% to minimise false positives and identify reliably altered individual 
splicing events. 
2.1.8 GENE ONTOLOGY ANALYSIS 
To determine specific biological processes significantly affected in particular disease 
conditions, Gene Ontology (GO) analysis was conducted using g:Profiler (Reimand et al. 
2016). A statistical over-representation test was used in order to identify biological 
processes most represented by genes dysregulated in disease condition datasets. Over-
representation was determined by comparing the set of significantly dysregulated 
genes to the overall expressed gene set.  
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2.2 INDIVIDUAL NUCLEOTIDE RESOLUTION CROSS-LINKING AND 
IMMUNOPRECIPITATION  
Individual nucleotide resolution cross-linking and immunoprecipitation (iCLIP) was 
conducted to assess direct binding of TDP-43 to its RNA targets (Huppertz et al. 2014). 
Several solutions were prepared for this protocol – protocol is depicted in Figure 2.10, 
solutions are outlined in Table 2.6 - Table 2.10.  
 
Figure 2.10. Schematic overview of iCLIP protocol from sample crosslinking 
through to libraries ready for sequencing (Huppertz et al. 2014).  
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Lysis buffer High-salt wash PNK buffer 
5x PNK pH 6.5 
buffer 
50 mM Tris-HCl 
pH 7.4 
50 mM Tris-HCl pH 
7.4 
20 mM Tris-HCl 
pH 6.5 
350 mM Tris-HCl 
pH 6.5 
100 mM NaCl 1 M NaCl 10 mM MgCl2 50 mM MgCl2 
1 % Igepal CA-630 
(Sigma-Aldrich) 
1 % Igepal CA-630 
(Sigma-Aldrich) 
0.2 % Tween-20 5 mM dithiothreitol 
0.1 % SDS 0.1 % SDS 
  0.5 % sodium 
deoxycholate 
0.5 % sodium 
deoxycholate 
Table 2.6. Table of buffers utilised in iCLIP experiment (1/2). 
4x Ligation buffer PK buffer PK buffer + 7M 
urea 
StrepBead wash 
buffer 
200 nM Tris-HCl pH 
7.8 
100 mM Tris-HCl 
pH 7.4 
100 mM Tris-HCl 
pH 7.4 
100 mM Tris-HCl 
pH 7 
40 mM MgCl2 50 mM NaCl 50 mM NaCl 1 M NaCl 
4 mM dithiothreitol 10 mM EDTA 10 mM EDTA 10 mM EDTA 
  7 M urea 0.1 % Tween-20 
Table 2.7. Table of buffers utilised in iCLIP experiment (2/2). 
3’ end RNA 
dephosphorylation 
3’ adaptor ligation 5’ end labelling 
Reagent µl Reagent µl Reagent µl 
5X PNK pH 6.5 buffer 4 4X Ligation buffer 5 T4 PNK (NEB) 0.2 
T4 PNK (NEB) 0.5 RNA ligase (NEB) 1 32P-γ-ATP 0.5 
RNasin (Promega) 0.5 RNasin (Promega) 0.5 
10X PNK buffer 
(NEB) 
0.4 
ddH₂O 15 
Pre-adenylated 
L3-App 20 µM 
1.5 ddH₂O 2.9 
 PEG400 4  
Table 2.8. Table of reaction mixes utilised in iCLIP experiment (1/3). 
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Reverse transcription 5’ end primer ligation cDNA precipitation 
Reagent µl Reagent µl Reagent µl 
iCLIP primer 
(HPLC purified) 
1 
10X CircLigase 
buffer II 
(Epicentre) 
0.8 
Glycoblue 
(Ambion) 
1 
dNTP mix (10 mM) 0.5 
CircLigase 
(Epicentre) 
0.4 
Sodium acetate 
(3 M) pH 5.5 
40 
Heat to 70°C for 5 min MnCl2 (50 mM) 0.3 Absolute ethanol 
100
0 
5X RT buffer 2 ddH₂O 6.5 
 
 
0.1 M DTT 0.5 Heat to 60 °C for 1 h 
RNasin 0.25 
FastDigest buffer 
(Fermentas) 
3 
SuperScript III 0.25 10 µM Cut_oligo 1 
 ddH₂O 26 
Table 2.9. Table of reaction mixes utilised in iCLIP experiment (2/3). 
Preparatory PCR 
amplification 
PCR amplification 
Reagent µl Reagent µl 
cDNA 1 cDNA 10 
P5Solexa/P3Solexa 
(10 µM) 
0.25 
P5Solexa/P3Solex
a 
(10 µM) 
1 
Accuprime Supermix 1 
(Thermo Fisher 
Scientific) 
5 
Accuprime 
Supermix 1 
(Thermo Fisher 
Scientific) 
20 
ddH₂O 3.75 ddH₂O 9 
Table 2.10. Table of reaction mixes utilised in iCLIP experiment (3/3). 
2.2.1 UV CROSS-LINKING 
Dissected tissues were homogenised at a ratio of 10 µl phosphate buffered saline (PBS) 
(VWR International) per mg of tissue by thoroughly passing tissue through 
sequentially smaller pipette tips. The lysate was transferred to an appropriately sized 
tissue culture plate, placed on ice, and irradiated four times with UV light at 100 
mJ/cm² using the Stratagene Stratalinker 2400 (Agilent Technologies) at a wavelength 
of 254 nm. The lysate was then snap frozen on dry ice until further use.   
  
42 
 
2.2.2 IMMUNOPRECIPITATION AND LABELLING 
Immunoprecipitation was conducted using antibodies conjugated to magnetic beads to 
pull out the protein of interest. 100 µl Dynabeads Protein A (Thermo Fisher Scientific) 
was washed twice with 900 µl lysis buffer (Table 2.6) before being conjugated with 5 
µg of the desired antibody and further washed with 900 µl lysis buffer. A small 
proportion of the beads was not conjugated to antibody and kept to be used as a 
negative control. Separately, the cell lysate protein concentrations were measured and 
normalised using the DC Protein Assay (Bio-Rad Laboratories). To determine 
concentration, five dilutions BSA protein standards were prepared in lysis buffer at 2 
mg/ml, 1 mg/ml, 0.5 mg/ml, 0.25 mg/ml and lysis buffer only, and 5 µl were plated 
into a 96-well plate in duplicate. 5 µl protein samples were plated in duplicate 
undiluted. 20 µl reagent S, a surfactant solution for colorimetric assays, was added to 1 
ml reagent A, an alkaline copper tartrate solution, and 25 µl this mix was added to each 
standard and protein sample. 200 µl reagent B, a dilute Folin reagent, was then added 
to each sample, and the samples were put on a gentle shake for 10 min before being 
analysed using a Tecan Sunrise Reader (Tecan) to measure the absorbance signal 
intensity at 562 nm using XFluor software (Tecan).  
Once protein concentration had been standardised, samples were sonicated for ten 
cycles with alternating 30 s on/off at low intensity using the Bioruptor Sonicator 
(Diagenode). 0.1 units/ml RNase I (Thermo Fisher Scientific) and 2 µl Turbo DNase 
(Thermo Fisher Scientific) were then added to shorten RNA transcripts and remove 
bound DNA. A sample was treated with a higher concentration of 0.25 units/ml RNase I 
as a negative control. Both variants were incubated at 37 °C for 3 min shaking at 1,100 
rpm. The samples were then centrifuged at 4 °C at 21,800 xg for 10 min. These lysates 
were then mixed with the antibody-conjugated beads (or no-antibody beads as 
negative control) at 4 °C for 16 h. The beads were then washed twice with high-salt 
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wash and further twice with PNK buffer (both in Table 2.6), before being resuspended 
in 1 ml PNK buffer. The RNA transcripts attached to the immunoprecipitated protein 
were then dephosphorylated at the 3’ end using the 3’ end dephosphorylation mix 
(Table 2.8) incubated at 37 °C for 20 min in an Eppendorf Thermomixer (Eppendorf) 
shaking at 1,100 rpm. The samples were washed with PNK buffer, then high-salt wash, 
then twice more with PNK buffer. To ligate the adaptor to the 3’end of the transcripts, 
the samples were resuspended in 20 µl 3’ adaptor ligation mix (Table 2.8) and 
incubated at 16 °C for 16 h in an Eppendorf Thermomixer shaking at 1,100 rpm. The 
samples were then washed twice with PNK buffer, then high-salt wash, then again 
twice with PNK buffer. 20 % of each sample was collected for radiolabelling. In a lab 
designated to radioisotope experimentation, 4 µl 5’ end labelling mix (Table 2.8) was 
added to these samples and incubated at 37 °C for 5 min shaking in an Eppendorf 
Thermomixer at 1,100 rpm. Samples were then washed with 200 µl PNK buffer before 
20 µl NuPAGE loading buffer (Invitrogen) was added. These samples were then added 
to the remaining 80 % of samples not radiolabelled.  
2.2.3 SDS-PAGE AND NITROCELLULOSE TRANSFER 
The samples were loaded onto a 4-12 % NuPAGE Bis-Tris 1.5 mm 10-well gel 
(Invitrogen). All 20 µl each sample was loaded onto the gel, alongside 4 µl the protein 
size marker PAGE ruler plus (Fermentas). Gels were used in conjunction with the XCell 
SureLock Mini-Cell Electrophoresis System (Thermo Fisher Scientific) filled with 0.5 l 
1X NuPAGE MOPS running buffer (Invitrogen) for 50 min at 180 V. Once completed, the 
dye front was removed, and the samples transferred to 0.2 µm Protan BA85 
Nitrocellulose Membrane (Whatman) using the XCell II Blot Module (Thermo Fisher 
Scientific) filled with 1X Tris-Glycine Electroblotting Buffer (National Diagnostics) with 
10 % methanol added for 2 h at 30 V. After transfer, the membrane was washed with 
44 
 
PBS buffer and wrapped in saran wrap, before being exposed to Fuji film (Thermo 
Fisher Scientific) at -80 °C for either 1 h, 4 h or 16 h.  
2.2.4 RNA ISOLATION 
Using the high-RNase sample as a guide protein marker in the absence of RNA binding, 
the protein-RNA complexes were isolated by using the autoradiograph created in step 
2.2.3 as a mask to cut the desired product sizes from the nitrocellulose membrane. The 
membrane fragments were then placed into LoBind tubes and 200 µl PK buffer was 
added to each fragment. 10 µl proteinase K (Roche) was further added, and the mix 
was incubated at 37 °C for 20 min shaking at 1,100 rpm. 200 µl PK buffer and 7 M urea 
were then added and the mix was again incubated at 37 °C for 20 min shaking at 1,100 
rpm. The supernatant was collected and added, along with 400 µl 
Phenol:Chloroform:Isoamyl Alcohol (Sigma-Aldrich) to a 2 ml Phase Lock Gel Heavy 
tube (VWR). These were incubated at 30 °C for 5 min shaking at 1,100 rpm, and the 
phases were separated by then centrifuging for 5 min at 13,000 rpm. The aqueous 
layer was then transferred to a new tube and precipitated cDNA precipitation mix for 
16 h at -20 °C. Once precipitated, the samples were centrifuged at 4 °C for 20 min at 
15,000 rpm to collect as pellets. The pellets were resuspended in 5.5 µl ddH₂O. 
2.2.5 REVERSE TRANSCRIPTION 
Reverse transcription of the RNA to cDNA was carried out with the reverse 
transcription mix (Table 2.9). Once all reagents had been added, the samples were 
incubated at 25 °C for 5 min, 42 °C for 20 min, 50 °C for 40 min, 80 °C for 5 min and 
then cooled to 4 °C. 1.65 µl 1 M NaOH was then added and samples were incubated at 
98 °C for 20 min to hydrolyse remaining RNA. 20 µl 1 M Hepes-NaOH pH 7.3 was added 
to eliminate radioactivity. At this point, the biological replicate samples were 
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multiplexed. 350 µl TE buffer and cDNA precipitation mix (Table 2.9) were both added 
to the samples to precipitate the cDNA at -20 °C for 16 h.  
2.2.6 GEL PURIFICATION 
Precipitate was collected by centrifuging samples at 4 °C for 15 min at 15,000 rpm. The 
subsequent pellet was washed with 500 µl 80 % ethanol (diluted in ddH₂O), 
centrifuged briefly to re-collect pellet, and resuspended in 6 µl ddH₂O. 6 µl 2X TBE-urea 
loading buffer (Invitrogen) was added to the cDNA, and also to the Low molecular 
weight protein marker (NEB). The XCell SureLock Mini-Cell Electrophoresis System 
was used for the gel electrophoresis, and the chamber was filled with 800 ml TBE 
running buffer. The full 12 µl of each sample was loaded to each well of a 6 % TBE-urea 
gel and electrophoresed for 40 min at 180 V. 2 µl SYBR green II stock solution was 
diluted in 10 ml TBE buffer, and the TBE-urea gel was immersed in this solution and 
visualised by UV transillumination.  
Using a scalpel blade, two bands were cut from each sample, one between 75-95 
nucleotides (nt) and the other between 95-200 nt. The isolated gel pieces were each 
placed into a 0.5 ml LoBind tube with three holes punctured into the bottom using a 21 
G needle, and each of these tubes was then placed inside a 1.5 ml LoBind tube. 400 µl 
TBE was added, and the samples were centrifuged for 5 min at 8,000 rpm. The samples 
were incubated at 37 °C for 1 h shaking at 1,100 rpm, cooled on dry ice for 2 min and 
further incubated again at 37 °C for 1 h shaking at 1,100 rpm. The liquid supernatant 
was transferred to a Costar SpinX column (Corning Incorporated) with two 1 cm 
diameter glass pre-filters (Whatman) placed inside. The columns were centrifuged for 
1 min at 13,000 rpm, and the resulting solution was added together with 400 µl RNA 
phenol/chloroform (Sigma-Aldrich) to a 2 ml Phase Lock Gel Heavy tube. These were 
incubated at 30 °C for 5 min shaking at 1,100 rpm, with phase separation subsequently 
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conducted through centrifugation for 5 min at 13,000 rpm. The aqueous portion was 
again added together with 400 µl RNA phenol/chloroform (Sigma-Aldrich) to a 2 ml 
Phase Lock Gel Heavy tube, incubated at 30 °C for 5 min shaking at 1,100 rpm, and 
phase separated by centrifugation for 5 min at 13,000 rpm. The aqueous layer was then 
transferred to a new 1.5 ml LoBind tube and precipitated with cDNA precipitation mix 
for 16 h at -20 °C. 
2.2.7 5’ END LIGATION OF PRIMER TO CDNA 
Precipitate was collected by centrifuging samples at 4 °C for 15 min at 15,000 rpm. The 
subsequent pellet was washed with 500 µl 80 % ethanol (diluted in ddH₂O), 
centrifuged briefly to re-collect pellet, and resuspended in the 8 µl 5’ end primer 
ligation mix (Table 2.9). The samples were incubated at 60 °C for 1 h. and the 
remaining 30 µl oligo annealing mix was added. The oligonucleotides were annealed by 
heating samples to 95 °C for 2 min, and then successively decreasing temperature by 1 
°C every 20 s down to 25 °C. Following annealing, 2 µl BamHI (Fast Fermentas) 
restriction enzyme was incubated at 37 °C for 30 min and then at 80 °C for 5 min. 
Precipitation of the cDNA was conducted using the cDNA precipitation mix for 16 h at -
20 °C.  
2.2.8 PCR AMPLIFICATION 
Prior to PCR amplification of the entire cDNA, a preparatory PCR was conducted on a 
small portion of cDNA to identify the appropriate number of cycles to be used for 
amplification. The preparatory PCR mix (Table 2.10) was processed using the PCR 
programme in Table 2.11. Samples were heated to 94 °C for 2 min, before undergoing 
20-30 cycles of 94 °C for 15 s, 65 °C for 15 s and 68 °C for 45 s, with cycle number being 
approximated by PCR product concentration. Finally, samples were heated to 68 °C for 
3 min and then cooled.   
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  20-30 cycles  
Temp 94 °C 94 °C 65 °C 68 °C 68 °C 
Time 2 min 15 s 15 s 45 s 3 min 
Table 2.11. PCR programme for preparatory PCR amplification. 
The PCR product was then mixed with 2 µl 5X TBE loading buffer and loaded onto a 6 
% TBE gel. The XCell SureLock Mini-Cell Electrophoresis System was used for the gel 
electrophoresis, and the chamber was filled with 800 ml TBE running buffer. The 
samples were electrophoresed at 180 V for 25 min. 2 µl SYBR green II stock solution 
was diluted in 10 ml TBE buffer, and the TBE-urea gel was immersed in this solution 
and visualised by UV transillumination. If over-amplification was present – in the form 
of smears extending above a solid band – then the cycle number was re-adjusted until 
over-amplification was no longer present. Once the desired cycle number had been 
established, the remaining cDNA was amplified. This was carried out in batches of two 
to guard against PCR failure ending the experiment, and the cycle number was reduced 
by one to adjust for the higher concentration of cDNA being used. The PCR 
amplification mix (Table 2.10) was used, and the PCR programme was the same as for 
the preparatory PCR amplification with the additional slight cycle number adjustment. 
All PCR products were then multiplexed. The ratio for the multiplexing of the shorter 
and longer bands was determined by the intensity of the signal from the TBE gel under 
UV light.  
2.2.9 PURIFICATION OF LIBRARIES 
Purification of the multiplexed libraries is conducted to remove remaining PCR 
primers. To do this, 1.8 µl paramagnetic AMPure XP beads (Beckman Coulter) were 
added per 1 µl PCR product and mixed. The samples were left to bind for 5 min, and the 
beads were then collected using a magnetic stand. The beads were washed twice with 
500 µl 70 % ethanol (diluted in ddH₂O) and left to ensure the complete evaporation of 
the ethanol. The purified product was eluted in 40 µl TE buffer and vortexed for 30 s.  
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2.2.10 LIBRARY QUANTIFICATION AND SEQUENCING 
To establish the concentration of the cDNA libraries using the Agilent 2200 Tapestation 
System, the PCR products were electrophoresed on D1000 ScreenTape. The D1000 
ScreenTape, D1000 Ladder and D1000 Sample Buffer were allowed to equilibrate to 
room temperature for 30 min. 3 µl D1000 Sample Buffer was then added to 1 µl the 
multiplexed library, and also 1 µl D1000 Ladder. All samples were then mixed using the 
IKA vortexer and adaptor at 2,000 rpm for 1 min, and then loaded into the Agilent 2200 
Tapestation System along with the D1000 ScreenTape. The D1000 ScreenTape 
programme was performed, and the results of the gel electrophoresis produced the 
size range and nanomolar concentration of the multiplexed library. Sequencing of the 
library was kindly conducted by the Ule Lab on the HiSeq 2500 using the standard 
Illumina protocol for 50bp single-end sequencing (Huppertz et al. 2014).  
2.2.11 BIOINFORMATICS ANALYSIS 
Processing of raw iCLIP data was conducted using the iCount pipeline (Curk 2010). 
Briefly, reads were mapped to the UCSC mm10/GRCm38 genome assembly, and only 
reads mapped uniquely to a single region were used for further analysis. Crosslink 
peaks were identified using the iCount peak finding algorithm, which compared 
enrichment levels in identified binding sites in comparison to shuffled data. Crosslink 
clusters were defined as peaks which passed a false discovery rate threshold of 0.05, 
and peaks five nucleotides apart or closer were merged into the same cluster. Similar 
methods of iCLIP analysis are explored in Haberman et al. (2017). 
Kmer analysis was further conducted using the kmer enrichment branch of the iCount 
pipeline (Curk 2010). Pentamer (5-nt kmer) frequencies were determined for each 
possible pentamer in the datasets. Permutation analysis was used to determine the 
mean frequencies of each pentamer  by chance, and pentamer enrichment involved 
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determining the magnitude and significance of the increase in actual pentamer 
frequency in comparison to mean random permutation frequency.  
2.3 QUANTSEQ LIBRARY PREPARATION AND SEQUENCING 
 
Figure 2.11. Schematic overview of QuantSeq protocol used (Lexogen). 
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2.3.1 FIRST STRAND CDNA SYNTHESIS 
QuantSeq library preparation was conducted using the 3’ mRNA-Seq Library Prep Kit 
FWD (Lexogen) following manufacturer’s instructions. 150 ng of each RNA sample was 
diluted in 5 µl ddH2O. 5 µl First Strand cDNA Synthesis Mix 1 (FS1) was added to each 
sample, and the mixture was incubated at 85 °C for 3 min, and then cooled to 42 °C. A 
mastermix containing 9.5 µl First Strand cDNA Synthesis Mix 2 (FS2) and 0.5 µl Enzyme 
Mix 1 (E1) per sample was prepared, and 10 µl of this mastermix was added to each 
RNA / FS1 mixture. Each mixture was further incubated at 42 °C for 15 min. Remaining 
RNA was removed by adding 5 µl RNA Removal Solution (RS) to each sample and 
aspirating. Each sample was incubated at 95 °C for 10 min and then cooled to 25 °C.  
2.3.2 SECOND STRAND SYNTHESIS 
To create double stranded DNA (dsDNA), 10 µl Second Strand Synthesis Mix 1 (SS1) 
was added to each sample. The mixture was incubated at 98 °C for 1 min and then 
slowly cooled to 25 °C at a rate of 0.5 °C/s. The mixture was further incubated at 25 °C 
for 30 min. A mastermix containing 4 µl Second Strand Synthesis Mix 2 (SS2) and 1 µl 
Enzyme Mix 2 (E2) was prepared, and 5 µl of the mastermix added to each sample. This 
mixture was incubated at 25 °C for 15 min.  
2.3.3 PURIFICATION 
To remove residual reaction components, samples were purified. 16 µl resuspended 
Purification Beads (PB) were added to each reaction, and incubated at room 
temperature for 5 min. The samples were then placed onto a magnetic rack for 5 min, 
and while the beads were attached to the side of the tube, all supernatant was removed 
and discarded. The samples were then removed from the magnetic rack, each sample 
was resuspended in 40 µl Elution Buffer (EB) and the mixture was incubated at room 
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temperature for 2 min. 56 µl Purification Solution (PS) was added to the mixture, 
mixed thoroughly and incubated at room temperature for 5 min. The samples were 
again placed onto a magnetic rack, the beads were allowed to collect for 5 min, and the 
supernatant was removed and discarded. Whilst remaining on the magnetic rack, 120 
µl 80 % ethanol was added to the samples and incubated for 30 s. The supernatant was 
then removed and discarded, and this wash step was repeated once more. The samples 
were then left on the magnetic rack for 5 min to let the beads air dry, after which they 
were removed from the magnetic rack and rinsed with 20 µl EB and incubated at room 
temperature for 2 min. The samples were placed on the magnetic rack once more and 
this time 17 µl of the supernatant was collected and transferred to a fresh tube. 
2.3.4 LIBRARY AMPLIFICATION   
A mastermix of 7 µl PCR Mix (PCRM) and 1 µl Enzyme Mix 3 (E3) was prepared for 
each sample. 8 µl of the mastermix was added to each 17 µl library sample. 5 µl i7 index 
was added per sample, ensuring a unique i7 index was used for each library. The 
library was amplified by initially heating to 98 °C for 30 s, then 26 cycles consisting of 
each of 98 °C for 10 s, 65 °C for 20 s and 72 °C for 1 min, and then a final heating of 72 
°C for 1 min followed by cooling to 10 °C, as outlined in Table 2.12 below. 
  26 cycles  
Temp 98 °C 98 °C 65 °C 72 °C 72 °C 
Time 30 s 10 s 20 s 30 s 1 min 
Table 2.12. PCR programme for QuantSeq library amplification. 
2.3.5 LIBRARY PURIFICATION 
30 µl resuspended PB was added to each amplified library, and incubated at room 
temperature for 5 min. Samples were then placed on the magnetic rack and the beads 
were allowed to dry for 5 min. The supernatant was removed and discarded. Samples 
were removed from the magnetic rack and washed with 30 µl EB, beads resuspended 
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and incubated for 2 min. 30 µl PS was added to each sample and incubated at room 
temperature for 5 min. Samples were then placed back on the magnetic rack for 5 min, 
and the supernatant was removed and discarded. Samples were kept on the magnetic 
rack and washed with 120 µl 80 % ethanol with 30 s incubation twice. Beads were kept 
on the magnetic rack to dry for 5 min, and then 20 µl EB was added. Samples were 
removed from the magnetic rack and resuspended and incubated for 2 min. Samples 
were again placed onto the magnetic rack for 5 min, and this time the 17 µl supernatant 
was transferred to a fresh tube as final libraries.  
2.3.6 LIBRARY QUANTIFICATION AND SEQUENCING 
To establish the concentration of the cDNA libraries using the Agilent 2200 Tapestation 
System, the PCR products were electrophoresed on D1000 ScreenTape. The D1000 
ScreenTape, D1000 Ladder and D1000 Sample Buffer were allowed to equilibrate to 
room temperature for 30 min. 3 µl D1000 Sample Buffer was then added to 1 µl of the 
multiplexed library, and also 1 µl D1000 Ladder. All samples were then mixed using the 
IKA vortexer and adaptor at 2,000 rpm for 1 min, and then loaded into the Agilent 2200 
Tapestation System along with the D1000 ScreenTape. The D1000 ScreenTape 
programme was performed, and the results of the gel electrophoresis produced the 
size range and nanomolar concentration of the multiplexed library. Sequencing of the 
library was conducted by UCL Genomics on the MiSeq using the standard Illumina 
protocol for 50bp single-end sequencing. Processing of the data was conducted by 
Gregor Rot using his published pipeline (Rot et al. 2017). 
2.4 CELL CULTURE 
Standard cell culture practice was used to grow the immortalised MEFs and human 
fibroblasts. Cells were cultured in DMEM (Gibco) supplemented with 10 % FBS 
(Invitrogen), 1 % L-glutamine (Invitrogen) and 1 % penicillin / streptomycin 
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(Invitrogen) in 75 cm2 culturing flasks in a 37 °C incubator with 5 % CO2. Cells were 
split upon 80-90% visual confluence, typically after 48-72 hrs. Splitting involved 
washing cells with PBS (Invitrogen) and then adding 4 ml 0.05 % Trypsin (Invitrogen) 
and placing cells in the incubator for 2-5 min. 5 ml of warmed culture medium was 
then added to deactivate the trypsin. Cells were then collected and centrifuged at 300 
xg for 5 min to pellet, and resuspended in 2 ml warmed culture medium. Cells were 
then re-plated in fresh culture medium in new 75cm2 flasks. Typically cells were split 
1:5. When required, cells were frozen into 1ml aliquots with 90 % cell culture medium 
and 10 % DMSO (Invitrogen) and stored at -80 °C short term, or in a liquid nitrogen 
tank long term. 
2.5 IMMUNOHISTOCHEMISTRY 
2.5.1 TISSUE FIXATION  
Tissue fixation was outsourced to the MRC Mammalian Genetics Unit, Harwell. Briefly, 
mice were exsanguinated with 4 % PBS and then fixed with 4 % paraformaldehyde 
(PFA). The brain and spinal cord were dissected out and immersion fixed in 10 % 
buffered formal saline (BFS) (Pioneer Research Chemicals). 
2.5.2 TISSUE PROCESSING 
The brain and spinal cord were detached, and the spinal cord was further dissected 
into the cervical, thoracic and lumbar components. The cervical and lumbar regions 
were further equally subdivided into three regions, and the thoracic was subdivided 
into two regions, giving eight pieces of spinal cord tissue per animal. Each piece of 
tissue was placed into a plastic biopsy cassette in a pre-determined orientation and 
immersed in BFS. For paraffin embedding, samples were then placed in the Leica 
ASP300 S Automated Vacuum Tissue Processor (Leica Biosystems) and processed with 
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by immersion in 70 % ethanol for 1 hr once, 100 % ethanol for 1 hr five times, xylene 
for 1 hr three times and molten paraffin wax for 1 hr three times, as outlined in Table 
2.13: 
Reagent Time Repeat 
70 % Ethanol 1 h X1 
100 % Ethanol 1 h X5 
Xylene 1 h X3 
Molten paraffin wax 1 h X3 
Table 2.13. Tissue processing programme for paraffin embedding. 
Following the processing, samples were embedded in molten paraffin wax using the 
Leica EG1150H Tissue Embedding Center (Leica Biosystems) and then cooled to 
solidify using the Leica EG1150C cold plate (Leica Biosystems).  
2.5.3 TISSUE SECTIONING 
Tissue blocks were sectioned using the Leica RM2135 Rotary Microtome (Leica 
Biosystems) at -15 °C to obtain 4 µm-thick sections. Sections were then quickly 
mounted onto Superfrost Plus Microscope slides (Thermo Fisher Scientific). Sections 
were stored at 4 °C.  
2.5.4 DAB STAINING 
3,3′-Diaminobenzidine (DAB) staining was conducted by the Division of 
Neuropathology, UCL Institute of Neurology. Briefly, slides were pre-treated with SCC1, 
and the DAB-MAP kit was then used for 8 min with the Discovery XT (Ventana Medical 
Systems) before using staining protocols detailed in Table 2.14.  
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Primary antibody Secondary antibody 
Target Species Dilution Epitope Time Target Species Dilution Time 
P62 Rabbit 1:200 Polyclonal 6 h 
Anti-
rabbit 
Swine 1:500 1 h 
TDP-43 Rabbit 1:1000 Monoclonal 12 h 
Anti-
rabbit 
Donkey 1:500 
32 
min 
Ubiquitin Rabbit 1:200 Polyclonal 4 h 
Anti-
rabbit 
Donkey 1:500 1 h 
Table 2.14. Antibodies used for immunohistochemistry using DAB staining. 
2.5.5 FLUORESCENT STAINING 
Antigen retrieval was required prior to immunohistochemical staining of the paraffin 
embedded sections. Antigen retrieval was conducted manually with the protocol in 
Table 2.15. This process involved immersing samples in xylene for 5 min three times, 
100 % ethanol for 5 min twice, 90 % ethanol for 5 min once, 70 % ethanol for 5 min 
once and ddH2O three times, submerging the samples in containers containing the 
required solution each time. 
Reagent Time Repeat 
Xylene 5 min X3 
100 % Ethanol 5 min X2 
90 % Ethanol 5 min X1 
70 % Ethanol 5 min X1 
ddH₂O 5 min X3 
Table 2.15. Section processing protocol for immunohistochemistry using 
fluorescent staining.  
Sections were then placed in a pressure cooker (Criterion) filled with 1.5 l 10 mM 
sodium citrate buffer pH 6 and heated for 10 min at the highest setting. The sections 
were then gradually cooled and washed with PBS before blocking with 10 % normal 
horse serum diluted in PBS with 0.2 % Triton X-100 for 1 h. All primary and secondary 
antibodies were diluted in 10 % normal horse serum in PBS with 0.2 % Triton X-100 
(Table 2.16). All sections were incubated with primary antibody for 16 h, and 
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secondary antibody for 1 h. Three PBS washes were conducted between the blocking 
and primary antibody stage, and primary antibody and secondary antibody stage.   
Primary antibody 
Target Species Dilution Epitope Brand 
Catalogue 
no. 
P62 
Guinea 
pig 
1:250 Polyclonal Abcam Ab91526 
TDP-43 
(C-terminal) 
Rabbit 1:1000 Polyclonal Proteintech 12892-1-AP 
TDP-43 
(monoclonal) 
Mouse 1:1000 Monoclonal Abcam Ab104223 
TDP-43 
(phosphorylated) 
Rabbit 1:1000 Polyclonal Proteintech 22309-1-AP 
Tuj1 Rabbit 1:1000 Monoclonal Sigma T2200 
Ubiquitin Rabbit 1:200 Polyclonal Santa Cruz Sc-8017 
Table 2.16. Primary antibodies used for fluorescence immunohistochemistry.  
Secondary antibody 
Target Raised in Dilution Brand 
Catalogue 
no. 
Anti-guinea 
pig 
Goat 1:500 Abcam Ab150188 
Anti-rabbit Donkey 1:500 
Thermo 
Fisher 
A-21206 
Anti-mouse Donkey 1:500 
Thermo 
Fisher 
A-21202 
Table 2.17. Secondary antibodies used for fluorescence 
immunohistochemistry. 
Following staining, sections were further washed three times with PBS and then 
mounted to Thickness No. 1.5 cover glasses (VWR) with Prolong Anti-fade Mountant 
with DAPI (Thermo Fisher Scientific). Imaging was conducted using an Inverted Zeiss 
LSM 710 confocal microscope (Carl Zeiss). 
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2.6 STATISTICAL ANALYSIS 
Statistical hypothesis testing between two independent groups conducted with the two 
sample t-test where samples can be assumed to be normally distributed, and with the 
non-parametric Mann-Whitney test where normal distribution cannot be assumed and 
sample sizes were sufficiently low. Statistical hypothesis testing between multiple 
groups conducted with a one-way ANOVA where samples can be assumed to be 
normally distributed, and with the Kruskal-Wallis test where normal distribution 
cannot be assumed and sample sizes were sufficiently low. 
P-values graphically denoted by stars: * p < 0.05, ** p < 0.01, *** p < 0.001. Unless 
otherwise stated, error bars denote the mean and standard error of the mean.  
For untargeted RNA-Seq data analysis, p-value refers to final p-value adjusted for 
multiple testing using the Benjamini-Hochberg method.  
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CHAPTER 3   
F210I MODEL TRANSCRIPTOME DYSREGULATION  
3.1 INTRODUCTION 
3.1.1 RNA RECOGNITION MOTIFS IN ALS 
The RBD of TDP-43 has been poorly studied in the context of ALS, particularly in the 
form of mouse models (Lutz 2018). This is to be expected, given the prominence of LCD 
mutations in TDP-ALS, but this does not lessen the need for understanding of how 
dysfunction of the RBD contributes to ALS pathology. Importantly, a mutation in the 
RBD of TDP-43, D169G in RRM1, has been found to cause ALS (Kabashi, Paul N. 
Valdmanis, et al. 2008). This mutation is found between α2 and β4 within loop 5 of 
RRM1 (Austin et al. 2014).  
The effect of this mutation, and the reason it results in symptoms similar to the 
numerous LCD mutations, is unclear. Study of the mutation’s effect on TDP-43 binding 
found that neither TDP-43-RNA binding nor TDP-43-hnRNP binding was substantially 
altered (Ayala et al. 2011; McDonald et al. 2011; Bentmann et al. 2012). It does, 
however, cause higher thermal stability of the protein (Austin et al. 2014), and this 
mutant TDP-43 is cleaved by caspase 3 more efficiently, resulting in greater production 
of the 35 kDa fragments (Chiang et al. 2016). This fragment has been associated with 
TDP-43 aggregation and toxicity, and the increase in cleavage efficiency was not caused 
by other TDP-ALS mutations outside the RBD, such as A90V, G287S, G294A, G298S and 
A315T (Chiang et al. 2016), suggesting that perhaps RBD mutations have a unique 
mechanism of pathology. The RBD has also been reported as important in the 
pathogenicity of the 35 kDa fragment and its role in sequestration of wildtype full-
length TDP-43 (Che et al. 2015). 
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Even in study of the RBD of TDP-43, it is RRM1 which receives the most attention, due 
to the minor role RRM2 plays in direct binding to RNA (Lukavsky et al. 2013). RRM2 
also plays a lesser role in TDP-43 binding to its target UG repeat motifs (Kuo et al. 
2009). Furthermore, there exists a strong correlation between RNA binding affinity and 
inhibitory splicing function in RRM1, but the same is not true for RRM2 (Kuo et al. 
2009). Double point mutation in two residues of the RRM2, K192A and E261A, had 
minimal effects in RNA binding affinity, whereas similar mutations in RRM1 had more 
substantial impact (Lukavsky et al. 2013). However, despite the lack of direct binding, 
RRM2 is still likely to have a strong influence in overall binding of TDP-43 with RNA. 
Interaction between RRM1 and RRM2 increases affinity for UG repeat motifs in 
comparison to RRM1 alone (Lukavsky et al. 2013). It may be involved in indirect 
control of TDP-43 dimerisation prior to target binding (Lukavsky et al. 2013), and 
additionally play a role in directing of splicing factors with less specific target motifs, 
such as hnRNP A2 (D’Ambrogio et al. 2009). Interestingly, mutation of RRM2 of TDP-43 
in NSC-34 cells was associated with cytoplasmic TDP-43- and ubiquitin-positive 
inclusions, demonstrating that RRM2 mutation could incite TDP-43 pathology (Maurel 
et al. 2018).  
RRM2 is also an area of focus in regards to TDP-43 pathology due to the cleavage of 
TDP-43. TDP-43 is cleaved to form 35 kDa and 25 kDa C-terminal fragments, both of 
which have been implicated in TDP-43 aggregation and toxicity (Johnson et al. 2008). 
In particular, the formation of the 25 kDa fragment involves cleavage of RRM2, at 
arginine residue 208. Study of this fragment has shown that it is able to recapitulate the 
pathological features of TDP-43 as seen in TDP-43 proteinopathies (Zhang et al. 2009; 
Wei et al. 2016). RRM2 is typically of stable structure, but cleavage at R208 leaves the 
remaining RRM2 region of the C-terminal fragment highly disordered and prone to 
aggregation (Wei et al. 2016). Its solubility is also lost (Zhang et al. 2009; Wang et al. 
2013; Morgan et al. 2017), and the exposed β strands may assemble into amyloid-like 
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inclusions (Wang et al. 2013; Guenther et al. 2018). Alongside this, RRM2 cleavage also 
removes inter-domain interaction in TDP-43 to expose a large proportion of the LCD, 
making this domain too more prone to aggregation (Wei et al. 2016). Therefore, RRM2 
cleavage may have dual action underlying TDP-43 proteinopathy.  
In relation to the F210I mutation, phenylalanine residues have been identified as vital 
for RNA binding properties in protein-RNA interactions (Jones et al. 2001). For TDP-43 
in particular, phenylalanine residues are crucial for UG repeat binding (Lukavsky et al. 
2013). The F210I mutation lies in the helix α1 of TDP-43, and is unlikely to be involved 
in direct RNA binding (Ramos, 2015, personal communication). However, it may be 
important for indirect modulation of TDP-43-RNA processing functionality, especially 
as it is conserved between mice and humans. This also means that study of the F210I 
mouse model may be able to recapitulate the effects of similar mutations in human 
settings.  
3.1.2 PREVIOUS STUDY OF THE F210I MOUSE MODEL  
 
Figure 3.12. TDP-43 domains and location of the F210I mutation within the 
RRM2 domain. 
 Original characterisation of the F210I mutation (Figure 3.12) was conducted in vitro, 
with initial insight into the effects of the mutation on splicing investigated using the 
cystic fibrosis transmembrane conductance regulator (CFTR) minigene assay. TDP-43 
has been well characterised in its ability bind to the UG repeats at the 3’ splice site of 
exon 9 of the CFTR gene and repress inclusion of the exon (Niksic et al. 1999; Buratti & 
Baralle 2001; Buratti et al. 2001; Pagani, Stuani, et al. 2003; Pagani, Buratti, et al. 2003; 
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Buratti et al. 2004; Ayala et al. 2006; Buratti et al. 2007). As CFTR exon 9 is not spliced 
by TDP-43 in mice (Buratti et al. 2001), a minigene construct has been designed based 
on the exon and surrounding sequences, in order to test TDP-43 splicing function in 
mouse models. Wildtype TDP-43 typically splices exon 9 of this minigene at a ratio of 
50 %, resulting in exon skipping in half of the minigene constructs, whereas siRNA-
mediated TDP-43 KD in HeLa cells results in almost complete levels of exon 9 inclusion 
in the minigene. Further tests established that both human and mouse wildtype TDP-
43 expression are able to rescue the KD effects and restore exon 9 splicing levels to 50 
% (Figure 3.13) (Ricketts 2012).  
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Figure 3.13. CFTR minigene assay showing RT-PCR results and % exon 9 
inclusion in (left) wildtype TDP-43, (middle left) TDP-43 KD, (middle right) TDP-
43 rescue with human TDP-43, (right) TDP-43 rescue with V5-tagged mouse 
TDP-43 construct in HeLa cells. Presence of TDP-43 targetting siRNA indicated by 
‘+’. Exon 9 inclusion at approximately 50 % in wildtype conditions, substantially 
increased upon TDP-43 KD and rescured by both human and mouse TDP-43 
expression. Minigene isoforms for exon 9 inclusion and skipping labelled. Cryptic 
splice site resulting in isoform between full exon 9 inclusion and skipping not 
included in measurements. Example bands for V5, TDP-43 and Tubulin labelled. 
Error bars display SEM (Ricketts, 2012).  
Having characterised wildtype TDP-43 regulation of the CFTR minigene, and the effect 
of TDP-43 KD, the effect of the F210I mutation was next investigated by transfecting 
mutated TDP-43 into HeLa cells post-siRNA-mediated TDP-43 KD and measuring 
splicing rescue levels. The mutation was found to be unable to completely rescue the 
effects of TDP-43 KD, and cause significantly greater levels of exon inclusion in the 
CFTR minigene in comparison to equivalent levels of wildtype TDP-43 (Figure 3.14). 
This suggested a deficiency in ability of F210I TDP-43 to repress the splicing of the 
exon (Ricketts 2012).  
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Figure 3.14. CFTR minigene assay showing RT-PCR results and % exon 9 
inclusion in (left) wildtype TDP-43, (middle left) TDP-43 KD, (middle right) TDP-
43 rescue with V5-tagged mouse TDP-43 construct, (right) TDP-43 rescue with 
V5-tagged mouse F210I-TDP-43 in HeLa cells. Presence of TDP-43 siRNA 
indicated by ‘+’. Exon 9 inclusion at approximately 50 % in wildtype conditions, 
substantially increased upon TDP-43 KD, rescured by wildtype mouse TDP-43 
expression, but only partially rescued by F210I mutant TDP-43 expression. 
Minigene isoforms for exon 9 inclusion and skipping labelled. Example bands for 
V5, TDP-43 and Tubulin labelled. Error bars display SEM (Ricketts 2012). 
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There was significant reduction in F210I TDP-43 ability to repress splicing of CFTR 
exon 9 in comparison to wildtype in HeLa cells upon transfection of the mutated mouse 
construct. Following this, the splicing of the CFTR minigene was tested ex vivo in 
wildtype, F210I heterozygous or F210I homozygous MEFs derived from E14.5 mice. 
After electroporation of MEFs with the minigene construct, results matched the effects 
seen in HeLa cells. F210I mutation resulted in an increase in exon 9 inclusion in the 
CFTR minigene in comparison to wildtype TDP-43, and the effect was dose dependent 
(Figure 3.15). In homozygous F210I MEFs, exon inclusion levels were close to 100 %, 
indicating almost complete failure of normal TDP-43 function, exon repression.  
 
Figure 3.15. CFTR minigene assay showing RT-PCR results and % exon 9 
inclusion in (left) wildtype TDP-43, (middle) heterozygous F210I TDP-43, (right) 
homozygous F210I TDP-43 in MEFs. Significant and dose dependent increase in 
exon 9 inclusion as a result of F210I mutation. Minigene isoforms for exon 9 
inclusion and skipping labelled. Error bars show SEM. Results from Abraham 
Acevedo Arozena. 
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Having established the apparent loss of function in TDP-43 splicing activity on the 
CFTR exon 9 minigene, known targets of TDP-43 alternative splicing regulation were 
explored to elucidate whether the reduced splicing control occurred in endogenous 
transcript targets. RT-PCR was conducted for Sort1 exon 18, an alternative splicing 
event in which TDP-43 functions to repress exon inclusion (Prudencio et al. 2012). In 
the F210I MEFs, an analogous, significant, dose-dependent reduction in exon 
repression in the CFTR exon 9 minigene was again observed (Figure 3.16). Comparable 
results were also obtained for other TDP-43-mediated alternative splicing events in 
Eif4h and Dnajc5. This effect was concordant with expected results in the context of 
loss of function in TDP-43 splicing.  
 
Figure 3.16. RT-PCR results and quantification for inclusion levels of Sort1 exon 
18 in wildtype, heterozygous F210I and homozygous F210I MEFs. Significant and 
dose dependent increase in exon 18 inclusion of Sort1 as a result of F210I 
mutation. Isoforms for exon 18 inclusion and skipping labelled. Error bars show 
SEM. Results from Abraham Acevedo Arozena. 
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Alongside the loss of splicing regulation in TDP-43 targets, the F210I mutation also 
resulted in a change in RNA binding. An electrophoretic mobility shift assay (EMSA) 
was conducted with wildtype and F210I TDP-43 of increasing concentrations, and the 
binding of TDP-43 to oligonucleotides containing six UG repeats was measured, a 
sequence to which TDP-43 binds with high affinity. Intensity for TDP-43 binding to the 
target motif was severely reduced in the F210I mutant in comparison to wildtype at 
equivalent protein concentrations (Figure 3.17). This suggested a loss of TDP-43 
binding ability to UG repeats, and, in conjunction with the loss of splicing activity, 
raised the possibility that the F210I mutation resulted in a hypomorphic allele and 
severe loss of function in TDP-43 RNA processing activity.  
 
Figure 3.17. EMSA for increasing concentrations of wildtype and F210I TDP-43 
binding to radiolabelled oligonucleotide sequences containing known TDP-43 
target motifs of six UG repeats, indicated by ‘+’. Reduction in UG repeat binding 
as a result of F210I mutation. Results from Abraham Acevedo Arozena.  
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The F210I mutation disrupted the ability of TDP-43 to regulate aspects of RNA 
processing, leading to instances of molecular dysregulation. Alongside the changes at 
the RNA level, TDP-43 protein localisation in MEFs was also investigated. However, in 
this aspect there were no differences evident in the F210I heterozygous or 
homozygous models, with TDP-43 primarily nuclear-localised with no sign of 
cytoplasmic mislocalisation or aggregates.  
The F210I mouse model was also re-derived following characterisation of the ENU 
mutagenesis-induced mutation, as described in 1.3.3 TDP-ALS models, in order to 
study the phenotype that would result from the effects the mutation. Mice were 
backcrossed from the founder C57BL/6J / DBA/2J mixed background to a pure 
C57BL/6J background (Ricketts 2012). As previously outlined, developmental 
knockout of TDP-43 is rapidly lethal in early embryonic life (Kraemer et al. 2010; Wu et 
al. 2009; Sephton et al. 2010). In keeping with this, the embryos homozygous for the 
F210I mutation were not viable, with the mutations proving perinatally lethal, 
suggesting that the F210I mutation may have considerable impact on development of 
the mouse embryo. This did, however, provide sufficient time to study the embryonic 
model for molecular and phenotypic changes, as well as obtain primary cells for 
culture, such as MEFs.  
Prior to lethality, homozygous F210I embryos showed developmental delay in size and 
weight, as well as eye, bone and cleft palate development, according to investigation by 
Erwin Pauws (Figure 3.18). This further suggested a widespread impact of the 
dysfunctional F210I TDP-43 on overall development. Heterozygous mice were broadly 
healthy and survived until adulthood with no change in lifespan or phenotype, 
implicating the autoregulatory ability of TDP-43 in ameliorating the effects of a 
hypomorphic F210I allele.  
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Figure 3.18. Phenotype in F210I embryonic mice. (Top left) Significant reduction 
in embryo size at E16.5 and E18.5 in homozygous F210I mice, (bottom left) 
significant reduction in placental weight at E16.5 and E18.5 in homozygous F210I 
mice, (right) developmental delay in the eye at E14.5, cleft palate at E14.5 and 
bone at E16.5, identified by Erwin Pauws. Error bars show SEM.  
3.2  RESULTS AND DISCUSSION 
3.2.1 RNA SEQUENCING OF F210I OVERVIEW 
The initial low-throughput investigation into the consequences of the F210I mutation 
on TDP-43 function suggested effects analogous to TDP-43 loss of function, and 
dysregulation of downstream RNA targets such as Sort1. Alongside this, the severe 
developmental phenotype in the homozygous F210I models suggested a substantial 
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impact of the mutation in TDP-43 function. To further explore this possibility and gain 
a more complete understanding of the overall landscape of F210I effects on RNA 
processing, high throughput RNA sequencing studies were conducted on several F210I 
time points and tissue types. The data was processed with specific investigation into 
differential gene expression and alternative splicing changes in mind.  
To establish the extent of RNA processing change as a result of the mutation, poly-A 
purified RNA sequencing was conducted on F210I mouse embryonic heads.  Age E14.5 
was chosen to allow study of homozygous as well as heterozygous models, enabling 
identification of dose-dependent effects. Sequencing was conducted as in 2.1.6 RNA 
sequencing, with short 35 bp paired-end reads at an approximate sequencing depth of 
20 M unique reads per sample (n = 3). Differential gene expression and alternative 
splicing analyses of the homozygous E14.5 model in comparison to wildtype, as 
outlined in 2.1.7 Bioinformatics analysis, determined 1184 differentially expressed 
genes were present in this model, alongside 67 splicing changes. Therefore it was 
evident that the F210I mutation caused widespread dysregulation in gene expression 
and splicing control even at the early developmental stages, in accordance with the 
early phenotype development in this model.    
In stark contrast to the homozygous model, the heterozygous F210I datasets suggested 
minimal differences in comparison to wildtype in alternative splicing. This was fitting 
with the absence of phenotype during development in heterozygous F210I models. 
Additionally, previous studies into mouse models hemizygous for Tardbp unanimously 
agree that there is minimal phenotype in comparison to wildtype controls at the early 
developmental stages (Wu et al. 2009; Kraemer et al. 2010; Sephton et al. 2010). Given 
the lack of impact from complete loss of function in one Tardbp allele, it follows that a 
single missense mutation in only one Tardbp allele would also have minor effects on 
mouse development. However, thorough sequencing and analysis of the adult 
70 
 
heterozygous model (n = 5), showed that signs of molecular dysregulation remained 
minimal at ages at which hemizygous Tardbp models develop motor performance 
deficits (Kraemer et al. 2010). This suggested that although the F210I mutation was 
capable of behaving as a hypomorphic allele and causing severe phenotype through 
loss of function effects, it was not equivalent to full knockout of a Tardbp allele.  
Upon more thorough investigation into the splicing events detected in the RNA-Seq 
datasets, it was apparent that a substantial number of exons contained few aligned 
reads, due to the relatively low read depth per sample. This meant that any inferring 
differential exon usage in these exons would be very difficult to do with high 
confidence. The very short reads used to conduct this sequencing, 35 bp, also meant 
the chance of a read overlapping an exon-exon boundary, and therefore containing 
information on the splice junctions present, was minimal, making splicing detection 
through junction analysis difficult.  
To enable a more thorough investigation into the evidently widespread alternative 
splicing changes present in the F210I model, another RNA-Seq dataset was generated 
from F210I E14.5 forebrain (n = 4). The sequencing for this dataset was conducted 
using much longer 150 bp paired-end reads, with a read depth of approximately 60 M 
per sample. Heterozygous models were omitted from this sequencing dataset given the 
absence of molecular changes seen previously. As with the prior sequencing dataset 
analysis, widespread RNA changes were again detected. Remarkably, 2,730 genes were 
judged to be differentially expressed, and alternative splicing analysis revealed 230 
splicing events differentially used in the homozygous F210I embryonic mouse brain. 
The marked increase in differential gene expression and alternative splicing changes 
detected is likely due to the increased power of the follow-up RNA-Seq experiment. As 
a result, this was the primary RNA-Seq dataset used to investigate RNA processing 
dysfunction in the homozygous F210I mouse.  
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RNA-Seq 
dataset 
Samples 
Read 
length 
(bp) 
Average 
reads per 
sample 
(~millions) 
Differentially 
expressed 
genes 
Alternatively 
spliced 
regions 
F210I 
embryonic 
head 
3 WT, 3 
HOM 
35 x2 20 1184 67 
F210I 
embryonic 
brain 
4 WT, 4 
HOM 
150 x2 60 2730 230 
F210I adult 
spinal cord 
5 WT, 7 
HET 
75 x2 45 16 2 
Table 3.18. Overview of F210I RNA-Seq datasets and analysis as described 
in Chapter 2 – Materials and Methods.  
3.2.2 F210I ICLIP OVERVIEW 
RNA sequencing was conducted to understand the scope of RNA processing disruption 
as a result of TDP-43 loss of function mutation. However, the initial analysis of F210I-
mutated TDP-43 interaction with target sequences through EMSA also revealed an 
indiscriminate reduction in RNA-binding. Therefore, in order to understand whether 
the loss of function effect was due to a change in transcripts targeted by F210I TDP-43, 
a change in target sequence from the high wildtype affinity to UG repeats, or a general 
reduction in RNA binding ability, we conducted individual nucleotide resolution 
crosslinking and immunoprecipitation (iCLIP) (König et al. 2010) on homozygous 
F210I E18.5 spinal cords. Libraries were successfully developed from two wildtype 
samples and two homozygous embryonic F210I forebrains. Alongside answering 
questions in general TDP-43-RNA interaction, the ability to detect TDP-43 binding sites 
on target transcripts to a single nucleotide resolution enabled us to implicate changes 
in direct TDP-43 binding in the context of patterns of RNA dysregulation.  
A total of 3,097,210 crosslinked sites were detected in the wildtype embryonic 
forebrain samples, in comparison to 2,575,533 across the homozygous embryonic 
F210I mutants. Upon filtering of these peaks as suggested in the iCount pipeline, 4,479 
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genes were detected as targets in both embryonic wildtype replicates, and 4,950 genes 
were common in both embryonic homozygous F210I samples. Interestingly, 4,690 
genes were shared targets in each of one wildtype and one homozygous F210I iCLIP 
dataset, suggesting substantial similarity in the two groups and no large scale change in 
gene targeting as a result of F210I mutation (Table 3.19).  
Sample Peaks 
Peaks FDR < 
0.05 
Genes 
Shared 
genes 
within 
genotype 
Shared 
genes 
between 
genotypes 
WT 1 1,782,003 224,668 5,521 
4,479 
4,690 
WT 2 1,582,011 292,857 6,431 
HOM 1 1,658,355 368,525 7,227 
4,950 
HOM 2 1,161,790 201,477 5,917 
Table 3.19. Overview of embryonic iCLIP datasets for wildtype and 
homozygous F210I forebrain. Analysis conducted as described in 2.2.11 
iCLIP Bioinformatics. Shared genes within genotype represents number of 
genes targeted in both replicates of one genotype. Shared genes between 
genotypes represents number of genes targeted in at least one replicate 
of each genotype.  
As previously outlined, TDP-43 has been shown to target UG repeat sequences with 
high affinity (Buratti & Baralle 2001). Wildtype TDP-43 binding to UG repeats was also 
established in our hands with the EMSA using UG repeat oligonucleotides. F210I TDP-
43 also bound to the UG repeat oligonucleotides, but with reduced intensity. To check 
whether TDP-43 binding to UG repeats was enriched in our iCLIP dataset, we analysed 
the pentamer enrichment levels for every possible pentamer in each iCLIP replicate. In 
both wildtype and F210I datasets, the two replicates showed exceptionally similar 
enrichment levels for each pentamer, with Pearson correlation coefficients > 0.95 
(Figure 3.19). Given the similarity between replicates, downstream analysis was 
conducted on grouped replicates for each dataset.  
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Figure 3.19. Scatter plot of enrichment for every pentamer in replicate iCLIP 
datasets for wildtype (left) and homozygous F210I E18.5 forebrain (right) in 
comparison to mean random predicted enrichment. Each dot represents one of 
the 1024 possible pentamer combinations. Strong correlation in pentamer 
enrichment in both wildtype and F210I datasets. 
A subset of pentamers showed much greater levels of enrichment in both wildtype and 
F210I datasets. We next analysed whether in our iCLIP data, TDP-43 preferentially 
directly bound to UG repeats as had been previously reported. We determined that the 
two most enriched pentamers were the two possible variants of UG repeats, or TG 
repeats as the case would be for cDNA – TGTGT and GTGTG. Also heavily enriched were 
all pentamers containing the 4 nt of TGTG or GTGT, and additionally many pentamers 
with a 3 nt TGT or GTG sequence (Figure 3.20). This result tallied well with previous 
reports that TDP-43 targets UG regions, and has higher affinity for longer length UG 
repeats (Ayala et al. 2005). Having observed the reduced binding of F210I TDP-43 for 
UG repeats in the EMSA, we also sought to determine whether the mutation altered 
TDP-43 targeting of UG repeats in favour of other sequences. We found that in the 
F210I iCLIP data there was enrichment for UG repeats, with the TGTGT and GTGTG 
pentamers being most heavily enriched. Furthermore, the enrichment levels for each 
pentamer were very similar between the wildtype and F210I datasets, with a Pearson 
correlation coefficient of 0.95 (Figure 3.20).  
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Figure 3.20. Pentamer enrichment for WT and homozygous F210I iCLIP datasets. 
Z-score measures enrichment of pentamer above mean predicted random 
enrichment. Pentamer sequences containing TG repeats highlighted by colour 
and size, with these pentamers enriched. Strong pentamer enrichment 
correlation with Pearson coefficient of 0.95. 
This suggested that our iCLIP data not only agreed with previous findings, but 
additionally that the F210I mutation had no substantial effect on TDP-43 targeting of 
UG repeats. Instead, the reduced binding to UG repeat nucleotides seen in the EMSA 
was likely due to a global reduction in TDP-43 binding ability to RNA due to RRM2 
mutation. This effect was further observed during iCLIP library preparation, with 
F210I TDP-43 showing reduced radio-labelled RNA intensity in comparison to 
wildtype (Figure 3.21). 
 
Figure 3.21. Autoradiograph of TDP-43-RNA complexes for two wildtype and two 
homozygous F210I samples. “dTDP-43” represents dimerised TDP-43, “mTDP-
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43” indicates monomeric TDP-43. Lower RNA signal intensity in F210I samples in 
comparison to wildtype at these markers, with protein levels having been 
normalised.  
Alongside TDP-43 target motifs, another aspect of global TDP-43 binding site analysis 
of interest was the region binding preferences of TDP-43 on target transcripts. TDP-43 
has previously been reported to bind abundantly in intronic regions of protein coding 
genes, with particularly noteworthy binding in deep intronic regions (Tollervey et al. 
2011). We determined the comparative frequency of significant TDP-43 binding peaks 
in all target transcripts, split into sub-regions (5’UTR, 3’UTR, open reading frame 
[ORF], non-coding RNA [ncRNA], intron, intergenic and antisense). We found that in 
wildtype embryonic mouse forebrain, TDP-43 overwhelmingly bound to introns of 
target transcripts (79 %). 10 % of binding was restricted to intergenic regions, with a 
minority of peaks assigned to the remaining sub-regions (Figure 3.22). Previous CLIP 
data suggested TDP-43 binding to introns constituted 58 % of all binding sites in 
mouse brain, and instead 74 % in cell lines (Tollervey et al. 2011), but this discrepancy 
may be due to the study being conducted on adult mouse brain as opposed to our 
embryonic forebrain model.   
Having determined the transcript region binding profile of wildtype TDP-43 in 
embryonic mouse forebrain, we next analysed whether the F210I mutation would have 
any effect on target regions. Once again, we found very little difference between the 
RRM mutant and wildtype TDP-43. Intron binding was again the far and away the most 
common target region (78 %) and intergenic regions the second (11 %) (Figure 3.22). 
No sub-region showed a greater than 1 % difference in proportion of TDP-43 binding. 
This, alongside the maintained targeting of UG repeat regions, suggested that F210I 
TDP-43 did not affect targeting of specific transcript regions or sequences.  
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Figure 3.22. Percentage of wildtype and homozygous F210I iCLIP clusters which 
mapped to each sub-region of transcripts. Similar proportions of sub-region 
binding in F210I in comparison to wildtype.  
3.2.3 F210I TDP-43 AUTOREGULATION 
As previously outlined in 1.1.2 TARDBP isoforms and autoregulation, TDP-43 levels are 
tightly autoregulated through a feedback mechanism involving the alternative splicing 
and polyadenylation of Tardbp transcripts as a consequence of TDP-43 binding.  
First, we confirmed that TDP-43 directly bound to Tardbp transcripts in our iCLIP 
datasets. In the wildtype mouse, TDP-43 peaks were detected throughout the entirety 
of intron 7 of the Tardbp transcript, which is the intron containing polyadenylation site 
pA1 and the region previously described to show high TDP-43 CLIP cluster density, the 
TDPBR (Figure 3.23). Alongside substantial binding in intron 7, peaks were also 
discernible in introns 3 and 6, but with far fewer individual total binding sites. This 
binding pattern was consistent with previous reports highlighting the TDPBR as the 
primary region for TDP-43 binding to Tardbp transcripts (Ayala et al. 2011; 
Polymenidou et al. 2011).  
We also sought to determine whether the F210I mutation had any effect on TDP-43 
binding to its own transcripts. The iCLIP data from the homozygous F210I model 
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showed strikingly similar binding patterns for the mutated TDP-43 protein in 
comparison to the wildtype. Once again, the majority of peaks were aligned to intron 7 
in Tardbp, across the TDPBR (Figure 3.23). Binding sites were again also detected in 
introns 3 and 6 to a lesser degree. This suggested that the F210I mutation had no 
noticeable effect on TDP-43 binding regions in Tardbp transcripts. This result was also 
fitting with global iCLIP analysis that suggested TDP-43 target motifs, sequences, and 
target regions were not altered in the F210I model.  
 
 
Figure 3.23. Tardbp transcript with iCLIP peak sites denoting TDP-43 binding in 
wildtype and homozygous F210I iCLIP datasets. Similar binding sites in F210I 
iCLIP dataset in comparison to wildtype.  
Alongside the UG repeat oligonucleotide EMSA experiment on wildtype and F210I TDP-
43, another EMSA had previously been conducted targeting sequences based off of the 
34 nt TDPBR. Results from this EMSA showed similarity to the UG repeat EMSA, with 
F210I TDP-43 showing a reduction in binding ability to the TDPBR sequence 
oligonucleotides in comparison to wildtype (Figure 3.24). In combination with our 
iCLIP results, this experiment adds further evidence to the change in RNA binding in 
F210I TDP-43 being as a result of a general reduction in binding ability as opposed to 
specific differences in TDP-43 targeting.  
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Figure 3.24. EMSA for increasing concentrations of wildtype and F210I TDP-43 
binding to radiolabelled oligonucleotide sequences derived from the TDPBR of 
Tardbp transcripts, indicated by ‘+’. Lower signal intensity for TDPBR sequence 
binding in F210I TDP-43 in comparison to wildtype at equivalent protein 
concentrations (Ricketts 2012).  
 We established that TDP-43 targeting of the TDPBR was not substantially altered by 
the F210I mutation. However, as iCLIP is not a quantitative technique, we could not 
comment on the relative levels of TDP-43 binding in the wildtype and mutant models 
at this region. To investigate the consequences of a possible change in the 
autoregulation mechanism, we checked for changes in the level of Tardbp expression in 
the F210I model using the differential gene expression output of our RNA-Seq analysis. 
Tardbp was found to be significantly upregulated in the homozygous F210I embryonic 
forebrain dataset, with a log2 fold change of +0.57 and an adjusted p-value of 8.53e-19. 
This upregulation was in line with the expected outcome of the F210I mutation given 
its loss of function effects. An increase in Tardbp transcripts would enable a greater 
number of transcripts to be translated, leading to higher TDP-43 levels. This would in 
turn ideally compensate to some extent for the reduction in RNA binding of the F210I-
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mutant TDP-43 and the resulting RNA processing dysregulation. Importantly, increase 
in total TARDBP transcript levels is seen in post-mortem ALS spinal cord motor 
neurons (Mishra et al. 2007; Gitcho et al. 2009; Swarup, Phaneuf, Dupré, et al. 2011; 
Koyama et al. 2016). 
However, the increase in Tardbp translation would be dependent on the increase in 
Tardbp transcripts with the pA1 polyadenylation site; a mere increase in transcripts 
with pA2 and pA4 may be detectable in overall transcript expression levels but would 
not lead to an increase in protein. To understand whether the TDP-43 autoregulation 
mechanism itself was modulated to compensate for the F210I loss of function, the 
alternative splicing analysis from the RNA-Seq output was further investigated, with a 
focus around intron 7 splicing, known to be the key feature of the autoregulatory 
mechanism.  
As outlined in 1.1.2 TARDBP isoforms and autoregulation, splicing of intron 7 leads to 
usage of the pA2 polyadenylation site and subsequently the transcript is not translated. 
Retention of the intron can lead to usage of pA1 and formation of an isoform which can 
be translated to the TDP-43 protein, but it can also lead to the use of pA4 and an 
isoform that is retained in the intron and therefore not translated. When looking at 
levels of intron 7 retention, wildtype Percentage Spliced In (PSI) levels were on 
average at 95.7 %, meaning 4.3 % of sequenced transcripts contained spliced intron 7 
and would not be translated. In comparison, in the F210I model, intron 7 PSI levels for 
intron 7 retention amounted to 99.3 %, suggesting that just 0.7 % of sequenced 
transcripts would result in pA2 usage. This ΔPSI of 3.6 % would lead to changes in a 
substantial number of transcripts given the high expression levels of Tardbp, and as a 
result the difference was highly significant (adjusted p-value = 2.78e-15). Therefore, it is 
likely that a change in the autoregulation mechanism in the form of reduced intron 7 
splicing caused the increase in Tardbp transcript levels. If indeed the sequenced 
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transcripts are reflective of the spliced isoforms present prior to any degradation, then 
this would suggest that in the F210I model the autoregulatory response has shifted to 
produce almost complete levels of stable Tardbp transcript production. This would 
further imply that the ability of this mechanism to stabilise TDP-43 levels is close to its 
maximum capacity, and would therefore not be able to correct the molecular 
dysregulation that persists in the F210I model despite the autoregulation. However, 
other studies have reported far greater levels of splicing in Tardbp transcript pre-
mRNA (Sugai et al. 2018), suggesting the sequenced transcript isoforms do not 
represent an accurate snapshot of the true relative levels of each.  
It is important to note that although a proportion of transcripts were detected with 
intron 7 splicing, previous investigation into the effect of this alternative splicing has 
suggested that the resulting transcript would be unstable and lost through NMD, or 
another degradation mechanism (Eréndira Avendaño-Vázquez et al. 2012; Koyama et 
al. 2016). If this is the case, then the majority of transcripts which displayed pA2 usage 
would have very short half-lives, and the proportion of sequenced transcripts which 
showed intron 7 splicing would be severely under-representative of the total number 
of transcripts undergoing this splicing. This means that although the difference in 
splicing in the F210I model is substantial and significant, the true change may be much 
greater, but would not be detectable without incorporating a technique enabling 
sequencing of unstable transcripts, which was not conducted here.  
However, while pA2-utilising transcripts are not stable, another transcript isoform 
which is not translated, containing pA4, may be. Current studies suggest that this 
transcript is not translated either, but is not even exported into the cytoplasm and is 
instead retained in the nucleus (Eréndira Avendaño-Vázquez et al. 2012; Koyama et al. 
2016). In the nucleus, it is not apparent that the transcript is unstable or degraded in 
any manner. Therefore, in our RNA-Seq datasets, it is possible to detect this isoform 
81 
 
and compare levels with total transcript levels to gain and understanding of the 
number of Tardbp pA4 isoforms which are retained in the nucleus. As both pA1 and pA4 
result from the same pattern of splicing, this information cannot be obtained from the 
splicing output of the RNA-Seq analysis. However, by comparing the total number of 
reads in the Tardbp 3’UTR, it is evident that there is also a substantial reduction in 
reads aligning to the long transcript isoform, which would represent pA4 usage and 
therefore no translation (Figure 3.25). This would suggest a greater proportion of 
transcripts display pA1 usage. As a result there would an increase in proportion of 
transcripts being translated, in line with the expression and splicing data and the 
expected outcome given the apparent loss of function effects of the F210I mutation.  
 
Figure 3.25. Polyadenylation sites pA1 and pA4 annotated. Summed read count 
tracks for the 3’UTR of Tardbp transcripts in wildtype and homozygous F210I 
RNA-Seq datasets. Reduction in proportional read counts between pA1 and pA4 in 
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homozygous F210I RNA-Seq. Below are the iCLIP peaks denoting TDP-43 binding 
sites in wildtype and homozygous F210I iCLIP datasets, showing similarity in 
TDP-43 binding.  
The heterozygous F210I model showed no substantial molecular dysregulation, and it 
seemed likely that this was due to the autoregulation of TDP-43 producing greater 
levels of the wildtype transcripts and protein. However, in the low-depth RNA-Seq 
dataset, the heterozygous models showed no signs of this autoregulation in action. 
There was no detectable difference in intron 7 splicing, Tardbp 3’UTR long isoform 
usage, or overall Tardbp expression levels. The reason for the apparent lack of 
autoregulation is unclear, but the results in this case come with the notable caveat of 
low-depth, short read sequencing. In the adult heterozygous spinal cord dataset, again 
intron 7 splicing differences were not present, and long 3’UTR isoform usage was 
difficult to detect. However, unlike the embryonic heterozygous mouse, in the adult 
models there was a significant increase in overall Tardbp expression levels (log2 fold 
change +0.26, adjusted p-value 6.57e-3). It may be that the F210I mutation is not so 
severe as to warrant exceptional changes in autoregulation, and the subtle differences 
may not have been detected in the embryonic heterozygous dataset. In conjunction 
with effects of aging, and as TDP-43 levels naturally lower, the autoregulation may 
have become stronger, hence the significant increase in transcript expression in adult 
models. 
At the RNA level, the TDP-43 autoregulation mechanism shift as a result of the 
homozygous F210I loss of function mutation behaved exactly as expected, with a 
reduction in unstable and retained isoforms, a reduction in non-productive splicing, 
and an increase in overall Tardbp expression, all in conjunction with no obvious change 
in TDP-43 binding at the TDPBR. To examine whether the effect of this autoregulation 
was seen at the protein level, western blots for wildtype and F210I mutant TDP-43 
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protein were conducted. It would not be possible to obtain sufficient protein from 
embryonic forebrain, so protein levels were previously tested in heterozygous and 
homozygous F210I MEFs by Tom Ricketts at MRC Harwell. In contrast to the expected 
increase in protein levels given the autoregulation behaviour seen, significant 
reduction in TDP-43 protein levels in the homozygous MEFs was detected in 
comparison to wildtype, and also a trend towards lower TDP-43 levels in the 
heterozygous MEFs (Figure 3.26), although results varied by experiment (Ricketts 
2012). There would be understandable differences in the brain of the F210I mouse 
model in comparison to MEF cell tissue, but this work provides evidence that a 
reduction in TDP-43 levels does occur, alongside TDP-43 autoregulation, in the context 
of the F210I model. TDP-43 protein levels in young adult F210I heterozygous mice 
were also examined by western blot, and here a non-significant trend towards TDP-43 
downregulation (n = 3) was found (Figure 3.26), again with variable experimental 
results (Ricketts 2012). Although the adult F210I model did not show significant 
differences in Tardbp isoforms, upregulated Tardbp expression was identified, and so 
the trend towards TDP-43 protein downregulation is unexpected and surprising.  
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Figure 3.26. Western blot gel and quantification for TDP-43 in MEFs and young 
adult F210I mouse brain showing variable levels of TDP-43 in F210I models but  
significantly reduced in MEFs and trending towards a reduction in adult brain 
(Ricketts 2012). TDP-43 staining indicated in green, Actin in red. Quantification 
measured by signal intensity relative to Actin.  
Although the autoregulation change in homozygous F210I models tallies with the 
expected correction at the RNA level as a result of the loss of function effects of the 
mutation, the clear nature of the shift may come as somewhat of a surprise given 
previous study of similar mutations. Ayala et al. (2011) investigated the effects of 
mutations in the different domains of TDP-43 on the ability of the protein to 
autoregulate. To the RRM2 domain, in which the F210I mutation lies, they introduced 
F229L and F231L mutations in conjunction. In further tests, they separately introduced 
F147L and F149L mutations to the RRM1 domain. They transfected these mutated and 
tagged cDNA constructs into HEK293 cells, and measured the levels of endogenous 
TDP-43 24 hrs and 72 hrs after transfection. They found that mutation of the two 
phenylalanine residues in RRM1 completely prevented TDP-43 autoregulation, with no 
TDP-43 -
Actin- 
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change in endogenous TDP-43 protein levels even 72 hrs after overexpression was 
caused with the RRM1 mutant protein.  
In contrast, the results for RRM2 mutant expression closely resembled overexpression 
of the wildtype TDP-43, in that there was a strong autoregulatory response and, as the 
cDNA constructs could not be autoregulated, by 72 hrs endogenous TDP-43 levels had 
almost disappeared. Northern blotting for TDP-43 isoforms supported these findings, 
showing that the RRM1 mutations prevented the increase of non-productive and 
unstable isoforms, the RRM2 mutations did not, and allowed the autoregulatory 
mechanism to produce greater levels of these transcripts as was the case with 
wildtypes. These results suggested that phenylalanine mutations in the RRM2 domain 
did not cause any change in TDP-43 autoregulation, in contrast to mutation of RRM1. 
Combining this result with the possibility that the F210I mutation resides in a region of 
the RRM2 unlikely to be involved in direct RNA binding (Ramos, 2015, personal 
communication), it highlights the strong nature of the loss of function effects caused by 
the F210I mutation. Importantly, it also emphasises that mutations in RRM2 can too 
lead to changes in Tardbp autoregulation. 
3.2.4 DIFFERENTIAL GENE EXPRESSION IN F210I 
As outlined in the overview of RNA-Seq results for the F210I models, substantial 
differential gene expression was detected in the homozygous embryonic forebrain of 
these mice (2,730 genes with adjusted p-value < 0.1) (Figure 3.27), whereas 
heterozygous adults showed minimal significant changes (16 genes). Approximately 
equal instances of significant gene upregulation (1,335) and downregulation (1,395) 
were detected in the homozygous model. Similarly large scale RNA dysregulation has 
been previously reported upon TDP-43 loss of function (Polymenidou et al. 2011), 
highlighting the importance of TDP-43 in expression control of numerous genes. The 
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substantial dysregulation also caused by the F210I change, alongside the previously 
identified examples of loss of function effects in splicing and RNA binding as a result, 
further suggests that the F210I is a powerful hypomorphic mutation.  
 
Figure 3.27. Volcano plot for differential gene expression changes in homozygous 
F210I forebrain vs wildtype RNA-Seq dataset. Each dot represents one gene. 
Substantial significant changes in gene expression levels. Non-significant 
changes in grey, significant upregulation in red, significant downregulation in 
blue. Axes scaled at extremes for convenient visualisation. 
Given that approximately 13,500 genes contained reads in every sample of wildtype 
and F210I embryonic forebrain RNA-Seq, this would suggest about 20 % of the 
consistently expressed genes in this dataset showed dysregulation. Although the sheer 
number of gene expression changes may seem unreasonable, it is plausible due to the 
wide influence of TDP-43 on processing of the transcriptome. It is estimated from CLIP 
studies that TDP-43 binds to approximately 30 % of the entire mouse transcriptome 
(Polymenidou et al. 2011). To further understand the sizeable number of gene 
expression changes and identify specific pathways that may have been affected as a 
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result, gene ontology (GO) term enrichment analysis was performed on the significant 
changes, as described in 2.1.8 Gene ontology analysis. 
A total of 36 pathways and processes were found to be significantly affected by the 
gene expression changes. The majority of these were GO terms, with a particular focus 
on developmental pathways (anatomical structure development, system development, 
multicellular organism development and developmental process). Dysregulation in 
these pathways may go some way towards explaining the array of developmental 
problems in the early embryonic stages of the F210I homozygous mice, with specific 
deficits in structural development of the eye, bone and cleft palate. Also highlighted 
were pathways involved in ion channelling and transport (ion gated channel activity, 
passive transmembrane transporter activity, channel activity, ion channel activity, 
metal ion transmembrane transporter activity, transmembrane signalling receptor 
activity, cellular potassium ion transport, potassium ion transmembrane transport, 
signalling receptor activity, ion channel complex, cation channel activity, 
transmembrane transporter complex, extracellular ligand-gated ion channel activity, 
postsynapse). Unlike the developmental phenotype, no obvious link between the 
dysregulation of these pathways and the F210I phenotype has been identified, and 
given the number and specificity of these terms, it would be an avenue of study worth 
pursuing in the future. A connection between ion channel deficits and TDP-43 loss of 
function would be particularly interesting if it affected neuronal activity, which many of 
these terms could suggest.  
Intriguingly, alongside the variety of GO terms, one significantly affected pathway was 
identified from each of the KEGG and Reactome pathway databases. From the 
Reactome database, the term ‘Neuronal system’, was found to be significantly affected, 
furthering the suggestion that although a neuronal phenotype was not detected in the 
embryonic homozygous F210I mice, underlying neuronal changes may have occurred. 
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In addition to this is the term ‘Glutamatergic synapse’ that is highlighted from the KEGG 
database. This term neatly links the ion transport pathways affected in the GO terms to 
the neuronal system pathway affected in the Reactome, given the long-established 
reliance on glutamate transmission and recognition for motor neuron excitatory 
signalling (Baughman & Gilbert 1981). Glutamate signalling dysfunction has also been 
heavily implicated in ALS, with the prolonged excitation and slow clearance of the 
excitatory neurotransmitter proving toxic to motor neurons in ALS (Rothstein et al. 
1992; Urushitani et al. 1998; Kruman et al. 1999). The importance of this pathway to 
ALS is emphasised by the fact that for a long time Riluzole, a drug that modulates 
glutamate levels, was the only FDA-approved drug for treatment of ALS (Bensimon et 
al. 1994; Lacomblez et al. 1996). Glutamatergic phenotype was not studied in the F210I 
model, but the dysregulation of genes key to glutamatergic neurons adds weight to the 
requirement of further study of the F210I nervous system.  
3.2.5 DOWNREGULATION OF LONG GENES 
The dysregulation of such a large number of genes enabled detection of underlying 
patterns by which the genes were linked. Alongside the GO term analysis, this was also 
investigated in terms of the physical properties of the genes, not only the functional 
relevance. One pattern to emerge was the notable downregulation of the longest genes 
in particular. Analysis by Jack Humphrey determined that when ranked by level of 
dysregulation, with the most downregulated genes and most upregulated genes at 
opposite ends of the spectrum, the average intron length of the most downregulated 
genes was substantially longer than the average intron length of unchanged or 
upregulated genes (Figure 3.28). Analysis of gene regulation as a result of antisense 
oligonucleotide (ASO) – mediated KD of TDP-43 in adult mouse brain by Polymenidou 
et al. (2011) showed markedly similar results (Figure 3.28), once again highlighting the 
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similarity in effects of the F210I mutation and overall TDP-43 loss of function. The 
downregulation of long genes was not seen in adult heterozygous F210I models.  
 
Figure 3.28. Comparison of mean intron lengths in genes binned by level of 
dysregulation into equal groups in the F210I embryonic forebrain vs wildtype 
RNA-Seq dataset performed by Jack Humphrey. Mean intron length substantially 
higher in downregulated genes in the F210I dataset in comparison to wildtype. 
Similar analysis and results for TDP-43 ASO-mediated KD in grey (Polymenidou 
et al. 2011). 
To confirm the downregulation of long genes, a subset of these were selected for 
validation by qPCR, as described in 2.1.5 Quantitative PCR. The expression levels of 8 
long genes was shown to be significantly and substantially downregulated in the 
embryonic F210I homozygous forebrain in comparison to wildtype tissue (Figure 
3.29). 
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Figure 3.29. Fold changes in 8 long genes in homozygous embryonic F210I 
samples vs wildtype, each showing a significant, validated downregulation in the 
F210I model as measured by qPCR.  
Comparison of the magnitude of expression change in these genes showed that in 5 of 
the 8 genes showed very similar levels of change, whereas the other 3 showed greater 
downregulation in the qPCR validation. Given the technical stringency of RNA-Seq, it is 
likely that in some cases qPCR may overestimate the true level of expression change 
(Figure 3.30).  
 
Figure 3.30. Comparison of size of expression change in 8 long genes in 
homozygous embryonic F210I samples vs wildtype as measured by RNA-Seq and 
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qPCR. Magnitude of downregulation broadly equivalent in the two techniques, 
with qPCR in some cases resulting in overestimation of change. 
Study of TDP-43 KD resulting in long gene downregulation had also previously 
indicated that the downregulated long genes exhibited much greater levels of TDP-43 
binding in comparison to unchanged or upregulated genes. However, this was largely 
due to the increased length of the genes themselves, and the level of TDP-43 binding 
per base of transcript was not found to be substantially different in the downregulated 
genes compared to unchanged or upregulated (Polymenidou et al. 2011).  
To understand how TDP-43 binding interacted with the differently regulated genes in 
the F210I dataset, we examined the average iCLIP cluster coverage for TDP-43 binding 
in all transcripts, split by dysregulation and also gene length. Analysis by Jack 
Humphrey on genes in which the longest intron exceeded 100 kb in comparison to all 
other transcripts revealed that, in transcripts in which expression levels were 
unchanged, TDP-43 binding density was also unchanged (Figure 3.31). However, when 
these long transcripts were downregulated, they exhibited significantly higher levels of 
TDP-43 binding compared to both expression-unchanged long genes, and also 
compared to downregulated non-long genes. Intriguingly, it was also determined that 
the few long genes which displayed upregulation in the F210I model showed reduced 
TDP-43 binding density in comparison to unchanged long genes and also in 
comparison to upregulated non-long genes. This latter finding was not previously 
reported in the adult mouse TDP-43 KD study, and implies that as increased TDP-43 
binding may lead to repressed expression of long genes, an absence of TDP-43 binding 
can result in increased expression of some long genes too. The reason for this 
discrepancy in the two TDP-43 loss of function datasets is not clear, and may be related 
to the loss of full protein in TDP-43 KD as opposed to the mutation of the RBD of TDP-
43, with the LCD unaffected, in the F210I mutant model. 
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Figure 3.31. Comparison of per-base TDP-43 iCLIP cluster coverage in long and 
non-long genes also split by significant dysregulation. Long gene is here defined 
as a gene in which the longest intron exceeds 100kb in length. Genes which do 
not meet these criteria will be described as non-long genes. From left to right: 
expression-unchanged non-long genes, expression-unchanged long genes, 
downregulated non-long genes, downregulated long genes, upregulated non-long 
genes, upregulated long genes. Significantly higher levels of TDP-43 binding in 
downregulated long genes, and significantly lower levels in upregulated long 
genes. Boxplots plotted to show measurement of TDP-43 iCLIP cluster coverage 
in each group.  
The downregulation of these long genes as a result of TDP-43 binding has implications 
for the neurological aspect of ALS. It has been reported that many of the longest genes 
are involved in neuronal functioning (Polymenidou et al. 2011), and TDP-43 has been 
demonstrated to regulate transcripts that regulate neuronal development or have been 
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linked to neurodegenerative disease (Tollervey et al. 2011; Sephton et al. 2011). 
Therefore, the importance of TDP-43 regulation in these long genes linked to neuronal 
function has a strong basis. In addition to their increased length, the transcripts from 
these genes also exhibit complex splicing patterns (Zheng & Black 2013), and TDP-43 is 
also known to bind to distal sites within long introns to control splicing patterns 
(Tollervey et al. 2011).  
The precise mechanism by which TDP-43 binding regulates gene expression in general 
is unclear, as is the further, apparently specific, binding activity in relation to long gene 
regulation. One possibility is that TDP-43 binding may result in alternative splicing in 
these long intron genes, leading to unproductive transcripts. An example of this type of 
unproductive splicing-mediated expression control can be seen in the TDP-43 
autoregulation mechanism. In turn, a reduction in TDP-43 binding may mean 
alternative splicing shifts towards more stable isoforms and therefore an upregulation 
in these sequenced transcripts. The dysregulation of these long genes is also likely to 
account for some of the pathways identified from the general GO term analysis, and 
may therefore contribute to the neuronal pathways found to be most affected, namely 
glutamatergic neurons and ion channel transport. These results further indicate the 
need to study the nervous system development and functioning of the homozygous 
F210I model. Intriguingly, dysregulation in a similar subset of genes has also been 
found to result from FUS depletion, offering a connecting explanation for how mutually 
exclusive pathology of the two RBPs may both lead to similar phenotypes in ALS 
(Lagier-Tourenne et al. 2012). 
3.2.6 ALTERNATIVE SPLICING IN F210I 
Substantial changes in alternative splicing were also detected in the F210I embryonic 
homozygous RNA-Seq dataset. Of the 230 significantly altered splicing events (adjusted 
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p-value < 0.01), 81 showed a reduction in exon (or retained intron) inclusion, whereas 
85 showed increased exon or intron retention (Figure 3.32), but the splicing events 
with the largest ΔPSI values were exon inclusions.  
 
Figure 3.32. Volcano plot for cassette exon alternative splicing changes in 
homozygous F210I forebrain vs wildtype RNA-Seq dataset. Each dot represents 
one splicing event. Larger magnitude of change seen in exon inclusion events in 
comparison to exon skipping. Non-significant changes in grey, significant 
decrease in exon inclusion in red, significant increase in exon inclusion in blue. 
A further 48 events represented differences in 5’UTR and 3’UTR start sites ,with 35 
events exhibiting an increase in proximal splice site usage, and the other 13 showing 
more distal splice site use. The remaining number of splicing events were 
characterised as alternative first exon, alternative last exon or mutually exclusive exon. 
Interestingly, 74 of the 230 significantly alternatively spliced genes also showed 
significant changes in expression levels. In contrast to homozygous F210I models, 
heterozygous adult mice showed just two significantly altered splicing events.  
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As reported previously, TDP-43 KD in adult mouse striatum resulted in the 
dysregulation of 601 transcripts, compared to 2,730 in our F210I loss of function 
dataset, but 965 alternative splicing changes, versus 230 in the F210I (Polymenidou et 
al. 2011). Although it is not possible to strictly compare these numbers given the 
different methods of data processing and statistical analysis, the large discrepancy in 
number of differentially expressed and alternatively spliced genes warrants further 
comment, particularly given the similarity of the F210I and TDP-43 KD effects in 
specific long gene dysregulation. The shift away from changes in alternative splicing in 
particular may be due to the loss of function in F210I TDP-43 specifically affecting RNA 
binding. The C-terminal domain, required for protein-protein interaction, remains 
perfectly functional, and may be able to compensate for RNA binding deficits through 
modulation of splicing factor recruitment and interaction. In contrast, knockdown of 
TDP-43 levels in general would result in loss of both RNA binding and splicing factor 
interaction, which may have a more severe effect on alternative splicing control. In 
relation to modelling the TDP-43 loss in ALS, nuclear depletion of TDP-43 in motor 
neuron-like NSC-34 cells was also found to result in widespread changes in alternative 
splicing (Highley et al. 2014), and splicing changes have also been demonstrated in ALS 
patient tissue (Xiao et al. 2011). 
Importantly, despite a strong level of conservation in the TDP-43 protein structure and 
function, and shared targets for splicing control in mouse and human such as the 
Tardbp/TARDBP gene itself, there remain key differences in the two settings. One 
previous study identified five splicing changes validated to be altered upon TDP-43 KD 
in a human setting: POLDIP3, STAG2, FNIP1, BRD8 and MADD (De Conti et al. 2015). In 
the F210I mouse model, a similar feature of exon skipping was seen in the Poldip3, and 
this event had previously been reported in other studies (Shiga et al. 2012; Yang et al. 
2014), demonstrating a similar function for TDP-43 in mice and humans. However, the 
four other splicing changes identified and confirmed in the HEK293 cells were not 
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changed in the F210I model. Given the thorough sequencing conducted in the 
embryonic homozygous F210I RNA-Seq dataset, it seems likely that the lack of change 
in these splicing targets points may point to a difference in importance of TDP-43 in 
these splicing events in the two species.  
Unlike differential gene expression analysis, GO enrichment for significant changes in 
alternative splicing revealed no specifically affected pathways.  
3.2.7 CRYPTIC EXON INCLUSION 
As was the case with differential gene expression analysis, an intriguing pattern of 
change was detected in the alternative splicing behaviour in homozygous F210I 
models, namely the inclusion of “cryptic exons” in a number of transcripts. Cryptic 
exons here refer to typically intronic regions of transcripts that showed increased 
levels of splicing into processed transcripts. Unlike retained intron events, also linked 
to ALS (Luisier et al. 2018), cryptic exons are spliced by activation of unfavoured 
cryptic splice sites (Kapustin et al. 2011). Cryptic exons were first described in relation 
to TDP-43 loss of function in an investigation into TDP-43 knockout (KO) effects on 
mouse embryonic stem cells (mESCs) (Ling et al. 2015). Upon conditional KO of TDP-
43 and subsequent RNA-Seq, the authors noticed that several regions annotated as 
intronic contained read profiles similar to neighbouring exons. When they further 
analysed previously published datasets, they found the same phenomena occurring 
elsewhere also. These cryptic exons typically resembled cassette exons, but also 
involved alternative UTR sequences, exon extensions, and alternative polyadenylation 
sites. It was predicted that the majority of these cryptic exons would result in a 
premature stop codon (PTC) and cause NMD of the transcript. Concluding that TDP-43 
loss of repression was responsible for the appearance of these exons, forced repression 
of the cryptic exons ameliorated the cell-death phenotype that occurred as a result of 
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TDP-43 loss. As the cryptic exons occurred primarily in deep intronic regions, they 
were not predicted to be conserved in human settings. However, the phenomena of 
cryptic exons could be conserved, even if precise location was not, and a different set of 
cryptic exons were detected in HeLa cells upon TDP-43 loss. Crucially, two of these 
exons were further found to be increased in ALS patient tissue, suggesting a disease-
relevant role for this type of alternative splicing. Since the original study, cryptic exon 
inclusion upon TDP-43 knockdown has been further studied and corroborated, 
emphasising the role of TDP-43 loss of repression in cryptic exon inclusion (Tan et al. 
2016). 
Given the clear molecular signature of cryptic exon inclusion as a result of TDP-43 loss 
of function, we expected that the F210I mutation would cause a similar pattern of 
splicing dysregulation. Indeed, several cryptic exons were discovered in the 
homozygous F210I embryonic forebrain RNA-Seq dataset, with a sizeable overlap with 
the cryptic exons detected in mESCs (Ling et al. 2015). An example gene with a cryptic 
exon as a result of F210I mutation, Adnp2, is shown in Figure 3.33. This cryptic exon 
was also identified in mESC TDP-43 KO (Ling et al. 2015).  
 
Figure 3.33. RNA-Seq read counts from wildtype and homozygous F210I datasets 
for part of the Adnp2 gene aligned to a reference. Overlaid with sashimi plot 
showing splicing patterns in each dataset, with number of each splice event 
annotated. PSI levels for the cryptic exon are calculated and listed to the right. No 
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detected instance of alternatively spliced exon inclusion in wildtype samples, but 
approximately half of all transcripts showed exon inclusion in the F210I dataset.  
Although the methods of analysis are not clear, it seems as though cryptic exon 
detection by Ling et al. (2015) was conducted in a manual manner. We adopted a more 
statistical approach to enable discovery of cryptic exons in our alternative splicing 
analysis datasets. Cryptic exons were defined as exons repressed in wildtype tissue, 
with a PSI of less than 0.05, or 5 %. Further, they were required to be significantly 
upregulated in test datasets (p < 0.01), and also required a ΔPSI increase of at least 
0.05, with prior annotation of the exon or isoform not taken into consideration. Using 
these selection criteria, 33 cryptic exons were identified (Figure 3.34).  
 
Figure 3.34. Cryptic exon (extreme splicing change) ΔPSI and level of significance 
for each of the 33 identified cryptic exons in homozygous embryonic F210I 
samples vs wildtype RNA-Seq dataset.  
A subset of these was then validated by RT-PCR, with all showing significant and 
substantial increases in inclusion levels in the F210I model (Figure 3.35). Neither 
these, nor any other, cryptic exons were identified in the heterozygous adult F210I 
dataset. 
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Figure 3.35. Top: Diagram of two possible isoforms from RT-PCR test, with 
cryptic exon denoted in blue. Middle: Example RT-PCR results visualised on 
Tapestation gels for five targets, with cryptic exon-containing transcripts and 
wildtype transcripts labelled. Cryptic exon transcripts only clearly evident in 
F210I samples. Bottom: Graphical and statistical analysis of cryptic exon 
inclusion levels for each target in wildtype and F210I samples.  
Similar to the cryptic exons identified by Ling et al. (2015), analysis by Jack Humphrey 
suggested that the vast majority of cryptic exons would result in a PTC and eventual 
NMD in the containing transcripts. To understand the consequence of this shift in 
transcript fate, the differential expression levels of cryptic exon-containing genes were 
investigated. 12 of the 33 cryptic exon genes showed significant differences in 
expression levels in the F210I dataset (Figure 3.36). Although this is a sizeable portion, 
it is not significant to cryptic exon-type alternative splicing when compared to overall 
levels of overlap between alternatively spliced transcripts and their differential 
expression (hypergeometric test, p = 0.35); 74 out of 230 alternative spliced 
transcripts showed significant dysregulation. However, a curious finding was that of 
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the differentially expressed cryptic exon transcripts, there were equal levels of up- and 
downregulation, whereas one would expect primarily downregulation given the 
predicted NMD fate of most of these transcripts. The reason for this discrepancy is 
unclear. One possibility is that some of these transcripts are additionally otherwise 
regulated, or themselves capable of autoregulation, and an increase in total transcript 
number has been induced to compensate for the greater proportion of transcripts 
being degraded.  
 
 
Figure 3.36. Volcano plot of differential gene expression in transcripts containing 
cryptic exons in homozygous embryonic F210I samples vs wildtype. Cryptic exon 
transcripts with significant changes in gene expression are highlighted by blue 
dots and labelled.  
Further understanding of NMD involvement in cryptic exon transcript processing is 
also required to garner a clearer picture of the number and prevalence of cryptic exons 
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as a result of TDP-43 loss of function. The cryptic exons seen in our and other RNA-Seq 
datasets are often in transcripts which should be degraded by NMD. NMD can be a 
somewhat inefficient process (Cusack et al. 2011), but it is not known whether these 
transcripts are being sequenced due to NMD inefficiency in general, or whether cryptic 
exon transcripts in particular possess properties which enables them to escape NMD. 
Tagging and sequencing of nascently formed transcripts upon NMD block would 
provide considerable insight into this question, and warrants further investigation.  
Ling et al. (2015) also noted that the majority of cryptic exons which resulted from 
TDP-43 loss were surrounded by UG repeats, and using previously published HITS-
CLIP data demonstrated that these regions were directly bound by TDP-43. Jack 
Humphrey performed similar analysis and found that a large subset of cryptic exons 
identified in the F210I RNA-Seq dataset showed proximal TDP-43 binding from the 
F210I iCLIP datasets. Binding of TDP-43 was particularly common within the cryptic 
exon or proximally to it, with binding in some introns around cryptic exons occurring 
more distally (Figure 3.37).  
 
 
Figure 3.37. TDP-43 binding sites in and around cryptic exons and flanking 
intronic regions. Each track represents TDP-43 binding sites from F210I iCLIP 
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datasets for TDP-43-bound transcripts, with summed coverage displayed on top. 
The central cryptic exon length has been normalised to enable analysis 
proximity of TDP-43-intron binding. Results from Jack Humphrey.  
The direct link between TDP-43 loss of function and cryptic exon inclusion is clear, and 
these results add yet more weight to the F210I as a model for TDP-43 loss of function 
in splicing activity. However, the link between these extreme splicing changes and a 
resulting disease phenotype is much less apparent, despite the discovery of two cryptic 
exon transcript isoforms seemingly specific to ALS/FTD (Ling et al. 2015). Specifically, 
the reasons behind cryptic exon transcripts leading to cell death need to be 
disentangled. 
One possibility is that it is not the specific transcripts containing the cryptic exons 
which are important, but the nature of cryptic exons themselves. Perhaps cryptic exon 
inclusion as a result of TDP-43 loss is actually a widespread phenomenon, not yet 
identified due to the degradation of most cryptic exon isoforms, and that the existence 
of such a large number of mis-spliced transcripts leads to overuse and an eventual loss 
of control of the cell’s degradation machinery. If the specific transcripts themselves are 
not vital to the final death of the cell, then cryptic exon processing could be further 
studied in mouse models to understand their role in human settings.  
Another hypothesis may be that there exists a specific subset of transcripts crucial for 
neuronal function in which cryptic exons are repressed by TDP-43, and in which, upon 
TDP-43 loss, the resulting cryptic exon inclusion and dysregulation would lead to 
neuronal cell death. In this case, where the cryptic exons themselves are more directly 
implicated in death of the cell, there are a number of problems with studying this 
mechanism. The most crucial hurdle is that, as a result of their primarily intronic 
location, cryptic exons are not conserved between mice and humans. Therefore, 
attempting to understand specific pathways in which cryptic exon transcripts are 
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involved in the F210I model is of limited use. Although the method by which cryptic 
exons occur could be further studied, the link between this and human motor neuron 
cell death will not be clarified. Even if human models are used to investigate TDP-43 
loss, there may still exist a lack of concordance between these models and patient 
motor neurons, as cryptic exons have been shown to be cell-specific as well as species 
specific (Jeong et al. 2017). For these reasons, the method for future investigation of 
these cryptic exons must utilise human motor neuron tissue. Modelling with iPSCs may 
be possible; it is not yet clear whether cryptic exon occurrence is also age-dependent.  
Nonetheless, despite these obstacles, the strong link between cryptic exons and TDP-43 
loss means that further investigation into their precise effects is vital. This is 
particularly true as cryptic exons as a result of TDP-43 loss are not ALS specific, having 
been found in the even more common neurodegenerative disease, Alzheimer’s (Sun et 
al. 2017). Excitingly, in this case the same two isoforms found in ALS/FTD patients but 
not controls by Ling et al. (2015) are found in the Alzheimer’s cases exhibiting nuclear 
TDP-43 loss, suggesting a common link between neurodegenerative diseases. This does 
however raise questions about cryptic exon specificity to the motor neuron changes in 
ALS. Additionally, as well as other diseases, other RBP loss has also been demonstrated 
to cause cryptic exons (Ling et al. 2016; McClory et al. 2018). That this feature is 
neither disease, nor protein specific may mean it is not the key feature underlying any 
one of these diseases or protein dysfunctions, but on the other hand it raises the 
possibility that it contributes to the molecular dysregulation and phenotype in a 
variety of disorders.  
3.2.8 F210I CONCLUSIONS 
The hypothesis that the F210I mutation resulted in a hypomorphic allele, and therefore 
a model of TDP-43 loss of function, was initiated through low-throughput splicing 
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analysis of known targets CFTR exon 9 and Sort1 exon 18, alongside a global reduction 
in RNA binding. Analysis of transcriptomic and iCLIP data from the homozygous F210I 
mouse model has confirmed this prediction, with numerous parallels in molecular 
dysregulation between the homozygous mice and various TDP-43 knockdown studies. 
Intriguingly, some mutations that disrupt RNA binding of TDP-43 have actually been 
reported to ameliorate TDP-43-mediated toxicity (Voigt et al. 2010). The substantial 
differential gene expression caused by the mutation affected pathways previously 
identified as being impacted by TDP-43 loss, and linked the dysregulation to neuronal 
functions. This was furthered by the specific disruption in both TDP-43 KD and F210I 
mutation in regulation of the longest genes, again linked to neuron processes. Both 
aspects of gene expression changes suggest F210I TDP-43 can replicate some of the 
effects of nuclear TDP-43 loss seen in ALS, and therefore acts as a useful model for 
understanding the molecular dysregulation that can result.  
The ability of TDP-43 to deal with the consequences of its own depletion is also 
explored in the F210I model, revealing a strong autoregulatory response due to the 
F210I loss of function mutation in a similar manner again to TDP-43 KD. However, the 
strong shift towards more transcripts resulting in productive Tardbp isoforms to be 
translated in the F210I animal, and the substantial molecular dysregulation that occurs 
despite this, may provide insight into the limitations of the autoregulatory mechanism, 
and the widespread consequences when this limit is reached. The alternative splicing 
changes, whilst not specifically related to neurons, highlighted the key feature of 
cryptic exons, for which the F210I model RNA-Seq and iCLIP strengthened the direct 
link to TDP-43 loss of function. Although the connection to resulting phenotypes is 
poorly understood, the link to cell death suggests that cryptic exon transcripts have 
significant consequences on cell survival.  
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A key finding of two cryptic exon isoforms which so far seem to be neurodegenerative 
disease-specific further suggests these often novel transcripts may be involved in 
disease progression, and it may be progression as opposed to initiation in which 
cryptic exons prove relevant. In summary, the F210I model provides novel insight into 
the effect of TDP-43 mutation-mediated loss of function in vivo, and highlights precise 
molecular signatures for which TDP-43 is crucial in development and the dysregulation 
that occurs when this control is lost.  
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CHAPTER 4  
M323K MODEL TRANSCRIPTOME DYSREGULATION AND 
PHENOTYPE  
4.1  INTRODUCTION 
4.1.1 TDP-43 LOW COMPLEXITY DOMAIN IN ALS 
Unlike the RRM mutation studied in the F210I mouse, several models for LCD 
mutations in TDP-43 exist (reviewed in Y.-C. Liu, Chiang, & Tsai, 2013), and this is 
primarily due to the vast majority of TDP-ALS mutations occurring in the disordered 
LCD. The broad region of interest is the amyloidogenic core region, comprised of 
residues 311-360, which is a hotspot for ALS-causing mutations in TDP-43 (Buratti 
2015). Within this region is a particularly important, completely conserved 319-341 
residue region. This highly conserved amino acid sequence contains the 321-330 
residue region which results in an α helical folding, surrounded by regions of disorder 
(Lim et al. 2016). This folding structure was found to be disrupted by TDP-ALS 
mutations (Conicella et al. 2016); the altered phase separation abilities that resulted 
may indicate a possible mechanism underlying TDP-43 dysfunction in ALS.  
Studying pathology, or other molecular dysregulation caused by TDP-ALS mutations, 
however, has proven difficult. Mouse models have, until recently, almost universally 
used transgenic expression of human TDP-43 constructs incorporating TDP-ALS 
mutations alongside the endogenous mouse TDP-43 expression to study the effects of 
the mutation (De Giorgio et al. 2018). These models often display a motor phenotype ( 
Wegorzewska et al. 2009; Zhou et al. 2010). However, as alluded to in 1.3.3 TDP-ALS 
mouse models, such mice have the key drawback of not allowing distinction between 
the effects of the mutation, and the effects of TDP-43 overexpression, which is itself 
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known to be toxic (Tsai et al. 2010; Wils et al. 2010; Xu et al. 2010). Study of these 
mutations is further complicated by the differences of effects even in the TDP-ALS 
mutations found in similar regions of the LCD. Investigation into the results of four 
mutations in the hotspot region of the LCD, Q331K, G335D, M337V and Q343R, found 
that each mutation had different effects on RNA processing dysregulation and 
aggregation formation (Jiang et al. 2016). The first TDP-ALS mutations discovered – 
Q331K and M337V (Sreedharan et al. 2008) – were not found to cause TDP-43 
aggregation, despite the evident inclusions seen in TDP-ALS patients with the same 
mutations.  
One intriguing study by Arnold et al. (2013) developed transgenic mouse models based 
on the aforementioned two TDP-ALS mutations, Q331K and M337V, but importantly 
determined the overall TDP-43 levels to be similar to endogenous TDP-43 in wildtype 
controls. This model showed substantial changes in alternative splicing of TDP-43 
targets, implicating the LCD domain in controlling TDP-43 splicing ability. The mouse 
also developed motor axon degeneration and displayed signs of motor neuron death, 
making it a model for neurodegeneration. However, it displayed no TDP-43 pathology, 
a hallmark of ALS, and therefore still failed to fully recapitulate the ALS phenotype 
(Arnold et al. 2013). As well as struggling to imitate patient phenotype, mouse models 
in general have also failed to accurately show changes in the transcriptome which 
relate to the changes seen in ALS patients, such as, for example, the opposite effects in 
expression changes of genes involved in stress response (Burns et al. 2015). Although 
differences would be expected, the fact that transcriptomic changes upon processes 
such as aging are well conserved between mouse and human settings (Burns et al. 
2015) gives hope that similar correlation for disease modelling is possible.  
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4.1.2 PREVIOUS STUDY OF THE M323K MOUSE MODEL 
 
Figure 4.38. TDP-43 domains and location of the M323K mutation within the LCD. 
The M323K mutation (Figure 4.38), although not yet found as a causative mutation in 
ALS patients, lies within the 20 amino acid stretch which influences TDP-43 α helix 
structure, and therefore could have an impact in the ability of TDP-43 to phase 
separate and lead to aggregation (Conicella et al. 2016). Turbidity tests undertaken by 
Nicolas Fawzi’s lab revealed this decreased propensity for phase separation in M323K 
mutant TDP-43 in comparison to wildtype, and similar to the effects of TDP-ALS 
mutation Q331K (Figure 4.39). 
 
Figure 4.39. Turbidity of wildtype and M323K and Q331K mutated TDP-43 C-
terminal fragments from residue 267-414 in the presence of 0-500 mM NaCl 
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quantified by optical density at 600 nm wavelength light. Measurements taken at 
5 min intervals over 12 hrs, experiment by Nicolas Fawzi. 
Initial characterisations of the effects of the M323K mutation were carried out similarly 
to the F210I mutation. To determine its impact upon TDP-43 splicing function, the 
CFTR minigene assay was again employed (Buratti et al. 2001). As outlined in Chapter 3 
F210I model transcriptome dysregulation, the F210I loss of function mutation 
replicated the effects of TDP-43 KD, in that it caused increased levels of exon inclusion 
in the CFTR minigene from the 50 % level of inclusion brought about by wildtype TDP-
43. Similar testing of V5-tagged M323K TDP-43 expression in HeLa cells with siRNA-
mediated endogenous TDP-43 KD revealed that in contrast to the increased exon 
inclusion of the F210I and TDP-43 KD, M323K TDP-43 showed no change in exon 9 
inclusion levels (Figure 4.40).  
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Figure 4.40. CFTR minigene assay showing RT-PCR results and % exon 9 
inclusion in (left) wildtype TDP-43, (middle left) TDP-43 KD, (middle right) TDP-
43 rescue with V5-tagged mouse TDP-43 construct, (right) TDP-43 rescue with 
V5-tagged mouse M323K-TDP-43 in HeLa cells. TDP-43 siRNA presence in 
experiment indicated by ‘+’. Exon 9 inclusion at approximately 50 % in wildtype 
conditions, substantially increased upon TDP-43 KD, rescured by wildtype 
mouse TDP-43 expression, and similarly rescued by M323K mutant TDP-43 
expression. Minigene isoforms for exon 9 inclusion and skipping labelled. 
Example bands for V5, TDP-43 and Tubulin labelled. Error bars show SEM 
(Ricketts 2012).  
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However, when this effect was also tested ex vivo, in MEFs derived from wildtype, 
heterozygous or homozygous M323K E14.5 mice, M323K TDP-43 showed a surprising 
dose-dependent decrease in exon inclusion. Exon inclusion levels were approximately 
50 % as expected for wildtype TDP-43-mediated splicing of CFTR exon 9, but were 
significantly reduced to 35 % in homozygous M323K MEFs (Figure 4.41). As this was 
the opposite to the loss of function effects modelled by the F210I mutation and TDP-43 
KD, this CFTR minigene assay in MEFs suggested that the M323K resulted in an 
unexpected gain of function in TDP-43 splicing activity.  
 
Figure 4.41. CFTR minigene assay showing RT-PCR results and % exon 9 
inclusion in (left) wildtype TDP-43, (middle) heterozygous M323K TDP-43, 
(right) homozygous M323K TDP-43 in MEFs. Significant and dose dependent 
increase in exon 9 inclusion as a result of M323K mutation. Minigene isoforms 
for exon 9 inclusion and skipping labelled. Results from Abraham Acevedo 
Arozena. Error bars show SEM. 
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Analysis of known splicing targets of TDP-43 furthered the notion of hyperactive 
splicing of TDP-43. Exon 18 of Sort1 is repressed by TDP-43 (Prudencio et al. 2012), 
and RT-PCR experiments revealed a loss in repression in F210I settings. Concordantly, 
the gain of function effect of M323K mutation resulted in increased repression of exon 
18 in the heterozygous mice and even more so in the homozygous models (Figure 
4.42). Splicing effects opposite to the F210I mutation were also seen by RT-PCR testing 
of alternative splicing events in Eif4h and Dnajc5, fitting with the respective loss of 
function versus gain of function splicing effects of the F210I and M323K mutations.  
 
Figure 4.42. RT-PCR results and quantification for inclusion levels of Sort1 exon 
18 in wildtype, heterozygous M323K and homozygous M323K MEFs. Significant 
and dose dependent decrease in exon 18 inclusion of Sort1 as a result of M323K 
mutation. Isoforms for exon 18 inclusion and skipping labelled. Results from 
Abraham Acevedo Arozena. Error bars show SEM. 
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The F210I mutation, as well as acting as a hypomorphic allele in TDP-43 splicing, also 
showed a global reduction in RNA binding ability. The effect of a gain of function in 
TDP-43 activity on RNA binding was not known, and testing using EMSA experiments 
for TDP-43 binding to oligonucleotides containing six UG repeats, the target motif of 
TDP-43, showed no difference in M323K mutant TDP-43 compared to wildtype (Figure 
4.43). It was therefore unclear whether the M323K mutation only caused a gain of 
function in the splicing activity of TDP-43 in particular, or if it was a general gain of 
function in TDP-43 activity mirroring the varied loss of function effects of the F210I 
mutation.  
 
Figure 4.43. Quantification of EMSA for wildtype and M323K TDP-43 binding to 
oligonucleotide sequences containing known TDP-43 target motifs of six UG 
repeats. No change in DLU (Digital Light Units) suggesting no change in TDP-43 
affinity for these sequences as a result of M323K mutation. Results from 
Abraham Acevedo Arozena. 
To study the effects of the M323K mutation in vivo, the M323K mouse model was re-
derived after characterisation of the ENU mutagenesis-generated mutation. Mice were 
initially backcrossed from the founder C57BL/6J / DBA/2J mixed background to a pure 
C57BL/6J background. On the pure background homozygous embryos were perinatally 
lethal, similar to the F210I mutation, while heterozygous models were viable. MEFs 
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were obtained for study from these models, and embryonic study was also conducted 
at this stage. However, when maintained on the mixed background, homozygous 
M323K mice not only survived to adulthood, but showed no reduction in lifespan. This 
effect of different mouse backgrounds has previously been reported (LeCouter et al. 
1998). Therefore, in order to study the effects of homozygous gain of function mutation 
of TDP-43, study of the adult M323K model was conducted on mice of mixed C57BL/6J 
/ DBA/2J background.  
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4.2 RESULTS AND DISCUSSION 
4.2.1 RNA SEQUENCING OF M323K OVERVIEW 
Investigation of splicing changes as a result of the M323K mutation in the LCD of TDP-
43 revealed a surprising counter-effect to the modulation seen as a result of TDP-43 KD 
or loss of function in the F210I, suggesting an unexpected gain of function in TDP-43 
splicing activity, in known splicing targets such as Sort1, Eif4h and Dnajc5. To 
investigate whether this gain of function held true across the transcriptome of TDP-43 
targets, and contrast the effects to the loss of function in splicing caused by the F210I 
mutation, we conducted RNA-Seq on the M323K model at the embryonic and adult 
time points, once again focusing on differential gene expression and alternative 
splicing.  
Initial sequencing of the M323K model was conducted on heterozygous and 
homozygous M323K E14.5 mouse heads, in keeping with the original F210I 
sequencing. Sequencing was conducted as described in 2.1.6 RNA Sequencing, using 35 
bp paired-end reads with sequencing depth of approximately 20 M unique reads per 
sample (n = 3). Differential gene expression and alternative splicing analyses were 
conducted as outlined in 2.1.7 Bioinformatics analysis. Similarly to the F210I model, 
heterozygous mice showed minimal changes in RNA dysregulation, with two significant 
changes in gene expression and a further two significant splicing alterations. 
Furthermore, however, comparatively few changes were also detected in the 
homozygous M323K embryonic model in comparison to the homozygous F210I, with 
53 differentially expressed genes and 11 splicing changes. This suggested that the 
M323K mutation had a reduced impact in RNA regulation during development of the 
mouse, in keeping with the ability of the homozygous M323K mice, but not the 
homozygous F210I mice, to survive until adulthood with no change in lifespan on a 
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mixed background. This difference also may be due to the absence of the global change 
in RNA binding ability in the M323K models as outlined in 4.1.2 Previous study of the 
M323K mouse model, in contrast to the reduced RNA binding resulting from the F210I 
mutation.  
Importantly, whereas only the heterozygous F210I models could be studied at adult 
time points, the homozygous equivalents could also be investigated in the M323K. As 
was the case with every other heterozygous model, adult heterozygous M323K mice 
showed minimal instances of RNA processing disruption. However, by 6 months, adult 
homozygous M323K spinal cord showed severe changes in both gene expression (1649 
genes significantly dysregulated) and splicing (295 splicing events significantly 
changed). The magnitude of these changes mirrored the substantial modifications seen 
in the homozygous F210I forebrain, and therefore suggested that the homozygous 
M323K mutation culminated in a serious effect on TDP-43 function in adulthood in 
mice.   
RNA-Seq 
dataset 
Samples 
Read 
length 
(bp) 
Average 
reads per 
sample 
(~millions) 
Differentially 
expressed 
genes 
Alternatively 
spliced 
regions 
M323K 
embryonic 
head 
3 WT, 3 
HOM 
35 x2 20 53 11 
M323K 
adult 
spinal cord 
4 WT, 5 
HOM 
75 x2 45 1649 295 
Table 4.20. Overview of M323K RNA-Seq experiments and analysis as 
described in Chapter 2 – Materials and Methods.  
4.2.2 M323K ICLIP OVERVIEW 
Given that the substantial molecular dysregulation in the M323K model only developed 
in adulthood, iCLIP was conducted on adult M323K tissue in contrast to the embryonic 
tissue of the F210I iCLIP dataset. Libraries were successfully developed from 
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homozygous M323K 6 month brain (wildtype n = 1, homozygous M323K n = 2). Once 
again, the aim of the experiment was to understand how TDP-43 binding in general 
was altered as a result of the M323K model in relation to the expression and splicing 
changes detected at this time point.  
The wildtype dataset revealed a total of 55,802 crosslinking peaks, compared to 45,863 
sites across the M323K homozygous model replicates. Once filtered for peaks with a 
false discovery rate of less than 0.05, as suggest by data processing in iCount,  a total of 
1,795 genes were found to contain these crosslinked sites, and whereas a total of 1,390 
genes exhibiting binding of TDP-43 across the two homozygous M323K mutant 
datasets, only 331 genes were detected to be shared targets in the latter replicates. It is 
not clear to what degree the variation across replicate gene targets, and also in peak 
numbers in general, is due to technical variability as opposed to true biological 
differences. Similarly, the large drop in total peak number in these adult mouse 
datasets compared to the embryonic wildtype and F210I data may be due to a 
combination of technical variation in experiments as well as changes in TDP-43 activity 
with aging. Although the M323K datasets may not capture the full spectrum of TDP-43 
binding in the adult mouse models, the binding sites that were detected are likely to be 
accurately representative of true binding, as 473 of the 513 gene targets detected in 
either the wildtype or homozygous M323K mutant datasets were also found to be 
targets of TDP-43 in the embryonic wildtype and homozygous F210I mutant iCLIP 
datasets too. 
Sample Peaks 
Peaks FDR < 
0.05 
Genes 
Shared 
genes 
within 
genotype 
Shared 
genes 
between 
genotypes 
WT 1 55,802 12,705 1,795 - 
513  HOM 1 16,576 2,920 643 
331 
HOM 2 29,287 6,439 1,078 
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Table 4.21. Overview of embryonic iCLIP datasets for wildtype and 
homozygous adult M323K forebrain. Analysis conducted as described in 
2.2.11 iCLIP Bioinformatics. Shared genes within genotype represents 
number of genes targeted in both replicates of one genotype. Sh ared 
genes between genotypes represents number of genes targeted in at least 
one replicate of each genotype.  
 
As described in 1.1.2 TDP-43 functions in RNA processing, TDP-43’s target motif 
typically consists of UG repeats (Buratti & Baralle 2001). Using EMSA experiments, it 
was determined that the binding to UG repeats was true for wildtype TDP-43, and also 
for M323K TDP-43 with no apparent difference. Pentamer enrichment analysis was 
conducted as outlined in 2.2.11 Bioinformatics analysis, with the UG (TG) contents of 
each pentamer annotated. In both wildtype and M323K datasets, the greatest pentamer 
enrichment was seen in pentamers containing only TG repeats: GTGTG and TGTGT.  
Further strong enrichment levels were seen for 4 nt sequences of TGTG and GTGT, and 
several variations of pentamers containing 3 nt sequences of TGT or GTG. In general, 
pentamer enrichment was very similar for wildtype and M323K TDP-43, with a 
Pearson correlation coefficient of 0.93 (Figure 4.44).  
 
Figure 4.44. Pentamer enrichment for wildtype and homozygous M323K iCLIP 
datasets. Z-scores measure pentamer enrichment in comparison to mean 
predicted random enrichment. Pentamer sequences containing TG repeats 
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highlighted by colour and size. Pentamers containing TG repeats heavily 
enriched. Strong pentamer enrichment correlation: Pearson correlation 
coefficient of 0.93.  
Similarly, embryonic F210I iCLIP data showed markedly comparable pentamer 
enrichment to the respective wildtype dataset. Given the similarity of the UG repeat 
pentamer enrichment in both mouse model datasets, the two were compared to 
highlight any subtle differences. This analysis revealed that although correlation 
remained strong, with UG pentamers the most enriched in both, there were a few 
pentamers which showed greater levels of enrichment in one mutant model compared 
to the other. However, this marginal difference was replicated in comparison of the two 
wildtype iCLIP datasets too, suggesting that it may be a difference in the binding motifs 
of embryonic TDP-43 versus adult TDP-43 (Figure 4.45).  
 
Figure 4.45. Pentamer enrichment comparisons for (left) homozygous F210I and 
homozygous M323K iCLIP datasets and (right) their respective wildtype controls, 
with enrichment measuring pentamer enrichment in comparison to mean 
predicted random enrichment. Greater differences seen in comparison to iCLIP 
datasets of the same time point. 
In summary, the iCLIP data for the M323K mouse suggested that, like the F210I model, 
the mutation had no obvious effect on TDP-43 targeting of UG repeats.  
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The F210I mutation was also not found to have any great change in sub-region binding 
of TDP-43. Splitting of transcripts into sub-regions of 5’UTR, 3’UTR, open reading 
frame (ORF), non-coding RNA (ncRNA), intron, intergenic and antisense, and analysing 
TDP-43 binding sites, showed equivalent levels of binding in the F210I model to 
wildtype in each. Similar analysis for the M323K model revealed the same result. Again, 
TDP-43 binding sites in each sub-region for the M323K mutant strongly matched 
wildtype, suggesting the M323K mutation also did not change TDP-43 target sub-
regions (Figure 4.46). Instead, there was again a greater apparent difference in 
embryonic versus adult TDP-43 binding, similar to the pentamer motif enrichments. 
Although the hierarchy of TDP-43 binding to sub-regions remained the same, the 
proportions of binding seen in adults were noticeably changed. The primary difference 
between the two time points was the reduction in intron binding, from 79 % to 53 %, 
and the increase in intergenic binding from 10 % to 29 %. The shift in the former fits 
with previous CLIP studies of TDP-43, which investigated binding in the adult mouse 
striatum and found intron binding accounted for 58 % of total (Tollervey et al. 2011), 
matching our adult mouse brain results but different to the embryonic mouse brain. 
However, the increase in intergenic region binding is as of yet unexplained.  
 
Figure 4.46. Percentage of iCLIP clusters which mapped to each sub-region of 
transcripts in (left) wildtype and homozygous F210I and (right) wildtype and 
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homozygous M323K. Similar proportions of sub-region binding in mutants 
compared to their respective wildtypes, but reduction in intron binding in the 
adult datasets versus embryonic.  
4.2.3 M323K TDP-43 AUTOREGULATION 
TDP-43 possesses an autoregulatory mechanism to control its own levels, as discussed 
in 1.1.2 TARDBP isoforms and autoregulation, and requires alternative splicing and 
polyadenylation of the Tardbp transcript.  
Given the apparent gain of function in TDP-43 splicing activity, and the resulting 
spectrum of RNA processing dysfunction, it was expected that the autoregulatory 
mechanism would shift to reduce TDP-43 levels towards wildtype equilibrium. 
However, differential gene expression output for the adult homozygous M323K mice 
revealed a clear increase in Tardbp levels instead (Figure 4.47), with a log2 fold change 
of +0.38 and an adjusted p-value of 1.44e-4 obtained from general differential gene 
expression analysis. It is similar, but of lower magnitude, to the upregulation of Tardbp 
seen in the loss of function homozygous F210I model. Whereas in F210I this would 
represent the appropriate compensation to the resulting loss of function effects, in the 
M323K model this upregulation implies an increase in TDP-43 protein levels, which in 
theory would worsen the molecular phenotype resulting from the gain of function in 
splicing activity of the protein. The reason for this increase in expression, which seems 
to be contrary to the desired restoration of wildtype TDP-43 activity, is not apparent. 
Drawing parallels with other mouse models of LCD mutations is made difficult by the 
artificial overexpression resulting from transgenic TDP-43 expression, no matter how 
slight. However, similar increases in TARDBP transcript levels have been established in 
post-mortem ALS spinal cord motor neurons (Mishra et al. 2007; Gitcho et al. 2009; 
Swarup, Phaneuf, Dupré, et al. 2011; Koyama et al. 2016). 
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Figure 4.47. DESeq2-normalised Tardbp counts (counts per million) in 
embryonic and adult M323K RNA-Seq data in heterozygous and homozygous 
models in comparison to wildtype. Significant difference in Tardbp transcripts in 
both homozygous model time points upon targeted analysis.  
The influence of TDP-43’s autoregulatory mechanism underlying this increase in 
Tardbp expression was confirmed by splicing analysis of the Tardbp transcript. Intron 
7 retention, was increased from a PSI of 89.9 % in sequenced Tardbp transcripts of 
wildtype mouse spinal cord to 95.6 % in the M323K mouse, resulting in a Δ PSI of 5.7 
%. Incredibly, this represents a stronger shift in the autoregulatory mechanism than 
the 3.6 % PSI in the homozygous F210I mouse.  
A point of note is the higher level of intron splicing, and therefore unstable transcript 
production, in the adult in comparison to the embryonic wildtype. Indeed, the 
increased intron 7 retention in the M323K adult mouse only reaches levels equivalent 
to the wildtype mouse embryo. This suggests that, provided the level of unstable 
Tardbp transcript sequencing remained constant across the two experiments, a greater 
proportion of mouse Tardbp transcripts are spliced to result in unproductive isoforms. 
This result tallies with previous investigations into the area, that found a significant 
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reduction in TDP-43 protein levels in the CNS of adult mice with no change in Tardbp 
transcript expression, implying a change in number of unproductive transcripts 
(Sephton et al. 2010; Huang et al. 2010). TDP-43 has been reported as particularly 
crucial in development (Wu et al. 2009; Kraemer et al. 2010; Sephton et al. 2010), and 
levels reduce with age (Huang et al. 2010; Sephton et al. 2010), but it is still of great 
importance in mature cells (Wu et al. 2012; Iguchi et al. 2013), and so the increase in 
transcripts targeted for degradation in adult versus embryonic models may aid the 
explanation of late onset of molecular dysregulation in the M323K models.  
Concordant with the increased Tardbp levels, and the increased intron 7 retention, and 
again contradicting the initially expected downregulation of Tardbp, a small decrease 
in Tardbp transcripts with the long isoform 3’UTR was also observed (Figure 4.48). 
This isoform represents isoforms utilising pA4, a polyadenylation site associated with 
transcript retention in the nucleus and no protein being translated. Therefore, a 
decrease in proportion of Tardbp transcripts with long 3’UTR isoforms would suggest 
an increase in TDP-43 protein production and a worsening of the gain of function 
effects brought about by the M323K mutation. 
 
124 
 
 
Figure 4.48. Polyadenylation sites pA1 and pA4 annotated. Read count tracks for 
the 3’UTR of Tardbp transcripts in embryonic wildtype and homozygous F210I 
RNA-Seq datasets, and adult wildtype and homozygous M323K RNA-Seq datasets. 
Sashimi plots show splice junction presence in each dataset. Reduction in 
proportional read counts between pA1 and pA4 in F210I and M323K mutants 
relative to respective wildtypes. Below are the iCLIP peaks denoting TDP-43 
binding sites in the wildtype F210I iCLIP dataset showing regions of TDP-43 
binding.  
Given the lack of molecular dysregulation seen in the heterozygous M323K models at 
both the developmental and adult stages, it was thought that the autoregulatory ability 
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of TDP-43 was able to suppress the effects of the mutation present in just one allele. 
However, as was the case with the heterozygous embryonic F210I model, general 
differential gene expression and alternative splicing analysis revealed no changes that 
would indicate the presence of autoregulation. TDP-43 levels were not significantly 
changed, intron 7 splicing was not altered, and differences in usage of the long 3’UTR 
isoform were not visible. However, targeted investigation specifically into Tardbp 
expression revealed significant increases in expression levels in the heterozygous and 
homozygous embryonic models. This result suggests that the increase in Tardbp 
expression is not restricted to a joint-effect of the M323K mutation and aging, and that 
the mutation is sufficient to trigger Tardbp expression increase.  
In the F210I model, the maintenance of high Tardbp levels at the RNA level to high 
TDP-43 protein levels was variable, and protein levels were not significantly higher in 
F210I mice. In a similar manner, the same was true for M323K mice. Normalised to 
wildtype TDP-43 levels, both the embryonic and adult M323K mice showed trends 
suggesting a possible increase in TDP-43, but this was highly variable and not a 
significant difference (Figure 4.49). The suspected reason for this is the comparatively 
low level of autoregulation required to compensate for the mutation in one allele 
culminating in minor changes in the aforementioned mechanisms that are not evident 
in low throughput protein analysis. TDP-43 levels are kept very stable, and so any 
autoregulatory change would only likely result in small changes in protein levels, even 
if the mutation of the protein has substantial impact on its function. Therefore, in order 
to identify this minor change, it is likely that higher sample sizes are required, and the 
3-4 samples used per genotype in this current study is insufficient, even more so given 
the apparent increase in variation in levels of TDP-43 in M323K models in comparison 
to wildtype.  
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Figure 4.49. TDP-43 protein expression levels in embryonic and adult M323K 
models normalised to wildtype controls. Quantification from western blot 
experiments for TDP-43 in comparison to Actin controls. No significant change in 
any mutant model. Results from Nicol Birsa.  
The finding that requires further clarification is the shift in autoregulation towards an 
increase in translatable Tardbp transcripts despite the gain of function effects of the 
M323K mutation. Whilst the underlying reason is unclear, the change does indicate a 
dysfunction of the ability of TDP-43 to appropriately autoregulate itself upon mutation 
of the LCD. This may provide the backdrop behind the increase in Tardbp levels, 
subsequent increase in cytoplasmic protein levels, and resulting protein aggregates 
induced by LCD mutations in TDP-ALS. Previous study of LCD mutation has shown that 
large changes can completely prevent the ability of TDP-43 to autoregulate itself, 
showing no downregulation of endogenous Tardbp expression or endogenous TDP-43 
protein levels despite overexpression due to induced expression of mutant LCD 
TARDBP cDNA (Ayala et al. 2011). However, this mutation was a substantial deletion of 
a key regulatory region of TDP-43. The M323K mutation lies within this large deletion, 
but the single missense mutation alone was not sufficient to replicate the effect. 
Crucially, the altered regulation also replicates the effect of the F210I mutation in 
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causing increased Tardbp transcript levels, providing a common feature of TDP-43 
dysregulation culminating from both loss of function and gain of function in TDP-43 
splicing activity. The fact that this phenomenon is seen in ALS patient settings further 
suggests that both loss of function and gain of function of TDP-43 could play a role in 
disease development.  
4.2.4 DIFFERENT GENE EXPRESSION IN M323K 
As summarised in 4.2.1 RNA Sequencing of M323K overview, heterozygous M323K 
models showed minimal changes in differential gene expression at both the embryonic 
and adult time points. The same was true for homozygous M323K embryos, but in 
contrast to this in the adult homozygous M323K spinal cords 1,649 genes were found 
to show changes in gene expression with an adjusted p-value < 0.1 (Figure 4.50). As 
with the homozygous F210I model, there were broadly equal levels of gene 
upregulation (756 genes) and downregulation (893 genes). A level of gene expression 
dysregulation on par with mutation of the RBD as with the F210I mutation was 
unexpected, and highlights the key role the LCD also plays in the ability of TDP-43 to 
control expression levels of gene targets.  
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Figure 4.50. Volcano plot for differential gene expression changes in homozygous 
M323K spinal cord RNA-Seq dataset vs wildtype. Each dot represents one gene. 
Substantial significant changes in gene expression levels. Non-significant 
changes in grey, significant upregulation in red, significant downregulation in 
blue.  
Unlike the F210I gene expression changes, which clustered around pathways involved 
in development and ion transport, the mass changes in the M323K adult spinal cord 
were not enriched for any pathways in the GO, KEGG or Reactome databases. Analysis 
by Jack Humphrey further revealed that the specific downregulation of long genes 
detected in the F210I dataset was also absent in M323K mice (Figure 4.51).  
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Figure 4.51. Comparison of mean intron lengths in genes binned by level of 
dysregulation in the M323K adult spinal cord RNA-Seq dataset performed by Jack 
Humphrey. No change in mean intron length in relation to changes in gene 
expression in the M323K dataset compared to wildtype. 
Despite both the homozygous F210I and M323K models showing expression changes 
in 15-20 % of the expressed transcriptome, the overlap between datasets was only 322 
genes. This is particularly surprising considering the target motif of TDP-43, UG repeat 
sequences, was not changed in the two models. They also showed strong correlation in 
iCLIP pentamer enrichment, suggesting the two mutant TDP-43 variants still bound to 
the same regions. The reason for the relatively low level of consistency in genes 
dysregulated in the two models is not clear, but a number of variables may contribute 
towards it. A key factor is will be the difference in model age, with substantial 
differences in gene expression likely to occur between embryonic development and 
mature adult CNS tissues independent of TDP-43 activity. The locations of the 
mutations is also likely to play a role, but segregating the specific effects of these is 
difficult, especially considering the mystery around how TDP-43 controls gene 
expression of targets in general. Finally, comparison between TDP-43 loss and 
130 
 
overexpression effects on gene expression regulation in flies has previously shown low 
levels of overlap in genes dysregulated by the two conditions (Hazelett et al. 2012).  
4.2.5 ALTERNATIVE SPLICING IN M323K 
Similarly to the F210I model, the homozygous M323K mouse RNA-Seq analysis 
revealed several differentially spliced genes alongside the changes in gene expression. 
295 splicing events were significantly changed in total, and of these, 98 showed an 
increase in exon or retained intron inclusion, compared to 127 with an increase in exon 
or retained intron skipping. However, opposite to the F210I, in the M323K model the 
largest Δ PSI values were exon skipping changes (Figure 4.52).  
 
Figure 4.52. Volcano plot for cassette exon alternative splicing changes in 
homozygous M323K spinal cord RNA-Seq dataset vs wildtype. Each dot 
represents one splicing event. Larger magnitude of change seen in exon skipping 
events in comparison to exon inclusion. Non-significant changes in grey, 
significant decrease in exon inclusion in red, significant increase in exon 
inclusion in blue. 
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Alongside the cassette exons and retained introns, 30 splicing events were shifted 
towards usage of proximal splice sites, and 14 showed increase in distal splice sites. A 
small number of events were then characterised as alternative first exons, alternative 
last exons or mutually exclusive exons. Curiously, exactly the same number of changed 
alternative splicing events was present in genes that also showed significant 
dysregulation, 74, in the homozygous M323K and F210I models. Once again, both adult 
heterozygous models and the embryonic homozygous M323K model all showed 
minimal changes in alternative splicing.  
Although the differences are not great, the adult homozygous M323K spinal cord shows 
reduced gene expression changes but more alternative splicing changes than the 
embryonic homozygous F210I forebrain. Although many variables are present, this 
difference may be partially explained by the different domains of TDP-43 the two 
mutations are present in. This is particularly true for the increase splicing changes in 
the M323K, where the mutation lies in a region critical for interaction with other 
hnRNPs and other splicing factors that work concurrently with TDP-43 to control 
splicing of nascent transcripts (D’Ambrogio et al. 2009). This mutation may inhibit the 
interaction with these splicing factors, resulting in the greater levels of splicing 
dysregulation. Currently, it is not known which protein interactions would be affected 
by the M323K mutation in TDP-43, but the spliceosome in general is thought to be 
defective in ALS settings (Tsuiji et al. 2013).  
The idea that the M323K mutation caused a gain of function in TDP-43 splicing activity 
was based on the low throughput RT-PCR experiments on known TDP-43 splicing 
targets of Sort1, Eif4h and Dnajc5, which showed that while the F210I mutation caused 
increased exon inclusion comparable with TDP-43 KD, M323K TDP-43 resulted in 
converse increases in exon skipping. Having obtained RNA-Seq datasets for both the 
TDP-43 loss of function and gain of function mouse models, TDP-43 transcript targets 
132 
 
could be compared on a large scale, to analyse whether the opposite effects of the two 
mutations held true throughout the transcriptome. First we validated that the splicing 
events detected as opposite by RT-PCR held true in the RNA-Seq data (Figure 4.53). 
Interestingly, previous study of Eif4h alternative splicing, known to be controlled by 
TDP-43, had demonstrated that increased exon inclusion of the regulated exon 
occurred upon TDP-43 loss (Yang et al. 2014). This finding was replicated by both the 
adult mouse TDP-43 KD data (Polymenidou et al. 2011), and our F210I loss of function 
model. However, the previous study found no effect of TDP-43 overexpression on 
alternative splicing of this Eif4h exon. In our M323K data, the increase in exon skipping 
was confirmed by both RT-PCR and in RNA-Seq analysis. This would be expected from 
a gain of function in TDP-43 splicing, and the discrepancy to the overexpression study 
may be due to interfering variables arising from TDP-43 overexpression; such variation 
is minimised in our gain of function model with endogenous gene mutation. 
 
Figure 4.53. RNA-Seq read counts and overlaid splicing sashimi plots for Sort1 
and Eif4h alternative splicing in homozygous F210I and M323K datasets with 
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respective wildtype controls. Embryonic wildtype iCLIP binding displayed 
underneath RNA-Seq reads. Increased exon inclusion in F210I model versus 
embryonic wildtype, and increased exon skipping in M323K model versus adult 
wildtype, in both Sort1 and Eif4h alternative splicing.  
Also incorporating alternative splicing data from the TDP-43 KD dataset in adult mouse 
striatum (Polymenidou et al. 2011), several other key splicing events were identified to 
be changed in opposite directions in TDP-43 loss and gain of function (Figure 4.54). 
These added further weight to the hypothesis that the M323K caused gain of function 
in TDP-43 splicing activity across a number of regulated splicing events in the 
transcriptome.  
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Figure 4.54. Alternative splicing of the same splicing event measured by Δ PSI 
across homozygous embryonic F210I and homozygous adult M323K RNA-Seq in 
key TDP-43 splicing targets, with banners above the graphs identifying how the 
splicing event was changed in TDP-43 KD in adult mouse brain (Polymenidou et al. 
2011).  
Alongside the opposite direction in splicing events in certain genes, a small number of 
genes also contained splicing events which were strongly changed in the same 
direction in both the F210I and the M323K models, such as Sema3f. It is likely that 
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these changes rely on a role of TDP-43 control of splicing distinct from the majority of 
targets.  
As was the case with the splicing changes in the homozygous F210I forebrain, no GO 
term enrichment was found in the alternative splicing analysis for the homozygous 
M323K spinal cord. This may be due to the widespread role of TDP-43 in regulating 
transcripts from a number of different varied pathways, and that no one pathway is 
specifically the root connection between the splicing dysregulation and subsequent 
disease pathology.  
4.2.6 SKIPTIC EXONS 
The F210I mutation resulted in a loss of repression of several intronic splice sites, 
resulting in the inclusion of a number of cryptic exons in the mutant mouse model 
which were completely absent from the wildtype. Given that this was a loss of function 
phenotype, similar cryptic exon splicing in the M323K model was expected to be 
absent. In concordance with this, cryptic exon presence in the M323K model was 
scarce, with no instances of cryptic splicing present in validated F210I cryptic exon 
transcripts such as Adnp2 (Figure 4.55). Only one cryptic exon from the F210I model 
was also found in M323K, a splicing event in Reep3. As with the rare splicing events 
modulated in the same direction by the two mutations, it is likely that the regulation of 
Reep3 splicing involves a separate mechanism to the bulk of splicing changes analysed 
here.  
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Figure 4.55. RNA-Seq read counts from homozygous F210I and M323K and 
respective wildtypes in the 3’ end of Adnp2. Overlaid sashimi plot showing 
splicing patterns in each dataset. Cryptic exon in Adnp2 gene found in F210I 
model, but absent from both wildtypes and also the homozygous M323K model.  
Whilst the absent of cryptic exons was predicted, the M323K mutation still showed 
large scale splicing changes, and so the presence of extreme splicing events resulting in 
transcripts specific to the mutant model was possible. TDP-43 often functions to 
repress exon inclusion, and loss of function through F210I mutation or TDP-43 KD lead 
to increased inclusion levels. Considering this, we examined the alternative splicing 
output of homozygous M323K models for extreme skipping events. These would be the 
opposite of cryptic exons, instead showing skipping of supposedly constitutively 
spliced exons, again resulting in novel transcripts in the M323K model but not 
wildtype. We adopted thresholds mirroring those set for cryptic exons, looking for 
alternative splicing events with an adjusted p-value of < 0.01, an average control PSI of 
greater than 0.95, and a Δ PSI of at least 0.05. This meant these extreme skipping 
events would be present in less than 5 % of wildtype transcripts, and show a significant 
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increase in skipping of 5 % or more in the M323K mice. Using these filters, we 
discovered 47 of these extreme skipping events in 44 genes, with an example in Herc2 
(Figure 4.56). Taking into account the opposite in effects to cryptic exons, and the 
skipping nature of the splicing, we termed these events ‘skiptic exons’ in further 
analysis.  
 
Figure 4.56. RNA-Seq read counts from homozygous F210I and M323K datasets 
along with respective wildtypes for part of the Herc2 gene aligned to a reference. 
Overlaid with sashimi plot showing splicing patterns in each dataset, with 
number of each splice event annotated. PSI levels for the skiptic exon are 
calculated and listed to the right. No detected instance of alternatively spliced 
exon skipping in wildtype samples or the F210I dataset, but a quarter of all 
transcripts showed exon skipping in the M323K dataset.  
A select number of these skiptic exons were then validated by RT-PCR, with all showing 
significant and substantial decreases in inclusion levels in the M323K model (Figure 
4.57).  
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Figure 4.57. Top: Diagram of two possible isoforms from RT-PCR test, with 
skiptic exon denoted in red. Middle: Example RT-PCR results visualised on 
Tapestation gels for seven targets, with skiptic exon-containing transcripts and 
wildtype transcripts labelled. Skiptic exon transcripts only clearly evident in 
M323K samples. Bottom: Graphical and statistical analysis of skiptic exon 
inclusion levels for each target in wildtype and M323K samples. 
As the phenomenon of skiptic exons was linked to the opposite effect of TDP-43 loss of 
function, the homozygous F210I embryonic dataset was reanalysed to investigate the 
presence of skiptic exons. In keeping with this hypothesis, fewer splicing events 
meeting skiptic exon criteria were detected in this F210I dataset, further suggesting 
that they were specifically linked to the gain of function effects of the M323K mutation 
(Figure 4.58). As with the Reep3 cryptic exon being the only instance present in both 
models, one skiptic exon was detected in both datasets too, within the Tsn gene. Again, 
this outlier is likely to result from a different method of TDP-43 regulation to the 
majority of skiptic exon splicing events. In general, the contrasting presence of cryptic 
and skiptic exons not only further demonstrated the opposite effects of F210I and 
M323K mutations on general TDP-43 splicing activity in the transcriptome, but also 
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highlighted similarly opposite roles in extreme splicing events leading to novel 
transcripts in the mutant models.  
 
Figure 4.58. Δ PSI and level of significance for each extreme splicing event 
(cryptic or skiptic exon) present in the homozygous F210I embryonic or 
homozygous M323K adult RNA-Seq datasets vs respective wildtype. Cryptic 
exons typically seen in the loss of function F210I model, skiptic exons seen more 
in the gain of function M323K model.  
A point of note is that alongside the common cryptic exon in Reep3, and common 
skiptic exon in Tsn, there was a cryptic exon in the embryonic F210I model, in Ppfibp1, 
in which the exon then became well expressed in adult wildtype mouse spinal cord and 
actually showed increased levels of skipping in the adult M323K spinal cord. Mirroring 
this, a skiptic exon in the adult M323K model, in Klhdc10, showed high levels of 
skipping in the embryonic wildtype forebrain, and even increased levels of inclusion in 
the embryonic F210I forebrain. These unique splicing events are unexplained, and 
highlight the complexity of splicing activity regulated by TDP-43, much of which cannot 
be simply explained by opposite effects in TDP-43 loss and gain of function, alongside 
some of the difficulties in comparing and contrasting mouse models at different ages.  
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Given the mirrored effects of F210I and M323K mutations for even the extreme 
splicing events, we further analysed respective F210I and M323K iCLIP data to 
understand how TDP-43 binding differed to result in these different effects. Proximal 
versus distal binding of TDP-43 to target splicing regions is known to influence level of 
exon inclusion/repression (Tollervey et al. 2011). Analysis by Jack Humphrey in F210I 
TDP-43 iCLIP clusters around cryptic exons in the F210I RNA-Seq showed marked 
similarity to M323K TDP-43 iCLIP clusters around skiptic exons in the M323K RNA-Seq 
(Figure 4.59). This suggested that both extreme splicing varieties culminated from 
similar binding proximity of TDP-43 to the alternatively spliced exon, and strengthened 
the hypothesis that the F210I and M323K mutations changed the results of TDP-43 
splicing specifically through a loss and gain of function in activity respectively. 
 
Figure 4.59. RNA maps show binding distribution of respective TDP-43 iCLIP 
clusters (positive and negative values on y-axis for increased and decreased ΔPSI 
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respectively) in cryptic exons in F210I (A) and skiptic exons in M323K (B); red 
and blue indicate when cluster coverage is increased above background set of 
non-regulated cassette exons (grey). Below, binding sites for the top 20 most 
significant cryptic exons (A) and skiptic exons (B) are plotted. Results from Jack 
Humphrey.  
Cryptic exons present in the F210I model were also predicted to cause NMD of the 
transcripts. However, differential gene expression analysis of cryptic exon transcripts 
showed equal levels of upregulation and downregulation, questioning the ability of the 
NMD mechanism to degrade the transcripts as predicted, and also raising the 
possibility of other regulatory mechanisms at play to compensate for the increase in 
unstable transcripts. Similar analysis was conducted on the skiptic exons by Jack 
Humphrey, and revealed that significantly downregulated genes were particularly 
enriched for skiptic exons, which was not true for upregulated genes (Figure 4.60). 
Furthermore, these downregulated genes contained a significantly greater proportion 
of skiptic exons which were predicted to trigger NMD. These findings together 
implicated skiptic exons in causing transcript degradation and downregulation.  
  
Figure 4.60. (Left) Dysregulated genes split by direction of regulation. Subsets 
then further split into those containing no cassette exons (grey), cassette exons 
(black), and cassette exons defined as skiptic exons (red). Downregulated genes 
significantly enriched most for skiptic exons. (Right) Downregulated or 
unchanged genes with extreme splicing events split by type of extreme splicing 
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event contained. Toxic NMD-predicted skiptic exons enriched in downregulated 
genes compared to unchanged genes. Results from Jack Humphrey.  
Skiptic exons were demonstrated to be linked to gain of function in TDP-43 splicing, 
resulting in novel transcripts that were dysregulated and predicted to be degraded as a 
result. This was similar to the effect of cryptic exons occurring from TDP-43 loss of 
function. However, one key difference is that while cryptic exons occur in typically 
intronic regions and show low levels of conservation between mice and humans (Ling 
et al. 2015), skiptic exons are typically constitutively expressed exons and therefore 
should generally be very well conserved. Analysis by Jack Humphrey confirmed this, 
with cryptic exons from the F210I dataset showing noticeably low PhyloP conservation 
scores, whereas M323K skiptic exons were very well conserved (Figure 4.61).  
 
Figure 4.61. Per-exon mean PhyloP conservation scores of F210I cryptic exons 
(CEs) and M323K skiptic exons (SEs) in comparison to all annotated mouse 
exons. Violin plots showing distribution of data with overlaid boxplots to show 
the median and quartiles. Outliers are plotted as black dots. Cryptic exons show 
low conservation levels, whereas skiptic exons show high levels of conservation. 
Results from Jack Humphrey. 
The difference in conservation level is crucial, given the aim of using mouse models to 
enable therapeutics for disease in patients, an aim for which models of 
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neurodegenerative disease have a particularly poor track record (Eaton & Wishart 
2017). Importantly, although the high level of skiptic exon conservation suggests that a 
similar splicing mechanism could take place were gain of function in TDP-43 splicing to 
occur in human settings, the mechanism by which TDP-43 mediates this splicing is 
often through binding to intronic regions around the exon rather than the exon itself, 
as shown by M323K iCLIP analysis specific to skiptic exons (Figure 4.59). To enable a 
similar function in humans, the introns surrounding the skiptic exons could also be 
conserved. Such conservation of non-coding regions of genes often provide indication 
of regulatory importance of the sequence, notably for the autoregulation of TDP-43 
itself at the TDPBR found within intron 7 of the Tardbp transcript (Ayala et al. 2011). 
To test this possibility, the conservation levels of intron regions around the skiptic 
exons between mouse and humans were also investigated. There is no consensus for 
quantification of sequence alignment, and several methods exist (Raghava & Barton 
2006). Variables include incorporating gaps in sequences, and the total length of 
sequence to average over. The approach used in this investigation calculated percent 
sequence identity by dividing the number of identical matches in sequence by the total 
number of aligned positions plus any internal gaps. To determine whether the introns 
were conserved over and above levels for typical exons, introns flanking constitutive 
exons which were always expressed in both control and mutant datasets were used as 
controls. Using this method, it was determined that the majority of introns surrounding 
skiptic exons were substantially more conserved than the introns flanking the control 
constitutive exons. (Figure 4.62). 
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Figure 4.62. Percentage identity sequence (PID) plotted for all aligned bases in 
mouse and human 5’ and 3’ introns for conserved skiptic exons. PID calculated 
by: 100 * (identical positions) / (aligned positions + internal gap positions). 
Black crossbar indicates mean intron PID score for each gene. Dashed lines 
indicate PID scores for introns around 100 most constitutively expressed exons 
(PSI > 0.99 in both wildtype and homozygous M323K RNA-Seq datasets, FDR > 
0.1) 5’ (red) and 3’ (blue). Most introns surrounding skiptic exons substantially 
more conserved than introns surrounding constitutively expressed exons.  
Another important measure prior to investigating the presence of skiptic exons in 
humans was the skiptic exon presence in heterozygous models. TDP-ALS mutations are 
typically autosomal dominant, and so often the disease stems from a heterozygous 
genotype. As previously discussed, much of the molecular dysregulation seen in the 
homozygous M323K model was not present in heterozygous models to a significant 
extent, and this was also true for most of the skiptic exons identified. However, the lack 
of significance does not necessarily exclude their presence – they may occur but not 
sufficiently to pass confidence thresholds. If this was the case, then we would expect to 
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see skipping in the same splicing events, but lower Δ PSI levels. Analysis of the adult 
heterozygous mice confirmed exactly this, all but one of the detected skiptic exons also 
showed increased skipping, and all but one these showed a lower Δ PSI in comparison 
homozygous counterparts (Figure 4.63). 
 
Figure 4.63. Δ PSI levels for skiptic exons from the homozygous adult M323K 
dataset also shown for heterozygous M323K adult mice vs respective wildtypes.  
Intriguingly, even within the relatively small subset of 47 skiptic exons, there seemed 
to be an enrichment of genes involved in the ubiquitin pathway, in particular E3 
ubiquitin ligases. Six genes – Herc2, Ube3c, Ube2e2, Wwp1, Ttc3 and Wsb1 – fit this 
description. E3 ubiquitin ligases function to either directly catalyse the ubiquitination 
of a protein, or as adaptors to facilitate the ubiquitination (Berndsen & Wolberger 
2014). Quantifying the precise enrichment of this subset of ubiquitin ligase genes 
containing skiptic exons is difficult, as the label describes a diverse group of proteins 
and the exact number with this function is very unclear (Ardley & Robinson 2005). 
146 
 
However, the link between extreme splicing events occurring in genes related to 
ubiquitin pathway function, and the subsequent ubiquitin pathology developed by the 
homozygous M323K mouse at the 2 year time point (4.2.8 M323K phenotype), cannot 
be ignored. Further work is required to examine this group of E3 ubiquitin ligases for 
further indication of RNA dysregulation, and to dissect precisely how the splicing 
changes in these genes could result in ubiquitin pathology.    
Given the link between skiptic exons and LCD mutation of TDP-43-mediated gain of 
function, we suspected that similar splicing could occur in mouse models with 
mutations found in TDP-ALS patients. This was confirmed in the Q331K mouse model, 
in which three of the validated skiptic exons were found to show increased skipping in 
the mutant models versus wildtype. This is further discussed in 5.2 Q331K mouse 
model. The high level of skiptic exon conservation between mice and humans of both 
the exons and surrounding introns, and their reduced presence in heterozygous TDP-
43 mutation, meant that it seemed entirely possible that similar splicing events would 
also occur in TDP-ALS patients. This theory was confirmed in fibroblasts from TDP-ALS 
patients, in which two of the validated skiptic exons, in PLOD1 and SLC6A6, were found 
to be increasingly skipped in TDP-ALS patients compared to controls. This result is 
discussed further in 5.4 TDP-ALS patient fibroblasts.  
4.2.7 POLYADENYLATION CHANGES IN M323K 
Although TDP-43 typically binds to intronic regions overall, in the cytoplasm TDP-43 is 
well known to bind to the 3’UTR of transcripts (Colombrita et al. 2012), suggesting it 
plays a role in the post-transcriptional regulation of the transcript too, likely 
controlling its translocation in the cytoplasm (Bramham & Wells 2007). We 
hypothesised that the gain of function effects of the M323K mutation may also 
influence the polyadenylation of TDP-43 target transcripts, perhaps through 
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controlling alternative splicing of cassette exons of the 3’UTR itself indirectly resulting 
in use of different polyadenylation sites, as is this case with the TDP-43 autoregulatory 
mechanism with Tardbp transcripts itself.  
To investigate this, the alternative splicing output from the RNA-Seq experiment was of 
limited used. This is because alternative polyadenylation site usage cannot necessarily 
be inferred by splicing events, and the RNA-Seq data spreads reads across the entire 
transcript, resulting in a limited number of reads being allocated to polyA sequences. 
We suspected these reads alone would be insufficient for study of alternative 
polyadenylation site usage. Therefore, we conducted QuantSeq on adult M323K 
homozygous mouse spinal cord, using the same RNA used for the initial RNA-Seq 
experiment. QuantSeq is a technique which focuses specifically on sequencing the 3’ 
end of transcripts, and therefore a much greater portion of reads can be used for study 
of polyA site usage. Processing of the QuantSeq data was conducted by Gregor Rot, 
using his previously published pipeline (Rot et al. 2017). Results from the QuantSeq 
experiment suggested alternative polyadenylation was occurring, but determining 
statistical differences between genotypes proved difficult. In order to obtain the most 
evident polyadenylation site usage changes, RNA-Seq data was also incorporated using 
visual analysis of cumulative reads, enabling identification of regions in which polyA 
site usage is so strongly changed that a noticeably different number of reads mapped to 
the respective isoforms resulting from the change. An example of this can be seen in 
the Brwd1 gene in Figure 4.64. 
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Figure 4.64. RNA-Seq reads for the 5’ end of Brwd1 transcripts in homozygous 
adult M323K spinal cord and wildtype. Two isoforms of Brwd1 annotated below. 
Summed read peaks normalised to height of reads for 3’UTR of short Brwd1 
isoform. Reads 5’ of this are aligned to the longer isoform, and there is a 
noticeable visual reduction in reads in wildtype compared to M323K data.  
By combining the QuantSeq and RNA-Seq data, a subset of ten targets were identified 
to show differences in polyadenylation. Four of these showed increased use of a 
proximal polyA site in the M323K models compared to wildtype in the RNA-Seq data, 
and another six showed preferential use of a more distal polyA site. In the QuantSeq 
data, these changes were broadly reflected, with the occasional contrary result in one 
example (Figure 4.65).  
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Figure 4.65. QuantSeq ratios for proximal vs distal polyA site usage in ten targets 
identified as likely showing alternative polyadenylation in the homozygous 
M323K RNA-Seq data. Direction of change in RNA-Seq data labelled at the top. 
QuantSeq data points for each sample shown to display no different effects 
caused by one sample. QuantSeq data broadly matches RNA-Seq data for the 
predicted changes in polyA site usage in the M323K model in comparison to 
wildtype.  
To ensure the polyadenylation changes were true, validation was attempted for the 
selected targets. Validation was performed as outlined in 2.1.4 Polymerase chain 
reaction, using the three primer method. Although this would not strictly confirm 
polyadenylation differences, it would confirm the 3’UTR usage changes that would 
result. Using this method, the ratio of isoforms using the long 3’UTR isoform, and 
therefore the distal polyA site, to total isoforms with any 3’UTR would be compared. 
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However, the attempted validation failed to prove the 3’UTR use changes seen in the 
sequencing datasets. Of the ten attempted validations, two targets failed to produce 
PCR products as expected. Another two provided too many isoforms to enable 
quantification. Of the remaining six, two were expected to show increased proximal 
polyA site usage, but upon testing showed no changes. Similarly, three of the four 
targets thought to show increased distal polyA site usage failed to replicate this upon 
testing with PCR. Only the change in Ppp2r5c showed the direction of change as 
expected (Figure 4.66).  
 
Figure 4.66. Validation of 3’UTR isoform use changes in the M323K model. Ratios 
for distal vs total polyA site usage, inferred from 3’UTR isoform measurement, in 
six targets identified as likely showing alternative polyadenylation in the 
homozygous M323K sequencing data. Direction of expected change labelled at 
151 
 
the top. Validation failed to replicate the expected changes in all but one target, 
Ppp2r5c. 
Despite one target seemingly successfully replicated upon PCR validation, the general 
failure of this method raised several questions. The inference of alternative polyA site 
usage from RNA-Seq summed read counts is not ideal, as this is an indirect measure 
seeing the effects of the supposed change. The QuantSeq analysis, which is a direct 
measure, requires further refinement before polyadenylation changes can be 
adequately and reliably detected. The validation method employed also relies on 
measurement of distal versus total 3’UTR expression, rather than proximal versus 
distal. Although the latter ratio can be inferred, the method likely requires validation in 
settings where the change is more confidently known before attempted measurements 
of differential 3’UTR isoform usage. It seems likely that 3’UTR and polyadenylation 
changes are indeed occurring in the homozygous M323K adult mouse spinal cord, but 
further work is required to identify and validate these changes appropriately. It is an 
important avenue of research in neurodegenerative models especially, as in neurons 
the systems regulating mRNA transcript trafficking and translation are vital for 
conferring the expression of the transcripts in axonal and dendritic compartments 
(Bramham & Wells 2007). TDP-43 is known to regulate this, particularly translation 
through alternative 3’UTR usage (Wang et al. 2008; Liu-Yesucevitz et al. 2011; Alami et 
al. 2014). TDP-ALS mutations have been demonstrated to disrupt the transport of these 
transcripts in axons (Alami et al. 2014), it remains to be seen whether the M323K 
mutation results in similar effects.   
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4.2.8 M323K PHENOTYPE 
The homozygous M323K mouse lived until adulthood with no change in lifespan, and 
this enabled study of pathology, and motor and behavioural phenotype, which was not 
possible in the embryonic homozygous F210I model.  
As the adult homozygous M323K spinal cord showed substantial molecular 
dysregulation, with changes in both differential gene expression and alternative 
splicing, it seemed possible that an underlying cause could be through mislocalisation 
of the TDP-43 protein. To investigate this, immunohistochemical analysis was 
conducted on the adult homozygous M323K spinal cord at 1 year and 2 year time 
points. However, staining for TDP-43 revealed no change in TDP-43 localisation 
(Figure 4.67). It was not depleted from the nucleus, not excessively mislocalised in the 
cytoplasm, and did not form aggregates upon visual assessment. Staining for C-
terminal fragments, 25 kDa and 35 kDa pathological fragments resulting from TDP-43 
cleavage (Johnson et al. 2008), also revealed no change. TDP-43 hyperphosphorylation, 
reported to occur alongside aggregation (Arai et al. 2006), was also not detected 
(Figure 4.67).  
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Figure 4.67. Staining panel for TDP-43 in adult homozygous M323K ventral horn 
of the lumbar spinal cord at the 2 year time point. Staining for TDP-43 N-terminal 
full length form showed no change in localisation or any aggregation. Staining for 
C-terminal TDP-43 to enable detection of pathological fragments showed no 
change in localisation or any aggregation. Staining for phosphorylated TDP-43 
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showed that hyperphosphorylation of TDP-43 was not present, while the positive 
staining for TDP-43 hyperphosphorylation in the positive control proved that 
technical failure was not the reason for the absence of TDP-43 
hyperphosphorylation staining in the M323K. Scale bar indicates 20 µm.  
Alongside TDP-43 pathology, ALS patients also typically display aggregation of 
components of the protein degradation pathway, such as p62 and ubiquitin, and so to 
understand whether protein degradation dysfunction was occurring in the absence of 
TDP-43 mislocalisation, these targets were also stained for. In contrast to TDP-43 itself, 
the M323K spinal cord was positive for both p62 and ubiquitin aggregation at the 2 
year time point (Figure 4.68). Aggregates were limited to the ventral horns of the 
spinal cord, around the motor neurons but not within them. They were absent from 
dorsal grey matter regions, which contain sensory neurons. 
 
Figure 4.68. DAB staining for p62 and ubiquitin in adult homozygous M323K 
ventral horn lumbar spinal cord at the 2 year time point. P62 and ubiquitin 
pathology (the latter labelled by white arrows) detected in the ventral horns of 
the M323K model but were absent from dorsal regions, and also absent from any 
regions in the wildtype spinal cord. Scale bar indicates 20 µm.  
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The p62 pathology was not restricted to the spinal cord in the CNS; p62 pathology was 
also identified in the brainstem regions of the adult homozygous M323K brain, but 
absent from non-motor regions such as the hippocampus (Figure 4.69).  
 
Figure 4.69. P62 pathology detected by DAB staining in the brainstem of 
homozygous M323K brain at the 2 year time point, but absent in the 
hippocampus and any wildtype region.  
Alongside the molecular dysregulation and pathology, the motor phenotype of M323K 
mice at the 2 year time point was also tested. Investigation by Bernadett Kalmar and 
Alan Mejia Maza revealed significant motor deficits in the M323K mice, in grip strength, 
muscle force, motor unit number and motor neuron number (Figure 4.70). 
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Figure 4.70. Motor phenotype investigation in homozygous M323K mice at 2 
years. (A) Female mice show significant 30 % grip strength deficit at 2 years, but 
no difference at 7 months. (B) Muscle strength deficit in the tibialis anterior (TA) 
muscle in M323K mice, with representative trace. (C) Motor unit number 
reduction in M323K mice in the extensor digitorum (EDL), with representative 
trace from one motor unit shown above. (D) 28 % reduction in motor neuron 
counts from the sciatic pool in L4-L5 regions of the lumbar spinal cord. Results 
from Bernadett Kalmar and Alan Mejia Maza.  
4.2.9 M323K CONCLUSIONS 
The M323K two year old mice showed substantial RNA processing dysfunction, with 
numerous differential gene and exon expression changes. At the same time point, 
investigation of the mouse phenotype revealed no TDP-43 pathology. The absence of 
massive TDP-43 nuclear depletion could be predicted by the lack of RNA dysregulation 
resembling either the F210I TDP-43 loss of function model, or TDP-43 KD data. There 
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was no specific downregulation of long genes, and examples of TDP-43 loss of function 
splicing and cryptic exon inclusion were minimal. Given that these were evident in our 
TDP-43 loss of function models it could be deduced that no significant loss of function 
was occurring in the M323K model and therefore no nuclear depletion would be seen. 
However, alongside the absence of loss of function effects was the gain of function in 
TDP-43 splicing activity and skiptic exons, for which the resulting phenotype could not 
be predicted as no prior models with similar changes were available. Added to this was 
the seemingly dysfunctional autoregulatory mechanism of TDP-43, resulting in 
increased Tardbp levels where reduced levels would restore normal TDP-43 function, 
and it was plausible that this would lead to an increase in protein levels in the 
cytoplasm. Overexpression of TDP-43 has been demonstrated to result in excessive 
TDP-43 in the cytoplasm and subsequent aggregation (Tsai et al. 2010; Wils et al. 2010; 
Xu et al. 2010).  
The detection of p62 and ubiquitin aggregates limited to the motor regions of the 
spinal cord and brain in the aged M323K models would further the presence of TDP-43 
aggregation, as they function in the protein degradation pathway (Bjørkøy et al. 2005; 
Komatsu et al. 2007; Pankiv et al. 2007). Proteins to be degraded are ubiquitinated and 
p62 acts as an adaptor to facilitate the degradation via either the proteasome or 
autophagy pathway (W. J. Liu et al. 2016) using interaction with the microtubule-
associated protein 1A/1B-light chain 3 protein (LC3) (Pankiv et al. 2007). Aggregations 
of both p62 and ubiquitin are themselves well-associated with ALS (Arai et al. 2006; 
Neumann et al. 2006; Mizuno et al. 2006), and mutation of the p62/SQSTM1 gene itself 
can cause ALS (Fecto et al. 2011).  
Impaired liquid-liquid phase separation is also implicated in TDP-ALS mutations and 
thought to cause TDP-43 pathology (Johnson et al. 2009; Zhang et al. 2009; Guo et al. 
2011), and the turbidity assay for M323K TDP-43, as described in   
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4.1.2 Previous study of the M323K mouse model (Figure 4.39), demonstrated a 
reduced ability of the mutated TDP-43 to phase separate. However, despite all of these 
indications, TDP-43 pathology was completely absent in the M323K model. This is in 
contrast to other mouse models with LCD mutations in TDP-43 (De Giorgio et al. 2018), 
however the type and extent of pathology varies even in these, and as most of the 
models involve transgenic expression of TDP-43, it is not possible to disentangle how 
much of the pathology results from the mutation alone.  
It has been established that TDP-43 aggregation is not necessary for cellular, or 
neuronal, toxicity to occur (Barmada et al. 2010; Arnold et al. 2013). Highlighting this 
point, a recent study on a mouse model with the Q331K TDP-ALS mutation knocked in 
via CRISPR was found to at no stage to display TDP-43 pathology, despite not having a 
truncated lifespan and developing a phenotype resembling FTD (M. A. White et al. 
2018). The only protein difference detected was a 45 % increase in nuclear TDP-43; 
this was not tested in the M323K mice and it would be of interest to see if it replicated 
the protein changes of a mouse with a TDP-ALS mutation. Studies of other ALS-related 
proteins such as SOD1 and FUS have conveyed the same results: transgenic 
overexpression of the protein can lead to a severe phenotype but mutation of the 
endogenous protein does not (Gurney et al. 1994; Mitchell et al. 2013; Joyce et al. 2015; 
Devoy et al. 2017; Scekic-Zahirovic et al. 2017). Such a link would also explain the 
absence of reduced lifespan in the models harbouring endogenous mutations.  
Intriguingly, the presence of p62 and ubiquitin aggregates suggests that a protein is 
indeed aggregated in the M323K model, just not TDP-43. The identity of this protein is 
unknown; further tests for hnRNP A1 and hnRNP K, both themselves linked to TDP-43 
pathology in ALS (Moujalled et al. 2017; Deshaies et al. 2018), have also proven 
negative. The idea that another RBP may be aggregated before TDP-43 itself upon TDP-
43 mutation is especially curious, and establishing the identity of this protein could 
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provide strong clues on the early pre-symptomatic changes undergone in TDP-ALS. The 
detection of similar pathology in both the brain and spinal cord resembles the pattern 
of change in ALS, in which both upper and lower motor neurons are affected, and the 
motor phenotype of the M323K mouse strongly demonstrates neurodegeneration and 
an ALS-like phenotype too.  
It is important to consider that at the embryonic and developmental stages, the 
homozygous M323K model showed no effects of the mutation, at the RNA level, in 
exhibiting any pathology or in any behavioural or phenotypic changes. However, the 
adults show mass changes in all of these aspects, suggesting they may all be linked. 
Crucially, the changes at the RNA level precede the development of motor phenotype, 
with the sizeable changes in differential gene expression and alternative splicing 
occurring in the six month old spinal cord on homozygous M323K animals, whereas a 
seven months these mice did not show a grip strength deficit, a phenotype that the 
older models proceeded to develop. This suggests the RNA changes may underlie the 
eventual phenotype of the mice, or at least provide the earliest indicator of the eventual 
neurodegeneration. The finding of conserved, novel, toxic, mutant specific skiptic exons 
that develop pre-symptomatically in adult models are likely to be of particular 
importance, although again whether that is through underlying causational changes or 
as early biomarkers is yet to be seen. In particular, the specific apparent enrichment of 
skiptic exons in genes coding for E3 ubiquitin ligases is of interest. These proteins 
function to directly or indirectly facilitate the ubiquitination of proteins for 
degradation, and a link between this RNA dysregulation and subsequent ubiquitin 
pathology developed by the 2 year old M323K mice implies a link between the two 
changes, although the exact mechanism behind this is not clear. 
Incorporating the array of dysregulation as a result of M323K mutation, it is clear that 
the M323K model provides novel insight into the importance of TDP-43 loss of function 
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versus gain of function debate. The adult homozygous M323K mouse shows no loss of 
function effects, including those that would result from nuclear depletion if it fully 
replicated TDP-43 pathology in ALS, only the effects of a gain of function in TDP-43 
splicing activity. Despite this, the mouse develops neurodegenerative pathology and a 
motor phenotype. Therefore, crucially, this model shows that LCD mutations in TDP-43 
can lead to a neurodegenerative phenotype through gain of function in TDP-43 activity, 
in the absence of any loss of function effects.  
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CHAPTER 5  
TRANSCRIPTOME DYSREGULATION IN OTHER MODELS OF 
ALS 
5.1 COMPOUND HETEROZYGOUS F210I / M323K MOUSE MODEL 
The TDP-43 F210I and M323K mouse models showed opposite effects on TDP-43 
splicing activity. This was demonstrated on a number of shared targets, such as the 
CFTR minigene assay in both HeLa cells and MEFs, as well as endogenous targets such 
as Sort1, Eif4h and Dnajc5. Comparing these effects to the dysregulation caused by 
TDP-43 KD established the F210I as causing a loss of function in TDP-43 splicing 
activity, whereas the M323K mutation caused the opposite, a gain of function. 
Therefore, we speculated that crossing these two models to produce compound 
heterozygous mice, with one Tardbp allele harbouring each mutation, may in effect 
cancel out some of the effects of the two mutations and result in a rescue of the RNA 
dysregulation.  
Both the homozygous F210I and M323K mice were not viable after birth when raised 
on a pure C57BL/6J background, indicating that both mutations had substantial impact 
on early development. In the case of the F210I, this meant only the embryonic stages of 
homozygous models could be studied to investigate phenotype resulting from the 
mutation. However, the homozygous M323K model was able to survive on a mixed 
C57BL/6J / DBA/2J background, and showed no change in lifespan. This allowed study 
of the homozygous M323K mutation at developmental and adult time points, and this 
adult model was used as the primary focus of study. 
To examine how the compound heterozygous mutation would affect embryonic 
viability, mice carrying one allele of each mutation were produced. While embryos 
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homozygous for either mutation were not viable, compound heterozygous 
F210I/M323K embryos were viable, suggesting a possible rescue effect of the two 
contrasting mutations. They did not follow expected Mendelian ratios, however, with 
just 8.8 % of pups possessing this genotype as opposed to the expected 25 %, 
suggesting a partial rescue (Figure 5.71).  
 
Figure 5.71. Diagram illustrating the F210I/M323K compound heterozygous 
model viability. Significant increase in survival of compound heterozygous model 
compared to homozygous F210I and homozygous M323K models (P < 0.05). (N) 
represents numbers of animals produced per genotype; % the percentage of 
mice observed per genotype and (expected %) the percentage of mice expected 
per genotype, calculated by Abraham Acevedo Arozena. 
However, it was important to remember that both embryonic heterozygous F210I and 
embryonic heterozygous M323K mice themselves showed minimal RNA processing 
changes, so it was not yet clear whether this was a true rescue of the effects with the 
two mutations counteracting each other.  
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To investigate this aspect further, splicing of known TDP-43 targets was examined. 
RNA-Seq was conducted on the compound heterozygous models at E14.5, the same 
time point used for our previous embryonic RNA-Seq studies. At this stage, the 
homozygous F210I model showed mass RNA dysregulation, with 1,184 genes showing 
changes in expression (adjusted p-value < 0.1) and 67 significant shifts in alternative 
splicing (adjusted p-value < 0.01). Although the homozygous M323K model primarily 
showed RNA processing changes at the later stage adult time point, embryonic models 
still displayed several examples of dysregulation, with 53 differentially expressed 
genes and 11 differentially used splicing events. In keeping with the posited rescue 
effect, compound heterozygous mice showed almost no RNA dysregulation, with just 9 
differentially expressed genes and no significant alternative splicing events, again 
suggesting that the mutations could be cancelling each other out.  
Crucially, this was also true when specific splicing events were examined. Eif4h was 
significantly differentially spliced in opposite directions in both embryonic 
homozygous models, with the F210I model displaying greater levels of exon inclusion 
and the M323K model greater levels of exon skipping. Exemplifying the counteracting 
effect of the compound heterozygosity for the F210I/M323K mutations, in this model 
Eif4h was not significantly differentially spliced from wildtype, showing a middling 
level of exon inclusion levels in between the effects of the F210I and M323K mutations 
alone (Figure 5.72).  
164 
 
 
Figure 5.72. RNA-Seq reads for each embryonic model with sashimi plots 
demonstrating splicing patterns overlaid. Number of reads annotating each 
splicing event annotated on sashimi plot, with Δ PSI values for the splicing event 
from SGSeq alternative splicing output displayed on the right. RefSeq annotated 
Eif4h transcript isoforms below. Compound heterozygous F210I/M323K model 
showed alternative splicing pattern similar to wildtype, in contrast with the 
greater exon inclusion levels in F210I and greater skipping levels in M323K 
models.  
Also absent from this model were any of the extreme splicing events from each 
homozygous model, neither cryptic exons nor skiptic exons were detected. 
Importantly, there was also no evidence for any autoregulation of TDP-43 occurring, 
with no increase in Tardbp transcript levels and no splicing change to indicate a shift in 
the mechanism from the RNA-Seq data. Therefore, the results for this compound mouse 
model followed on from previous results that suggested the two mutations had 
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opposite effects on TDP-43 splicing activity but shared splicing targets and binding 
regions, with the opposite effects caused specifically by changes in TDP-43 functioning 
activity levels. 
5.2 Q331K MOUSE MODEL 
The homozygous M323K model contained a mutation in the LCD of TDP-43, within the 
hotspot region in which several TDP-ALS mutations occur (Buratti 2015). As a result of 
the mutation, the mouse develops mass RNA dysregulation, novel skiptic exon 
skipping, protein degradation pathology and a neurodegenerative disease-like motor 
phenotype. However, the key drawback of this mouse model is that although similar, 
the M323K mutation itself has not yet been found to cause ALS in patients. Even within 
the LCD, different mutations have a variety of different effects on overall TDP-43 
dysfunction (Jiang et al. 2016), therefore it is not clear to what extent the M323K 
mimics the molecular dysregulation upon LCD mutation in TDP-ALS. To further 
investigate the level of this correlation, we investigated a mouse model with a knock-in 
Q331K mutation in the endogenous mouse Tardbp gene.  
The Q331K mutation (Figure 5.73) was amongst the first ALS-causative mutations 
identified in TDP-43 (Sreedharan et al. 2008). Since then, mouse models have been 
developed harbouring Q331K-mutated TDP-43 (Arnold et al. 2013; Mitchell et al. 
2015), however until recently these have involved transgenic expression of the 
mutated protein and therefore suffer from the previously described issues of this 
method. However, a study published earlier this year investigated a mouse model with 
the Q331K mutation introduced into the endogenous mouse Tardbp gene via CRISPR 
(M. A. White et al. 2018). This represented the first published knock-in mouse model of 
TDP-ALS. A similar model to this, also with the Q331K mutation CRISPR-induced into 
the mouse Tardbp gene, was concurrently investigated by Abraham Acevedo Arozena 
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at MRC Mammalian Genetics Unit, Harwell, Oxford, and then Unidad de Investigación, 
Hospital Universitario de Canarias, Fundación Canaria de Investigación Sanitaria and 
Instituto de Tecnologías Biomédicas (CIBICAN), La Laguna. To understand whether the 
RNA processing changes in the M323K model could be replicated by TDP-ALS 
mutations, a selection of the alternative splicing, and skiptic exon, changes were tested 
for in the homozygous adult Q331K mouse brain using RT-PCR.  
 
Figure 5.73. TDP-43 domains and location of the Q331K mutation with the LCD 
domain. 
The first investigation was to determine whether the Q331K mutation displayed a 
similar gain of function in TDP-43 splicing activity to the M323K mutation, and for this 
the CFTR minigene assay was again employed. In homozygous M323K MEFs, the 
mutant TDP-43 caused greater levels of exon 9 skipping in the CFTR minigene. This 
characterised it as a gain of TDP-43 splicing function mutant, as it opposed the loss of 
function exon 9 inclusion increase seen in F210I MEFs and also upon TDP-43 KD. In 
concordance with the M323K model, the Q331K MEFs also displayed a dose dependent 
increase in exon skipping, identifying the Q331K mutation too as causing a gain of 
function in TDP-43 splicing (Figure 5.74).  
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Figure 5.74. CFTR minigene assay showing RT-PCR results and % exon 9 
inclusion in (left) wildtype TDP-43, (middle) heterozygous Q331K TDP-43, 
(right) homozygous Q331K TDP-43. Significant and dose dependent increase in 
exon 9 inclusion as a result of Q331K mutation. Minigene isoforms for exon 9 
inclusion and skipping labelled. Results from Abraham Acevedo Arozena. 
The definition of the Q331K mutation as causing similar, gain of TDP-43 function-
mediated changes in alternative splicing to the M323K was strengthened by RT-PCR 
study into known TDP-43 alternative splicing targets such as Sort1, Eif4h and Kcnip2. 
These alternative splicing events also showed a dose dependent decrease in exon 
skipping in the Q331K model, parallel with the M323K mouse (Figure 5.75). 
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Figure 5.75. RT-PCR results and quantification for inclusion levels of Sort1 exon 
18, Eif4h exon 5 and Kcnip2 exon 3 in wildtype, heterozygous Q331K and 
homozygous Q331KI MEFs. Significant and dose dependent decrease in exon 
inclusion as a result of Q331K mutation. Results from Abraham Acevedo 
Arozena. 
As the well-defined splicing events showed similar changes in both the M323K and 
Q331K models, we further tested the Q331K transcriptome for the novel skiptic events 
described in 4.2.6 Skiptic exons. These events had not previously been described in 
relation to changes in TDP-43 functioning, but in the Q331K model Abraham Acevedo 
Arozena identified a subset of the validated skiptic exons from the M323K model which 
also showed significant increases in exon skipping (Figure 5.76).  
 
Figure 5.76. RT-PCR results and quantification for inclusion levels of M323K 
skiptic exons Ube3c exon 6, Pex16 exon 4 and Pacrgl exon 7 in wildtype, 
169 
 
heterozygous Q331K and homozygous Q331K MEFs. Significant and dose 
dependent decrease in skiptic exon inclusions as a result of Q331K mutation. 
Results from Abraham Acevedo Arozena. 
It is important to note that while the Q331K mouse replicates the effect of TDP-43 gain 
of splicing function seen in the M323K model, the magnitude of the changes are lower 
in the Q331K mutant. The skiptic exons in particular seen by RT-PCR showed 
significant skipping, but size of the change was far less than the equivalent RT-PCR 
tests for the M323K (Figure 4.57). One explanation for this could be that the Q331K 
mutation is simply ‘weaker’ than the M323K mutation, and therefore inducing a less 
severe TDP-43 gain of function phenotype. This theory is supported by the 
homozygous Q331K mice proving viable on a pure C57BL/6J background, unlike either 
the homozygous F210I or M323K embryos. Additionally, phenotype testing by 
Abraham Acevedo Arozena is currently underway, but initial results do not suggest a 
motor phenotype of the same severity as in the adult M323K model. Therefore, if the 
Q331K mutation is weaker, then it is to be expected that the splicing dysregulation that 
results will also be dampened in comparison to the M323K.   
Testing of a subset of targets in the Q331K model already known to be significantly 
changed in the M323K mouse demonstrated some level of correlation, but to truly 
understand the similarity of the effects of the two LCD mutations on transcriptome 
regulation, RNA sequencing was required. For this, we utilised RNA-Seq experiments 
conducted on the Q331K model for the previously mentioned study by White et al. 
(2018). In this investigation, the C>A mutation resulting in the Q331K amino acid 
change seen in TDP-ALS patients was incorporated into the mouse Tardbp gene using 
CRISPR. As with the Q331K mouse in the hands of Abraham Acevedo Arozena, the 
homozygous Q331K model on a pure C57BL/6J background was viable and survived 
with no apparent change in lifespan. These mice displayed limited changes in 
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behaviours such as rearing and hanging, but initially nothing concrete to suggest a 
disease phenotype. Similarly, they performed worse on the rotarod test, but rather 
than a motor phenotype, this was determined to be due to an increase in Q331K model 
weight brought about by increased feeding tendency. These mice also showed no TDP-
43 mislocalisation or pathology like the M323K model, but additionally also displayed 
no degenerative pathology, no motor neuron degeneration and motor unit loss. Thus, 
the M323K mutant more closely replicated the ALS disease phenotype than the mouse 
model harbouring the TDP-ALS mutation. However, further cognitive testing of the 
Q331K model revealed deficits in attention and memory, resembling a disease closer to 
dementia than motor neuron disease on the ALS-FTD spectrum.  
To understand the molecular dysregulation underlying this neurodegenerative disease 
phenotype, White and colleagues conducted RNA-Seq analysis on heterozygous and 
homozygous Q331K frontal cortex at 5 months and then 20 months of age (Gene 
Expression Omnibus reference GSE99354). They described a handful of specific 
differentially expressed genes and alternative splicing events but, outside of the 
previously detailed changes mentioned in the M323K model, such as in Tardbp, Sort1 
etc., none of the changes they mentioned were significantly altered in the M323K 
models.  
To gauge the true level of similarity between the Q331K and M323K models, the 
published RNA-Seq data was obtained and analysed using the same pipeline as the 
M323K analysis, removing a degree of technical variation. Broad analysis was then 
conducted on the correlation of changes seen in the heterozygous and homozygous 
models of both, with FDR correction thresholds modified to 0.05 for both differential 
gene expression and alternative splicing. Dataset names are abbreviated as follows:  
6 month homozygous M323K spinal cord – m323k_adult_hom,  
6 month heterozygous M323K spinal cord – m323k_adult_het,  
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5 month homozygous Q331K frontal cortex – q331k_5m_fc_hom,  
5 month heterozygous Q331K frontal cortex – q331k_5m_fc_het,  
20 month homozygous Q331K frontal cortex – q331k_20m_fc_hom,  
20 month heterozygous Q331K frontal cortex – q331k_20m_fc_het. 
In terms of differential gene expression, correlation analysis was conducted by 
comparing the log2 fold changes of genes differentially expressed in either dataset, and 
calculation of the Pearson correlation coefficient. For reference, the correlation plot 
and r value for the M323K homozygous model in comparison to the M323K 
heterozygous model was also included. The homozygous and heterozygous M323K 
RNA-Seq datasets showed strong positive correlation, demonstrating that despite only 
a small number of expression changes occurring in the heterozygous model, the 
direction of change was mostly replicated (Figure 5.77). This correlation was 
highlighted by an r value of 0.783. Comparison of the homozygous M323K RNA-Seq 
data, from 6 month spinal cord, with homozygous Q331K frontal cortex RNA-Seq at 5 
months and 20 months, also showed strong correlation in expression changes in both. 
The r values, although understandably smaller than comparison of the two M323K 
models, still suggested a high level of correlation, with values of 0.317 and 0.338 
respectively. Specific gene expression levels were not tested experimentally in the 
M323K and Q331K models, and so these analyses provided strong new evidence that 
expression changes in the two models were highly similar across the transcriptome. 
Similar analysis was also conducted for the heterozygous models at each time point, 
and comparison between each of these as well as to each homozygous model showed 
strong levels of correlation, with  comparison of no two datasets resulting in an r value 
of below 0.23 (Figure 5.77). 
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Figure 5.77. Scatter plots comparing significantly differentially expressed genes 
in either of the two compared RNA-Seq datasets measured by log2 fold change of 
mutant transcript vs wildtype. Comparisons are homozygous adult M323K vs 
each of heterozygous adult M323K, homozygous 5 month Q331K frontal cortex, 
and homozygous 20 month Q331K frontal cortex. Linear model fitted for each 
comparison. Pearson correlation coefficient annotated for each comparison. 
Strong positive correlation seen in each comparison.  
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Given the number of RNA-Seq datasets from the two models, the significant hits from 
each were also compared to determine the level of overlap. Two of the six datasets 
showed no differentially expressed genes – the heterozygous M323K adult dataset and 
the heterozygous Q331K 5 month frontal cortex. Comparison was analysed graphically 
using the UpSetR package (Conway et al. 2017). 
The vast majority of differentially expressed genes were unique to any one dataset 
(Figure 5.78). However, 29 genes showed changes in expression in every homozygous 
model dataset and 5 genes were differentially expressed in these three and also the 
aged heterozygous 20 month Q331K data. These five genes were Spop, Gid4, Gstm7, 
D2hgdh and Gm37277. Intriguingly, Spop, downregulated in each dataset, codes for a 
component of the E3 ubiquitin-protein ligase complex (Furukawa et al. 2003), the same 
category which was found to be enriched for skiptic exon transcripts in the 
homozygous M323K model. GID4 protein is also part of a ubiquitin ligase complex as 
highlighted by its gene ontology, and this gene is also downregulated in each dataset. 
The downregulation of two genes from this specific pathway, alongside the skiptic 
exons and the ubiquitin pathology in the more severe phenotype of the M323K model, 
further suggests that ubiquitin ligase complex activity is a key area for further study.  
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Figure 5.78. Comparison and quantification of overlap between the significantly 
differentially expressed gene sets from each of the analysed M323K and Q331K 
RNA-Seq datasets. Bar graph at the top indicates number of shared differentially 
expressed genes, dot matrix below indicates the datasets compared, and columns 
to the left show total size of differentially expressed genes set in each RNA-Seq 
dataset. Most differentially expressed genes unique to one RNA-Seq dataset, but 
five genes dysregulated in every dataset showing significant changes. 
Similar analyses were also conducted on the alternative splicing events for each M323K 
and Q331K dataset. Scatter plot comparison again showed strong correlation first 
between the M323K homozygous and heterozygous models, with an r value of 0.737 
(Figure 5.79). Comparison of the homozygous M323K alternative splicing to the events 
in the 5 month and 20 month homozygous Q331K models also showed sizeable 
correlation, with the r values of 0.522 and 0.49 noticeably higher than similar testing of 
the differential gene expressions correlations (Figure 5.79). Again, similar comparisons 
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were conducted with each heterozygous model, and every two way comparison 
showed positive correlation, with all r values above 0.38.  
The strong levels of correlation in significant alternative splicing events, even more so 
than the similarity seen in gene expression changes, is a further indicator of the 
similarity in transcriptome dysregulation in the two LCD mutants. Specific transcripts 
were already shown to modulate splicing in the same manner (Figure 5.75, Figure 
5.76); now the general transcriptome-wide splicing pattern was demonstrated as 
markedly similar between the two models across mutant copy number and time point 
differences. As it was the splicing changes that classed the M323K as a gain of function, 
the splicing pattern similarities further enabled the characterisation of the TDP-ALS 
mutation Q331K as also resulting in gain of TDP-43 splicing function. The enrichment 
of strong exon skipping changes as a result of Q331K TDP-43 mutation had also 
previously been described in a transgenic mouse model (Arnold et al. 2013). Notably, 
the Q331K splicing changes tended to exhibit smaller Δ PSI values than in M323K 
model in general, from which it could be inferred that the Q331K mutation may be the 
weaker mutation. This supports previous assertions given the reduced impact of the 
Q331K on known TDP-43 splicing targets, and the weaker phenotype in the 
homozygous mouse model.   
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Figure 5.79. Scatter plots comparing significantly differential splicing events in 
either of the two compared RNA-Seq datasets measured by log2 fold change of 
transcript in mutant vs respective wildtype. Comparisons are homozygous adult 
M323K vs each of heterozygous adult M323K, homozygous 5 month Q331K 
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frontal cortex, and homozygous 20 month Q331K frontal cortex. Linear model 
fitted for each comparison. Pearson correlation coefficient annotated for each 
comparison. Strong positive correlation seen in each comparison. 
In a similar manner to the differential expression analysis, overlap of significantly 
differently alternatively spliced genes from each dataset was also tested. Visualisation 
with the UpSetR package (Conway et al. 2017) again revealed that the majority of 
splicing changes were unique to the models showing the most changes overall (Figure 
5.80). 23 splicing events were significantly changed in each of the homozygous datasets 
but not in any of the heterozygous models. Further, 10 splicing events were detected to 
be changed in four of the six datasets.  
Intriguingly, one event was alternatively spliced differently in all datasets but the 
heterozygous aged Q331K model, and this was the previously discussed splicing of 
Eif4h. The alternatively spliced exon in this gene was increasingly skipped in each 
dataset, corroborating the gain of TDP-43 splicing function in the two mutations. 
However, remarkably there was also one event showing splicing changes in all six 
datasets (Figure 5.80), and this was a splicing change in Ttc3. Unlike Eif4h, Ttc3 has not 
been previously discussed, despite consistently showing splicing changes. This is due 
to several alternative splicing events being involved in the Ttc3 gene; the same is not 
true for Eif4h. The multiple isoforms of Ttc3 also renders validation of the splicing 
changes considerably more difficult. However, the Ttc3 gene is of great interest as it 
belongs to the same group of proteins already heavily implicated in the dysregulation 
caused by the LCD mutants – it is another E3 ubiquitin ligase. As previously mentioned 
in 4.2.6 Skiptic exons, E3 ubiquitin ligases are a diverse group of proteins involved in 
protein ubiquitination, either directly or indirectly as adaptors to facilitate the 
ubiquitination (Berndsen & Wolberger 2014). The changes in this subgroup of proteins 
in both gene expression and alternative splicing, occasionally resulting in novel 
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transcripts due to skiptic exons, and the subsequent ubiquitin pathology in the M323K 
model, together strongly implicate this pathway as dysfunctional in these TDP-43 LCD 
mutant models of neurodegeneration.  
 
Figure 5.80. Comparison and quantification of overlap between the significantly 
differentially spliced gene sets from each of the analysed M323K and Q331K 
RNA-Seq datasets. Bar graph at the top indicates number of shared differentially 
spliced events, dot matrix below indicates the datasets compared, and columns 
to the left show total size of the differentially spliced event set in each RNA-Seq 
dataset. Most differential splicing events were unique to one RNA-Seq dataset, 
but one splicing event was dysregulated in every dataset. 
Given the comparable changes in alternative splicing in the Q331K model compared to 
the M323K, extreme splicing events were also analysed in this dataset. Cryptic exons, 
shown to be as a result of loss of function in the F210I model, were minimal as 
expected. However, whereas 47 skiptic exons were identified in the M323K model, only 
5 skiptic events were detected in each of the homozygous Q331K 5 month and 20 
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month datasets. Two of these skiptic events were in both Q331K datasets, in Stt3b and 
Hsdl2. Interestingly, the skiptic exon in Hsdl2 was also detected as a skiptic exon in the 
M323K dataset, however overall level of overlap was poor. A reason for the lack of 
skiptic exons in the Q331K may have been technical, as the number of reads per sample 
in the Q331K RNA-Seq datasets were far less than in the M323K, and the skiptic exons 
were often rare splicing events. Therefore, although they may have shown a similar 
pattern of skipping, they may have not reached a sufficient level of significance to be 
classed as a skiptic exon. To test if this was true, the skiptic exon events from the 
homozygous M323K 6 month spinal cord dataset were also examined in each of the 
heterozygous and homozygous Q331K datasets in 5 month and 20 month frontal 
cortex. Analysis revealed that, with a couple of exceptions, the skiptic exons in the 
M323K tended to show increased skipping in the Q331K datasets too (Figure 5.81). 
However, the Δ PSI values for these events were generally much smaller than in the 
M323K. This is concordant with previous assertion that the Q331K is a weaker 
mutation than M323K. The relatively small magnitude of splicing changes prevents the 
identification of the M323K skiptic exons as skiptic in the Q331K dataset, but they do 
nonetheless typically show increased levels of skipping in each Q331K dataset. 
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Figure 5.81. Comparison of Δ PSI levels of the skiptic exons identified from the 
homozygous adult M323K RNA-Seq dataset in all other analysed LCD mutant 
datasets. In most splicing events, Δ PSI skipping was greatest in the homozygous 
adult M323K dataset, but showed reduced levels of skipping in other datasets. 
Several skiptic exon splicing events were not seen in the Q331K datasets.  
Both of the above comparison methods – the correlation analysis and the dataset 
overlaps – provide information on the similarity of the two datasets being analysed. 
However, they both have their drawbacks. The correlation analysis conveys the overall 
similarity of the two datasets, and the overlaps analysis provides specific instances of 
interesting change in the compared datasets, but neither makes use of the potential 
increase in statistical power to detect changes which would not be detected as 
significant in one dataset alone. These changes may show higher levels of variability, 
low levels of expression, or small but consistent changes, but may still prove of interest 
if occurring across the different models.  
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To find these changes, we also conducted a meta-analysis of the differential gene 
expression RNA-Seq datasets from the M323K and Q331K mutants. There are a 
number of methods by which this could have been conducted, and the first method 
trialled was using the Fisher method of p-value combination using the metaRNA-Seq 
package (Rau et al. 2014).  With the modified FDR threshold of 0.05, the homozygous 
M323K 6 month spinal cord dataset showed 757 changes in gene expression. With the 
same threshold, the homozygous Q331K 5 month frontal cortex dataset showed 370 
differentially expressed genes. Using a simple overlap method, the number of 
significant hits in both datasets amounts to just 90 genes, despite the clear strong 
correlation in gene expression level changes in the two datasets as shown in Figure 
5.77.  
However, using the Fisher method of p-value combination, 1,165 genes can be 
identified as significantly changed in terms of expression levels. The changes in 
significant hits is illustrated in Figure 5.82 below, in which the original FDR values of 
each gene for either dataset are plotted to enable visualisation. In red are genes which 
were identified as significant in either of the two datasets in the initial analysis, and 
remain significant upon Fisher combination. Black dots however represent genes 
which were classed as significant in either original analysis but not upon p-value 
combination. These genes are typically those that display significant change in one 
dataset but no evidence of any change in the other. In grey are genes not significant in 
any analysis. The genes in pink are those that were not originally classed as significant 
in either dataset but showed adjusted p-values approaching significance in both; these 
are the hits obtained with the increased power upon p-value combination. From the 
M323K dataset, 97 of the 757 genes lost significance upon p-value combination, but 
505 new genes were classed as significant. For the Q331K dataset just 16 genes were 
lost and 811 gained (Figure 5.82). The remarkably high number of new significant hits 
using this Fisher p-value combination method highlights the strong level of similarity 
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in the two datasets, with read depth and sample numbers in individual experiments the 
likely limiting factors due to which these genes are not detected upon simple dataset 
overlap.  
 
Figure 5.82. Adjusted p-values of all genes expressed in the homozygous adult 
M323K and homozygous 5 month Q331K RNA-Seq datasets compared, and the 
outcome of different tests for statistical significant illustrated. Red dots 
represent genes classed as significantly differently expressed in either individual 
dataset, and also upon p-value combination with the Fisher method. In black are 
genes classed as significant in either individual dataset but not upon p-value 
combination, in pink are genes not classed as significant in either individual 
dataset but significant upon p-value combination, and in grey are genes which 
show no significant differential expression upon either method.  
Although the Fisher method of p-value combination incorporates the increased power 
of two datasets in its meta-analysis, it does not take other information into account, 
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namely the direction of the change. This was artificially incorporated in the above 
analysis, but the removal of genes showing expression changes in opposite directions 
reduces the power of the analysis. Furthermore, features of the gene expression itself, 
such as normalised gene expression levels, are not used in the statistical test.  
This metric, alongside others such as gene-specific expression variability between 
samples, is incorporated into the modelling and statistical testing used in the initial 
differential gene expression analysis conducted through DESeq2, as outlined in 2.1.7 
Bioinformatics analysis. As both expression datasets come from similar RNA-Seq 
experiments, this gene-level information could be incorporated by conducting the 
meta-analysis on both datasets as one experiment, comparing wildtype to LCD-
mutants, with the addition of a study-specific covariate to identify the original dataset 
of each sample and take into account the technical variation resulting from the two 
different experiments. DESeq2 expression analysis of the M323K/Q331K mutants 
compared to wildtype with the covariate accounted for enabled the detection of 1,703 
significant events in total, substantially more than in either individual dataset.  
Figure 5.83 illustrates the changes in significant hits below, comparing the original FDR 
values from each dataset as above. Similarly to the Fisher p-value combination method, 
expression analysis of the two mutants with covariate addition again resulted in the 
loss of significance for some genes showing differences in expression patterns in the 
two models, shown in black. The genes detected as significant only upon covariate 
analysis, in pink, are also again mostly those approaching significance in both datasets. 
However, the clustering of these new hits is much more spread than upon p-value 
combination, and this is likely due to the additional incorporation of gene-level 
information in this analysis (Figure 5.83).  
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Figure 5.83. Adjusted p-values of all genes expressed in the homozygous adult 
M323K and homozygous 5 month Q331K RNA-Seq datasets compared, and the 
outcome of different tests for statistical significant illustrated. Red dots 
represent genes classed as significantly differently expressed in either individual 
dataset, and also upon joint analysis modelling with a covariate. In black are 
genes classed as significant in either individual dataset but not upon joint 
analysis, in pink are genes not classed as significant in either individual dataset 
but significant upon joint analysis, and in grey are genes which show no 
significant differential expression upon either method. 
Overall the two meta-analysis methods clearly demonstrate the advantage of 
combining datasets to increase statistical power of differential gene expression 
detection in the M323K and Q331K models, most likely resulting from the overall 
similarity in gene expression changes in the two datasets. The new hits in each method 
are slightly different; a safe approach may be to focus on genes highlighted by both 
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methods. This work is currently in its early stages, further work is required to validate 
whether the newly identified genes by either method truly exhibit changes in 
expression, and also to understand whether the gene hits lost through combination are 
really false positives in the context of TDP-43 LCD mutation-caused gene expression 
changes. If confirmed, the above methods provide ability to study a much more 
substantial set of gene expression changes, which may aid the targeting of specific 
niche pathways otherwise missed if datasets were compared through simple overlap.  
Following steps would also involve understanding the relevance of these non-model 
specific expression changes to disease, especially as gene expression dysregulation in 
the M323K model alone did not reveal any particularly affected pathways. The above 
methods would arguably prove more useful for the alternative splicing changes, given 
the stronger levels of correlation between the two datasets individually and the 
confirmed similarity in effect on a subset of TDP-43 targets. Perhaps this would also 
enable the detection of skiptic exons in both datasets, for which the statistical power of 
the Q331K dataset alone, due to the comparatively weaker sizes of change, may be 
insufficient.  
5.3 ALS PATIENT POST-MORTEM TISSUE 
Using the M323K and then the Q331K models, we established a pattern of alternative 
splicing in a subset of known TDP-43 targets which showed dysregulation upon LCD 
mutation. The direction of splicing changes in general was consistent between the two 
datasets, and specific events in genes such as Sort1 and Eif4h were validated to be 
significantly changed in both models. However, whilst this demonstrated the impact of 
LCD and TDP-ALS mutation in mouse models, it was not yet clear whether these 
changes would be translated into patients. Neurodegenerative disease mouse models 
typically have a poor record of leading to therapeutics for patients (Eaton & Wishart 
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2017). Specifically looking at the RNA, transcriptomic changes in mouse models also 
can show poor levels of conservation when looking into patient tissue with similar 
settings (Burns et al. 2015). A specific example of this is the alternative splicing of 
Sort1. It is well characterised to be controlled by TDP-43 to produce two stable 
isoforms in mice, but the repression of the analogous splicing event in human Sort1 is 
toxic (Prudencio et al. 2012). Therefore, it was of great importance to define precisely 
which of the disrupted RNA processing features from the M323K and Q331K mouse 
models were conserved in a human patient context. 
Currently, there is no high quality published data of mRNA sequencing in post-mortem 
TDP-ALS patient tissue, although several transcriptomic investigations into post-
mortem ALS tissue of other aetiologies have been conducted (Malaspina et al. 2001; 
Dangond et al. 2004; Jiang et al. 2005; Wang et al. 2006; Brockington et al. 2013; 
Highley et al. 2014). The design of these studies was not optimised for analysis of splice 
junctions, and as a result the presence of skiptic exons could not be analysed at a 
transcriptome-wide level. However, one of the key properties of skiptic exons is the 
conservation across mice and humans; therefore in theory the same skiptic exons 
detected in the adult diseased M323K mice could be occurring in post-mortem patient 
tissue.  
Therefore, the seven skiptic exons validated by RT-PCR in the M323K spinal cord RNA 
– Ankrd42, Herc2, Pacrgl, Pex16, Plod1, Slc6a6, Ube3c (Figure 4.57) – were examined for 
in post-mortem ALS tissue. In total, post-mortem tissue-derived RNA was tested from 
15 ALS, FTD or ALS-FTD patients alongside 3 controls. The tissue used for RNA 
extraction was the frontal cortex in each case bar one, in which the temporal lobe 
tissue was used. Patients had varied aetiology, with the disease cause of most not found 
in the most common ALS-linked genes, and C9ORF72 mutation the primary culprit of 
the identified causative genes. Patients were also variable for TDP-43 pathology, in 
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keeping with the estimation that 50 % of FTD patients show TDP-43 pathology in 
comparison to the greater than 95 % of ALS patients. 4 further patients diagnosed with 
Pick’s disease, who also displayed TDP-43 pathology, were included in the study. Of the 
seven targets – ANKRD42, HERC2, PACRGL, PEX16, PLOD1, SLC6A6 and UBE3C, only two 
showed presence of skiptic isoforms: SLC6A6 and UBE3C. SLC6A6 skiptic isoforms were 
present in both controls and patient tissue however, and there was no apparent 
difference in skiptic isoform prevalence upon quantification. Contrastingly, only one 
sample of all tested displayed the skiptic isoform of UBE3C, but in this patient the 
skiptic isoform was very prominent (Figure 5.84). The shortened isoform in this 
sample fitted with the expected size of skiptic exon transcripts, but sequencing of the 
PCR product is required to confirm the finding. This RNA sample was obtained from 
the frontal cortex a 69 year old male patient diagnosed with ALS, with no further 
information available to determine why this sample alone would exhibit this skiptic 
exon. 
 
Figure 5.84. Tapestation gel showing RT-PCR products for tested skiptic exon in 
UBE3C. First three samples are controls, the next nine are ALS/FTD patient 
samples with various aetiology. Wildtype and skiptic isoforms annotated. Skiptic 
exon isoform prominently seen in one ALS sample alone. 
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The variability in skiptic exon expression in UBE3C in comparison to the M323K model 
may be partially accounted for by the much greater level of natural variation present in 
the general population versus inbred mouse models. Although TDP-43 splicing activity 
is strongly linked to control of Ube3c splicing in our M323K mice, several other 
regulators are also like to be simultaneously involved, as is common for certain splicing 
events (Appocher et al. 2017). Each of these factors would possess their own level of 
variability, therefore consistent levels of skiptic exon presence would be unexpected. 
Additionally, the nature of RNA preservation in post-mortem tissue can be 
inconsistent, although this is not typically the case provided appropriate storage 
protocols are followed (K. White et al. 2018). However, this could be a problem in 
particular for unstable transcript isoforms, such as those with skiptic exons as 
previously demonstrated by the predicted NMD fate in several examples. Any skiptic 
exon transcripts present may have been degraded prior to tissue preservation and not 
available for amplification by PCR.  
Furthermore, it is important to note the heterogeneity of the samples also continues 
into the cause of disease. In the M323K model TDP-43 mutation was responsible for 
the splicing changes seen, but in these patients the causative mutation in most cases 
was unknown, and not found in the most common ALS-linked genes. Similarly, 
presence of TDP-43 pathology in these cases was not always clear. Therefore, it was 
not fully apparent what the expected splicing profile in these samples should be. 
However, the presence of an apparent skiptic exon isoform similar to the alternative 
splicing seen in the M323K model suggested that a similar disruption in TDP-43 
splicing activity could be conserved in ALS patient tissue.  
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5.4 TDP-ALS PATIENT FIBROBLASTS 
To gain a greater understanding for how precisely TDP-ALS mutations could influence 
splicing activity in patient tissue, fibroblasts were obtained from TDP-ALS patient skin 
biopsies. Fibroblasts were obtained from four TDP-ALS patients, three of whom 
possessed the A382T mutation (Kabashi, Paul N Valdmanis, et al. 2008), and one 
person the G298S mutation (Van Deerlin et al. 2008). Patients of both sexes were 
included, and one patient showed early onset ALS in comparison to the other three 
who had the more typical late onset (Figure 5.85). Four control lines were used for 
comparison.  
 
Figure 5.85. Sample details of TDP-ALS fibroblasts used. Site of onset, LL – lower 
limb, UL – upper limb, B – bulbar.  
Fibroblasts were cultured as described in 2.4 Cell culture, and splicing patterns were 
tested as outlined in 2.1.4 Polymerase chain reaction. To first understand whether the 
gain of TDP-43 splicing function that occurred as a result of LCD mutation in the 
investigated mouse models held true in TDP-ALS patients with similar mutations, the 
splicing of validated mouse targets, such as SORT1,  EIF4H, ATXN2 and DNAJC5, was 
tested. Alternative splicing was confirmed in three of these targets, and two of the 
patient samples showed substantial increase in exon skipping in each of these three 
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transcripts (Figure 5.86). However, the other two patients’ splicing profiles resembled 
the markedly consistent controls. This again showed the variability in true disease 
settings that is not replicated in inbred mouse models, but implied that in some 
patients the gain of TDP-43 splicing may hold true in a manner similar to the LCD 
mutant mouse models.  
 
Figure 5.86. Tapestation gel and quantification of RT-PCR tests for alternative 
splicing event changes in ATXN2, DNAJC5 and EIF4H in TDP-ALS fibroblast RNA 
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compared to wildtype. Two TDP-ALS samples showed reduced exon inclusion, 
but two showed wildtype levels, for each splicing event.  
Following on from this finding, the presence of the extreme splicing skiptic exon events 
were also examined. Each of the seven initially validated targets were tested for, and of 
these, ANKRD42, PACRGL, PLOD1 and SLC6A6 showed the presence of the skiptic exon 
isoform. Crucially, upon quantification, two of these targets – PLOD1 and SLC6A6 – 
further showed increased presence of the skiptic exon isoform in all 4 patient samples 
in comparison to controls, with both changes statistically significant (Figure 5.87). 
These findings, although still somewhat preliminary, encouragingly demonstrate that a 
subset of the novel splicing events identified as skiptic exons in LCD mutant mouse 
models show similar, although reduced, skipping changes in TDP-ALS patients. 
Furthermore, these results also implicate gain of function in TDP-43 splicing activity as 
being caused by LCD mutations in both mouse and human settings, thereby 
encouraging further study of the mouse model transcriptome to find similarly 
conserved RNA processing changes in ALS patients.  
192 
 
 
Figure 5.87. Tapestation gel and quantification of skiptic exon splicing in PLOD1 
and SLC6A6 in TDP-ALS samples compared to wildtype. In both splicing events, 
all TDP-ALS samples showed significantly increased presence of the skiptic 
isoform in comparison to wildtypes. 
The finding of conserved changes in alternative splicing of LCD-mutant mouse models 
also in TDP-ALS patient settings provides tremendous promise for the use of these 
mice as true models of disease. However, there remain many limitations to the 
translation of the mouse findings to a patient context. A key limitation of the 
aforementioned experiment is the use of fibroblasts for the splicing event profiling, a 
non-neuronal setting. ALS patients typically show impact on motor neurons 
specifically, in both the upper and lower motor neurons, suggesting either a motor 
neuron-specific change, or a change which for an unknown reason affects motor 
neurons above other cell types. In either case, studying motor neuron-specific changes 
is crucial to understanding the underlying mechanism. Additionally, if the extreme 
splicing changes resulting in novel transcripts like skiptic exons are of particular 
importance, then neuronal study is also vital due to transcriptome splicing showing 
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substantial cell-specific changes (Melé et al. 2015). Tied to this, the activity of hnRNPs, 
like TDP-43, are also changed in different cell types (McKee et al. 2005; Ling et al. 
2010). It is important to also consider that the skiptic isoforms tested for, and those 
identified as conserved in human patients, are not necessarily implicated in the disease 
itself, rather they serve to highlight that the conservation exists.  
Further work is required to examine the profile of all skiptic events identified in the 
M323K model with conserved exon skipping phenotype in the Q331K model. This is 
especially true for the E3 ubiquitin ligase linked genes Herc2, Ube3c, Ube2e2, Wwp1, 
Ttc3 and Wsb1, of which only two have so far been tested. Perhaps the simultaneous 
dysregulation of several genes involved in the ubiquitination and subsequent protein 
degradation pathways would provide a clear link between the shared ubiquitin 
phenotypes in the disease models and patient settings. To investigate this further, high-
throughput sequencing of the TDP-ALS mutant fibroblasts is required. Previous 
investigation into similar models has been conducted with microarray analysis 
(Highley et al. 2014), however high-depth RNA-Seq may be required for detection of 
the novel, rare, often unannotated skiptic exon events.  
5.6 HNRNP A1 CASE STUDY 
The overarching aim throughout this investigation has been to identify features of RNA 
processing which are dysregulated by TDP-43 mutation, and then further that the 
changes are conserved in TDP-ALS patients. Ideally, the changes should also 
themselves provide clues as to how the dysregulation could lead to a disease 
phenotype, rather than just a symptom of the mutation. Thus far, several examples of 
gene expression and splicing changes have been studied, and a number of these 
showed various levels of conservation in other models of loss or gain of TDP-43 
function, in the Q331K mouse model, and in patient settings of post-mortem tissue or 
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non-neuronal cell types. The skiptic exons, a novel subset of transcripts shown to link 
LCD mutation effects in TDP-43 between the studied mouse models and patient 
settings, nevertheless do not fulfil the aforementioned aim entirely. Although the link 
to E3 ubiquitin ligases exists, and warrants further investigation, the precise 
connection between skiptic isoforms and how this could even lead to a phenotype at 
the cellular level remains unclear. Furthermore, although the skipping phenomenon 
persists, the reduction in Δ PSI in the Q331K model and in patient tissues raises the 
question of how impactful the changes would really be. However, one splicing change 
has met the stated aim, in its consistency and its presence in an ALS-related gene: the 
alternative splicing of Hnrnpa1.  
Like TDP-43, hnRNP A1 is an RBP involved in several aspects of RNA processing ( 
Mayeda et al. 1994; Bekenstein & Soreq 2013; Jean-Philippe et al. 2013), it also 
contains two RRM domains, and a C-terminal LCD domain, and it is primarily found in 
the nucleus. Crucially, in disease it is mislocalised in a similar manner to TDP-43 too, 
showing cytoplasmic mislocalisation (Kim et al. 2013). Finally, as with TDP-43, 
mutations in the LCD of HNRNPA1 can cause ALS (Kim et al. 2013), although these 
mutations are exceptionally rare (Calini et al. 2013; Seelen et al. 2014). Therefore it is 
apparent that hnRNP A1 is a similar protein to TDP-43.  
A recent study by Deshaies et al. (2018) investigated the splicing of HNRNPA1 resulting 
in the formation of the protein isoform termed hnRNP A1-7B, a long isoform of hnRNP 
A1 that contained an extension of the LCD, elongated by 52 amino acids. This 
lengthening suggested a possible increased propensity for aggregation, and 
concordantly this hnRNP A1-7B was present in post-mortem ALS patient spinal motor 
neuron inclusions, although they were found distinct to TDP-43 aggregates, concordant 
with previous findings (Honda et al. 2015). Intriguingly, the transcript isoform that 
lead to translation of this longer protein was linked to loss of TDP-43 function. 
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Specifically, Deshaies et al. (2018) suggested that loss of TDP-43 reduced the 
repression of exon 7B, leading to its increased inclusion upon TDP-43 KD. These longer 
transcripts were then translated to produce greater levels of the aggregation prone 
hnRNP A1-7B protein. 
The direct binding of TDP-43 to HNRNPA1 transcripts in HeLa cells was determined by 
Deshaies et al. (2018) through immunoprecipitation of TDP-43 and subsequent RT-
PCR of the RNA attached. They further predicted computationally that the binding site 
of TDP-43 to the HNRNPA1 transcript would be surrounding the alternatively spliced 
exon 7B. To investigate this more thoroughly, we analysed our iCLIP datasets to 
determine the precise region of binding of TDP-43 to Hnrnpa1 in mice. In our wildtype 
mouse iCLIP data, TDP-43 was bound to the 3’UTR of Hnrnpa1 transcripts (Figure 
5.88). Importantly, this binding region was also conserved in human TDP-43 iCLIP data 
(Tollervey et al. 2011; Rogelj et al. 2012), although in humans an additional binding 
region was identified in exon 8. There was, however, no TDP-43 binding detected in the 
intronic regions surrounding exon 7B, or in exon 7B itself.  
 
Figure 5.88. Mouse and human Hnrnpa1/HNRNPA1 transcript isoforms. 
Alternatively spliced exon 7B highlighted in red. Respective mouse and human 
TDP-43 iCLIP data showing TDP-43 binding sites on Hnrnpa1/HNRNPA1 shown 
below.  
Furthermore, we thoroughly examined the hypothesis that loss of TDP-43 would lead 
to increased exon 7B inclusion in HNRNPA1. Two TDP-43 loss of function datasets were 
first utilised, our own homozygous embryonic F210I forebrain RNA-Seq dataset, and 
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the TDP-43 KD dataset from adult mouse striatum (Polymenidou et al. 2011). These 
two datasets have already been demonstrated to be highly concordant in terms of TDP-
43 splicing of known targets, thereby allowing classification of the F210I mutation as 
resulting in a hypomorphic allele. Intriguingly, loss of TDP-43 splicing activity in these 
our F210I dataset was more typically linked with lost repression, and therefore 
increased exon inclusion levels, which would fit with the finding by Deshaies et al. 
However, in this case the opposite was true – in both the F210I and TDP-43 KD 
datasets, loss of TDP-43 function resulted in significantly lower levels of exon inclusion 
(Figure 5.89), the opposite of the findings by Deshaies et al.  
We further analysed our RNA-Seq datasets for the adult M323K spinal cord, and the 
datasets for adult Q331K frontal cortex (M. A. White et al. 2018). These mutations have 
been demonstrated to cause a gain of function in TDP-43 splicing activity. Fittingly, in 
both the heterozygous and homozygous models, a dose dependent increase in exon 7B 
inclusion was detected in both mutants (Figure 5.89). Together, these six datasets 
comprehensively revealed that in mouse, Hnrnpa1 exon 7B inclusion was enhanced by 
TDP-43, even more so upon TDP-43 gain of function, and repressed by TDP-43 loss of 
function. 
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Figure 5.89. PSI values for Hnrnpa1 exon 7B in six published RNA-Seq datasets: 
TDP-43 ASO-KD (Polymenidou et al. 2011), F210I embryonic day 14.5 frontal 
cortex, M323K embryonic day 14.5 head, M323K 6-month spinal cord, Q331K 5-
month spinal cord and Q331K 20-month spinal cord (M. A. White et al. 2018), * p 
< 0.05, ** p < 0.01. Decreased exon 7B inclusion in TDP-43 loss of function 
models, in contrast to dose-dependent increase in exon 7B inclusion in M323K 
and Q331K TDP-43 gain of splicing function models. 
Importantly, the work by Deshaies et al. was primarily in HeLa cells, a human setting, 
whereas the examined RNA-Seq datasets were in mice. Although unlikely given the 
substantial sequence conservation in both TDP-43 and Hnrnpa1, it was possible that in 
humans TDP-43 would function to have the opposite effect in HNRNPA1 splicing. In 
order to test this, we additionally examined an RNA-Seq dataset from shRNA-mediated 
TDP-43 knockdown in motor neurons generated from wildtype human iPSCs (Kapeli et 
al. 2016). Concordant with the rest of our findings, the loss of TDP-43 resulted in 
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substantial reduction in HNRNPA1 exon 7B inclusion (Figure 5.90), refuting the 
possibility that regulation of this splicing event by TDP-43 was opposite in mouse and 
human tissues.  
 
Figure 5.90. Left: representative RNA-Seq trace of wildtype and TDP-43 
KD samples for HNRNPA1 exon 7b, highlighted in red. Sashimi splicing 
schematic overlaid. Proportion of exon inclusion annotated above exon, 
proportion of junctions annotating skipping annotated below. Right: PSI 
quantification of HNRNPA1 exon 7b in the human wildtype and TDP-43 KD 
dataset. Substantial increase in exon skipping as a result of TDP -43 KD 
illustrated in both cases.  
Therefore, in summary the investigation of HNRNPA1 splicing by TDP-43 convincingly 
contradicted the results published by Deshaies et al. In seven RNA-Seq datasets across 
mice and humans, loss of TDP-43 led to reduced inclusion of exon 7B in Hnrnpa1, and 
increased inclusion upon gain of TDP-43 splicing function. However, notably these 
findings agreed with Deshaies et al in that the increased prevalence of HNRNPA1-7B 
isoform was in the disease mouse models, M323K and Q331K, where Deshaies et al. 
found the increase primarily at the protein level in post-mortem ALS spinal cord motor 
neurons. Although the mechanism by which TDP-43 dysregulation leads to hnRNP A1-
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7B increase may differ in the two studies, the link between the increased long isoform 
and disease is comparable (Sivakumar et al. 2018).  
The details of the publicly available data can be found in these repositories:  
Dataset Repository Samples 
Read 
length 
Sequencing 
depth 
F210I/M323K 
NCBI Sequence 
Read Archive 
reference 
SRP133158 
See Chapter 2.1.6 RNA-Sequencing 
Mouse TDP- 43 KD 
NCBI Sequence 
Read Archive 
reference 
SRP005860 
4 WT, 4 KD 75 x2 ~45M reads 
Q331K 
Gene Expression 
Omnibus 
reference 
GSE99354 
5 months : 6 
WT, 6 HET, 8 
HOM 
20 months: 7 
WT, 10 HET, 10 
HOM 
100 x2 
5 months: 
~80M reads 
20 months: 
~100M 
reads 
Human TDP-43 KD 
Gene Expression 
Omnibus 
reference 
GSE77707 
3 WT, 2 KD 50 x2 ~30M reads 
Table 5.22. Datasets used in analysis of HNRNPA1 exon 7B splicing by 
TDP-43 with sequencing details and repository for each.  
The high relevance of HNRNPA1 to ALS heavily implicates this splicing event in 
particular to the mass RNA dysregulation seen upon TDP-43 dysregulation. The 
increased formation of the aggregate prone hnRNP A1-7B protein isoform may act as a 
secondary hit, leading to disrupted RNA processing of hnRNP A1 targets as well as the 
preceding gene expression and splicing changes caused by TDP-43 dysregulation. 
HnRNP A1 itself is known to be a vital protein, and like TDP-43 its transcript levels are 
tightly controlled through an autoregulatory mechanism (Suzuki & Matsuoka 2017). 
Complete loss of hnRNP A1 through KO in mice is embryonically lethal (Liu et al. 2017), 
while even low level of overexpression is toxic too (Suzuki & Matsuoka 2017), as is the 
case with TDP-43, demonstrating that this protein has functions which cannot be fully 
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compensated for. ALS-causative mutations in HNRNPA1 can also occur in regions of the 
LCD only present in isoforms detected exclusively in CNS tissue (Q. Liu et al. 2016), 
providing a link between the RBP dysfunction and motor neuron-specific effects in ALS. 
Further study of TDP-43 interaction with other hnRNPs and RBPs is necessary to 
understand whether a possible ‘domino’ effect could be underlying the substantial RNA 
dysregulation culminating from TDP-43 mutation.  
This finding is also highly relevant for the use of mouse models to study molecular 
dysregulation in human settings. The splicing of HNRNPA1 exon 7B provides a perfect 
example of a splicing event that is so strongly controlled solely by TDP-43 that opposite 
changes in TDP-43 splicing activity alone are sufficient to significantly change the 
strength of the splicing. The splicing also not only held true in mouse models with 
different mutation, and all the technical variations that come with a different study, but 
remarkably also substantially so in human neuronal cells. This represents powerful 
evidence that TDP-43 splicing activity strongly determines HNRNPA1 isoform 
production and eventual translation of an aggregate-prone protein variant, and 
therefore justifies the use of mouse models with mutations of the endogenous Tardbp 
gene for study of molecular signatures of neurodegeneration and ALS that can result 
from TDP-43 dysfunction (Fratta et al. 2018).  
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CHAPTER 6  
DISCUSSION AND CONCLUSIONS 
6.1 TDP-43 LOSS OF FUNCTION VS GAIN OF FUNCTION  
In this thesis, the transcriptomic dysregulation in several models of TDP-43 
dysfunction has been discussed. Primarily, analysis has focused on the F210I and 
M323K mutations, summarising previous research on the mutated proteins conducted 
in vitro and ex vivo, and outlining the current results from molecular characterisation 
of the mouse models. Initial investigation of the effects of the two mutations was 
carried out using the CFTR minigene assay, in order to elucidate the effects of either 
mutation on splicing activity. This assay, when conducted in MEFs obtained from 
homozygous mouse models with each of these mutations, revealed that the F210I 
mutation caused a loss of TDP-43-mediated repression of exon 9 in the minigene, 
suggesting it caused a loss of function in TDP-43 splicing. Conversely, the LCD mutation 
M323K caused an increase in exon 9 repression in the same assay, thereby implicating 
a surprising, opposite, gain of function in TDP-43 splicing activity. This characterisation 
of opposite effects in TDP-43 splicing due to the two mutations was solidified with 
further evidence of contrasting splicing changes in endogenous mouse TDP-43 splicing 
targets such as Sort1 exon 18 and Eif4h exon 5.  
Development of the mouse models with each mutation revealed the strong effects of 
both mutations in the developing embryonic stages of the mouse, with neither 
homozygous model viable on a pure C57BL/6J background. RNA sequencing of the 
homozygous embryo heads at E14.5 demonstrated that both mutations caused RNA 
dysregulation. In the F210I model, 1,184 genes were differentially expressed, and 67 
splicing events were significantly changed. With the M323K model, the dysregulation 
was less, as 53 genes showed expressed changes and 11 events altered splicing. 
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However, with the ability of the homozygous M323K mice to survive until adulthood on 
a mixed background, the effect of LCD mutation in all TDP-43 protein in mature models 
could be studied. By the 6 month time point, the homozygous M323K spinal cord 
showed greater levels of RNA processing disruption, with 1,649 genes and 295 splicing 
events significantly altered. High-depth sequencing of the embryonic homozygous 
F210I forebrain revealed more substantial levels of gene expression and splicing 
changes too, with 2,730 and 230 features changed respectively. The large scale of 
change upon mutation of either the RBD or LCD followed previous findings which 
suggested both were important in TDP-43 RNA processing activity (Buratti & Baralle 
2001; D’Ambrogio et al. 2009; Ayala et al. 2011).  
Utilising the RNA-Seq datasets showing the greatest extent of RNA processing 
disruption in each model, the loss of function effects of F210I TDP-43, and the opposite 
gain of function effects of M323K TDP-43, were confirmed again in a subset of known 
TDP-43 splicing events, primarily resulting in increased exon inclusion in the F210I 
model and increased exon skipping in the M323K. This pattern was also found when 
exploring the extreme splicing changes caused by TDP-43, defined here as novel 
splicing events which resulted from the mutation and were absent in wildtype controls, 
and hence culminated in the formation of mutant-specific transcripts. The F210I-
specific transcripts primarily showed inclusion of intronic regions, termed cryptic 
exons, whereas the M323K showed skipping of otherwise constitutive exons, here 
termed skiptic exons. Importantly, the loss of function characterisation of F210I was 
supported by similarly disturbed RNA processing upon TDP-43 KD in the CFTR 
minigene assay, splicing of endogenous mouse TDP-43 targets (Polymenidou et al. 
2011), and the occurrence of cryptic exons (Ling et al. 2015). Similarly, the M323K gain 
of function in TDP-43 splicing activity was supported by similar results from the TDP-
ALS mutant Q331K model, again in the same CFTR minigene assay, target genes such as 
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Sort1 and Eif4h, and skipping of the skiptic exons identified in M323K mice (M. A. 
White et al. 2018).   
The reason for the loss of function and gain of function effects of the two mutations are 
difficult to fully explain. The F210I mutation affected the RNA binding domain of TDP-
43, therefore the obvious expectation would be a change in RNA binding ability. 
Consistent with this, a reduction in TDP-43 binding to validated RNA targets – its target 
UG repeat motifs (Buratti & Baralle 2001), and its own Tardbp transcript binding 
region (Ayala et al. 2011) – demonstrated that the loss of TDP-43 function including 
RNA binding. As the F210I mutation is unlikely to affect a region directly binding to 
RNA itself (Ramos, 2015, personal communication), it is possible that a change in 
folding conformation of TDP-43 may result from the mutation. Linked to this, the 
regulatory role of RRM2 in TDP-43 RNA binding is likely to have been impaired. In 
particular, the alteration of a phenylalanine residue, often crucial for RNA binding, may 
be at the centre of the disturbed TDP-43 RNA processing function (Jones et al. 2001; 
Lukavsky et al. 2013). Currently, however, it is not yet clear as to what extent the 
general loss of TDP-43 binding to RNA targets is responsible for the loss of function 
splicing patterns seen. 
As well as supporting the F210I mutation as being a hypomorphic allele, the 
comparison to TDP-43 KD or KO data also demonstrated that the F210I TDP-43 still 
retained some function and the F210I allele was not equivalent to the severity of full 
allele KO. This is shown by the development of a degree of motor phenotype in adult 
mouse models hemizygous for Tardbp (Wu et al. 2009; Kraemer et al. 2010; Sephton et 
al. 2010), but no phenotype in adult heterozygous F210I mice. Additionally, although 
homozygous F210I mice were not viable, they typically showed perinatal lethality, 
whereas complete KO of TDP-43 is lethal at the very early stages of embryonic 
development (Wu et al. 2009; Kraemer et al. 2010; Sephton et al. 2010). The use of this 
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less severe model of TDP-43 loss of function therefore allowed a more complete level 
of in vivo study into the resulting effects. Intriguingly, the resemblance of previously 
reported effects of TDP-43 KD in adult mouse striatum seen in the embryonic mutant 
F210I model implies that a large degree of TDP-43 function is consistent throughout 
development and into the adult mouse.  
The gain of function effect of M323K is even more difficult to explain. Previously, the 
idea that LCD mutation of TDP-43 resulted in splicing changes opposite to those caused 
by loss of function was not known. However, during this investigation, this has become 
apparent across a number of targets and was shown to be true in the Q331K TDP-ALS 
mutation known to cause ALS in patients (Sreedharan et al. 2008). The mutation of the 
LCD domain suggests an impairment of protein-protein interaction (D’Ambrogio et al. 
2009). The functions of TDP-43 affected by this would therefore likely be its interaction 
with splicing factors and other RBPs to control splicing events, and also its ability to 
dimerise, phase separate and form stress granules during the stress response. 
However, the impairment of TDP-43 regulation of RNA targets has previously been 
reported in the context of LCD mutation, and sequencing of TDP-ALS models with LCD 
mutation has also shown substantial RNA dysregulation (Arnold et al. 2013), although 
as previously alluded to, the proportion of these changes resulting from the transgenic 
overexpression of TDP-43 alone is not possible to determine.  
Why the mutation would specifically cause the splicing role of TDP-43 to gain function 
is unclear. Perhaps the mutation causes TDP-43 to form a longer lasting interaction 
with target transcripts, resulting in greater inhibition of RNA Pol II splicing of the exons 
and culminating in greater exon skipping. However, no change in TDP-43 binding to 
target RNA sequences was seen in the same EMSA method that revealed the loss of 
binding due to F210I mutation. The mutation may be linked to a change in the 
recruitment of other hnRNPs to modulate splicing function; TDP-43 has been posited to 
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control directing of other hnRNPs with less high-affinity target motifs (D’Ambrogio et 
al. 2009).  
Given the possibly different mechanisms by which the F210I and M323K mutations 
caused the respective loss of function and gain of function effects of TDP-43 activity, 
the global change of TDP-43 binding activity to target transcripts was tested in both 
models using iCLIP. However, analysis revealed that the well-established TDP-43 target 
UG motifs remained the sequences for which the mutant TDP-43 proteins held the 
highest affinity. In both models, correlation for pentamer sequence enrichment 
compared to control animals remained strong. Alongside this, TDP-43 is known to bind 
to different sub-regions, particularly depending upon protein localisation (Tollervey et 
al. 2011; Colombrita et al. 2012), but proportion of TDP-43 binding sites in each sub-
region type closely resembled wildtype models. However, there was a noticeable 
reduction in intronic binding in the adult mouse forebrain compared to embryonic 
tissue. Currently, quantification of changes in TDP-43 binding at specific sites is 
difficult to determine. If an appropriate method can be found, then this data can be 
used to understand whether the loss of function splicing effects in the F210I mutant 
are caused by reduced binding of the protein to RNA targets, or whether the mutant 
TDP-43 exhibits reduced activity even when bound to targets. No difference in M323K 
TDP-43-RNA binding has been detected, but similar investigation could be useful to 
indicate how this mutation triggers the gain of function in TDP-43.  
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6.2 TDP-43 AUTOREGULATION 
The TDP-43 autoregulatory mechanism by which it regulates translation levels of its 
own Tardbp transcripts is an intricate and complex process, involving differences in 
binding, splicing, polyA usage and expression level changes (Polymenidou et al. 2011; 
Ayala et al. 2011; Eréndira Avendaño-Vázquez et al. 2012; Koyama et al. 2016). In the 
F210I model, the loss of function effects were somewhat compensated for by TDP-43 
autoregulation. The increased retention of intron 7 resulted in the upregulated 
formation of stable transcripts capable of being exported from the nucleus and 
eventually translated (Ayala et al. 2011). Similarly, the reduction in transcripts with 
long 3’UTR isoforms reduced the proportion of transcripts unavailable for translation, 
as these isoforms are thought to be retained in the nucleus (Koyama et al. 2016).  
This forcing of long 3’UTR usage is thought to be at least partially due to excessive TDP-
43 binding to the TDPBR and blocking of the pA1 polyA site required to form 
translatable transcripts, therefore quantifiable iCLIP data would further the detection 
of TDP-43 binding changes to reduce the production of this long isoform in the F210I 
model, a feature that currently can only be detected visually by examined summed RNA 
reads. This dual mechanism for production of stable and exported Tardbp transcripts 
resulted in the expected increase in Tardbp transcript levels overall, suggesting the 
autoregulation mechanism was functioning to negate the loss of function effects of the 
F210I TDP-43. Although evidence of the autoregulatory mechanism in action was 
difficult to detect in the heterozygous F210I models, it remained the likely reason for 
the presence of one hypomorphic allele not causing any noticeable phenotype in the 
animal model.  
In the case of the M323K TDP-43, the mutation caused the opposite expected effect. 
Given the gain of function in TDP-43 splicing activity, regulation of TDP-43 function 
back towards wildtype levels should require a reduction of Tardbp transcript levels, as 
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well as shifts in Tardbp splicing to enable this. Instead, the homozygous M323K model 
showed similar characteristics to the F210I model, with intron 7 retention again 
increased. The greater use of pA1 instead of pA2 and pA4 would result in higher Tardbp 
levels, and concordantly significantly raised Tardbp expression was detected. The 
reason for the autoregulatory mechanism behaving in this way was not apparent, as 
this would theoretically cause a worsening of the gain of function molecular phenotype 
that the M323K model displayed. That the mutation of the LCD of TDP-43 can cause an 
apparent disturbance in the autoregulatory mechanism may provide clues as to how 
this process is impaired in TDP-ALS patients. The Q331K patient mutation has already 
been characterised as causing gain of function in TDP-43 splicing activity, like M323K, 
and the molecular environment of patient tissue is also known to harbour raised 
TARDBP levels (Mishra et al. 2007; Gitcho et al. 2009; Swarup, Phaneuf, Dupré, et al. 
2011; Koyama et al. 2016), suggesting a similar counterproductive TDP-43 regulation 
process could be taking place.  
The unwarranted increase in functional TDP-43 mRNA levels could lead to increased 
TDP-43 protein levels, a feature which was occasionally detected but inconsistently so 
in the LCD-mutant mouse tissues. The increased presence of TDP-43 may result in an 
accumulation, overwhelming a cell’s systems to deal with this problem through protein 
degradation and culminating in the formation of TDP-43-positive aggregates in the 
cytoplasm, also positive for degradation factors such as p62 and ubiquitin. The 
aggregated TDP-43 would not be functional, therefore it may lead to a vicious cycle in 
which TDP-43 levels remain unnecessarily upregulated and lead to the aggregation of 
more and more TDP-43 protein. Although the M323K model developed a motor 
phenotype and neurodegeneration, it did not display any TDP-43 pathology. Therefore, 
the disrupted autoregulation does not immediately result in TDP-43 accumulation; the 
pathology hallmark of ALS may be not be a feature of early stages of the disease.  
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6.3 DIFFERENTIAL GENE EXPRESSION 
Gene expression changes were widespread in the homozygous F210I model even at the 
early embryonic stages, while in the homozygous M323K model they were only evident 
in the adult mouse. Furthermore, the homozygous F210I mouse exhibited the specific 
downregulation of genes containing the longest introns. These genes were previously 
shown to be downregulated upon TDP-43 KD in the adult mouse striatum 
(Polymenidou et al. 2011), and so provided further evidence of the loss of function 
effects of the F210I mutation. 
This feature of TDP-43 loss of function is particularly interesting in the context of 
neurodegenerative disease as many of the longest genes have been implicated in 
neuronal functions (Polymenidou et al. 2011), which follows from the demonstrated 
importance of TDP-43 in regulating transcripts involved in neuronal development 
(Sephton et al. 2011; Tollervey et al. 2011). Fittingly, GO enrichment analysis 
implicated pathways involved in neuronal function and ion transport. Therefore, this 
phenomenon provides a link between TDP-43 dysfunction and impact specific to 
neurons, including the upper and motor neurons most evidently affected in ALS. 
Furthermore, neuronal genes often require complex splicing (Zheng & Black 2013), and 
impaired TDP-43 splicing behaviour in the F210I model has been well established. 
Therefore, the loss of function of TDP-43 could impact both the expression and splicing 
of this subset of long genes enriched for genes involved in neuronal function.  
No neuronal phenotype was detected in the F210I model, however a major caveat in 
the study of phenotype resulting from homozygosity for this mutation is that the 
models were perinatally lethal and the range of phenotypes that could be either 
displayed or studied was limited. It remains to be seen whether the long gene 
downregulation could underlie neuronal dysfunction and motor phenotype.  
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Although the homozygous M323K model did not show many changes in gene 
expression during development, by six months there were several hundred genes that 
could be detected by differential gene expression analysis. However, whereas the 
F210I model showed specific patterns of gene dysregulation, such as the enrichment of 
long genes, no such pattern was evident in the M323K model, and long gene 
dysregulation itself was not enriched or reduced in comparison to expected levels. GO 
enrichment analysis also failed to reveal any particularly effected pathways. Despite 
this, the presence of a subset of genes dysregulated by TDP-43 gain of function is likely 
to exist, as significant correlation was observed in the change in expression levels of 
genes dysregulated in either the M323K or Q331K models (M. A. White et al. 2018). 
Meta-analysis of these two models was further able to detect a substantially higher 
number of significantly differentially expressed genes, suggesting that gene 
dysregulation not identified as significant in either original model still showed similar 
direction of change. Initial GO enrichment analysis of the genes identified via meta-
analysis using either the Fisher p-value combination method or the re-analysis with 
DESeq2 of both datasets jointly with the addition of the study-specific covariate to the 
model still failed to identify notably affected pathways. However, this analysis is still in 
the early stages, and further work is required to verify the accuracy of hits obtained, 
and lost, by either meta-analysis method. The derivation of an LCD-mutant specific 
subset of dysregulated genes would also provide higher accuracy in the search for 
candidate genes similarly dysregulated in TDP-ALS patients.  
Intriguingly, the overlap in genes differentially expressed in both TDP-43 loss and gain 
of function in the F210I and M323K models was markedly poor. This phenomenon has 
previously been reported, in Drosophila, in which TDP-43 KD and overexpression 
primarily caused the dysregulation of a mostly different group of genes (Hazelett et al. 
2012). In the case of these mouse models, this could also be as a result of the likely 
different mechanisms by which the mutations have induced functional change. The 
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F210I mutation shows overall reduction in RNA binding, suggesting all target 
transcripts could be affected. The M323K mutation, meanwhile, is likely to cause 
changes in TDP-43 interaction with other proteins, and in this case it is plausible that 
the interaction with some cofactors is affected more than others. However, this 
explanation is countered by the analysis of the compound heterozygous F210I/M323K 
model showing very few significantly dysregulated genes, implying that the mutations 
did indeed have an apparent counteracting effect. One feature that could be further 
investigated is the finding of genes that show matching direction of dysregulation upon 
both F210I and M323K mutation. These genes may represent failure of TDP-43 
function upon LCD mutation, similar to the misregulation of the Tardbp transcript 
itself, and pinpoint candidate genes for analysis in patient settings.  
6.4 ALTERNATIVE SPLICING 
Alternative splicing analysis was the primary method by which both the F210I loss of 
function and M323K gain of function effects were characterised, firstly using the CFTR 
minigene assay and later using RT-PCR analysis of mutant TDP-43 splicing changes in 
known target transcripts. However, it was not until transcriptome-wide analysis of the 
splicing changes that the extent of changes in TDP-43 function was understood. Firstly, 
the increased exon inclusion representing loss of TDP-43 repression was further 
identified in the transcriptomic data for the F210I model in targets such as Sort1 and 
Eif4h, and iCLIP data for TDP-43 confirmed the direct binding of TDP-43 at these 
splicing events. Importantly, the correlation between the F210I model and TDP-43 KD 
was further strengthened by the presence of the extreme splicing events resulting in 
cryptic exons in both models. The TDP-43 KD study by Ling, Pletnikova, Troncoso, & 
Wong, 2015, revealed the presence of supposedly intronic regions of transcripts being 
spliced into a subset of transcripts due to loss of TDP-43 repression upon KD, and a 
similar phenomenon was observed and validated in the F210I model. These cryptic 
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exons are predicted to be toxic, often causing frameshifts and a PTC, suggesting they 
are eventually degraded, however expression changes in these transcripts showed 
equal levels of up- and downregulation.  
The M323K model RNA-Seq datasets also confirmed the mis-splicing of Sort1 and Eif4h, 
in this case causing increased exon skipping compared to controls. Extreme splicing 
events were also identified in these models, but rather than cryptic exons, it was 
skipping of supposedly constitutive exons that were predominantly detected, here 
termed skiptic exons. These skiptic exon events, like the cryptic exons of the F210I, 
were often predicted to cause NMD of the transcript, but in this case enriched 
downregulation of skiptic exon transcripts was also detected. Whilst the Q331K model 
did not exhibit skiptic exons to the same extent as the M323K model, the majority of 
skiptic events from the M323K did at least show some level of skipping in the Q331K. 
This again suggests that the difference in TDP-43 splicing in the two mutations may be 
due to a weaker effect of the Q331K mutation. 
 Importantly, comparison of TDP-43 binding proximity to both cryptic and skiptic 
exons in each of the F210I and M323K models showed notably similar patterns, again 
suggesting that the difference in TDP-43 splicing of these events in the two mutants 
was not caused by changes in binding targets, but changes in functioning when bound.  
The progression of study of these splicing events of interest in human settings 
provided mixed results. As well as the differences in TDP-43 function in difference 
species, the heterogeneity of TDP-ALS patients in comparison to inbred mouse models 
added another level of variability. Splicing of confirmed mouse TDP-43 targets in 
humans revealed similar patterns of exon skipping as a result of LCD mutation in some 
patients, but others with the same mutation showed splicing levels comparable to 
controls. However, despite this heterogeneity, skiptic exons isoforms were investigated 
in human settings due to the high level of conservation of these exons between mice 
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and humans, in comparison to the negligible levels of correlation in cryptic exons 
between species. Indeed, skiptic exon isoforms were consistently detected, and further, 
increased skipping identified, in TDP-ALS fibroblasts. This validated the use of mouse 
models with endogenous mutations, such as the M323K, for study of molecular 
dysregulation caused by LCD mutations of TDP-43.  
Of the seven mouse skiptic targets tested, four of the splicing events resulting in skiptic 
isoforms were detected in humans, and two showed significantly increased skipping in 
TDP-ALS patients. This represents a remarkably high level of consistency between 
mouse and human TDP-43-LCD mutation effects, and further work to test the presence 
of similar skiptic exon events in patient settings is warranted.  
This is particularly true for the set of genes coding for E3 ubiquitin ligases. This diverse 
group of genes, involved in both the direct and indirect ubiquitination of proteins for 
degradation (Berndsen & Wolberger 2014), have repeatedly been implicated in this 
study. Six of the 47 skiptic events were in genes involved in this pathway -- Herc2, 
Ube3c, Ube2e2, Wwp1, Ttc3 and Wsb1 – and alongside this the top hits for the overlap 
analysis of features dysregulated by both M323K and Q331K mutation were genes 
involved in similar ubiquitin ligase functions – Spop and Gid4 by differential gene 
expression and Ttc3 by alternative splicing changes. The dysregulation of a number of 
these genes, combined with the development of ubiquitin pathology in the M323K CNS 
tissue by the 2 year time point, heavily implicates this pathway as dysregulated. 
Previous transcriptomic meta-analysis of pathways affected in ALS has also identified 
related affected pathways, such as protein turnover (Cooper-Knock et al. 2012). The 
regulation of this group of genes next requires analysis in TDP-ALS patient CNS tissues, 
which also typically show ubiquitin pathology (Arai et al. 2006; Neumann et al. 2006).  
The ability to find a splicing change as a result of TDP-43 mutation that showed 
expected effects in both loss of function and gain of function models was hampered by 
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substantial variation in every aspect of study, in both the technical variation caused by 
differences in experimental procedures, library preparation and sequencing 
specifications, and the biological variation attributed to different species, different 
tissues and different ages of models. Incredibly, despite all of these confounding 
variables, the splicing of exon 7B of Hnrnpa1 was found to be consistently altered as 
expected by TDP-43 dysfunction. In loss of function models such as TDP-43 KD and 
F210I mutation in mouse models, a reduction in Hnrnpa1 exon 7B inclusion was 
detected, suggesting that TDP-43 functions to enhance exon inclusion. Concordantly, in 
gain of function models such as the M323K mouse at the developing embryonic and 
adult time points, and the Q331K model at the adult and aged time points, exon 7B was 
increasingly included, and the effect was dose dependent, suggesting the effect was not 
eradicated by any TDP-43 autoregulation. This link between TDP-43 and HNRNPA1 
splicing was further established in human loss of function models, where TDP-43 KD 
once again caused significant and substantial reduction in exon 7B inclusion in 
HNRNPA1 transcripts (Sivakumar et al. 2018).  
Together these results presented a splicing event in an ALS-linked protein, hnRNP A1, 
which is strongly linked to TDP-43 function and dysregulation upon change in TDP-43 
function (Kim et al. 2013; Deshaies et al. 2018). Further investigation of the splicing 
and gene expression levels of other hnRNPs is warranted, to gain a more complete 
understanding of the interplay involved and how TDP-43 dysfunction may indirectly 
affect the RNA processing of several more transcripts. Importantly, this HNRNPA1 
splicing also represents clear validation in the use of mouse models for study of patient 
disease, including the use of those not even containing TDP-ALS patient mutations, 
such as the M323K model.  
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6.5 PHENOTYPE 
Unlike the molecular and transcriptomic analysis, comprehensive phenotype 
comparison between the effects of TDP-43 loss and gain of function could not be 
completed. This was because the homozygous F210I model, in which the TDP-43 loss 
of function in splicing was so evident, was perinatally lethal, and so only the 
developmental phenotype could be studied. In this context, substantial developmental 
defects were identified, including size and weight deficiency, alongside a two day 
developmental delay in the eye, bone and cleft palate. This added to the well-supported 
idea that TDP-43 is crucial for normal development. However, no CNS or neuronal 
specific deficiencies were identified in the embryonic model, therefore commenting on 
the phenotype of TDP-43 loss of function that may be linked to ALS is difficult. 
Importantly, the substantial effects of TDP-43 loss are not restricted to developmental 
stages, with KO of TDP-43 in mature neurons causing toxicity and neurodegeneration 
(Iguchi et al. 2013). This implies that, were the homozygous F210I adult models 
available for study, they could show a similar phenotype.  
The survival of the homozygous M323K model on a mixed C57BL/6J / DBA/2J mixed 
background enabled investigation of phenotype resulting from homozygous LCD 
mutation, the ENU model more closely resembling TARDBP mutation in ALS than the 
F210I. Developmental phenotypes in this model were not evident, suggesting the gain 
of function effects may not have had the same severity as the F210I loss of function 
effects. However, the six month M323K model showed substantial RNA dysregulation, 
and this preceded the development of a motor phenotype in the two year model. In this 
aged model, grip strength deficits, muscle force reduction, motor unit count reduction, 
and motor neuron count reduction were all detected, along with p62 and ubiquitin 
pathology in the ventral horns of the spinal cord and also the brainstem.  
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These are all signs of neurodegeneration and linked to an ALS phenotype, however 
absent in this model were the TDP-43 pathology and reduced lifespan also associated 
with ALS in human disease, raising questions as to how applicable the underlying 
molecular changes are in true cases of ALS. However, not all ALS cases display TPD-43 
pathology, such as those caused by mutations in SOD1 or FUS, and phenotype as in the 
disease can also prove variable, with a small subset of patients surviving far longer 
than the typical 3-5 years post-disease onset. Additionally, other mouse models of 
disease have shown similar differences to ALS pathology. The development of a motor 
phenotype in the absence of TDP-43 nuclear depletion and mislocalisation has been 
previously reported in a transgenic TDP-ALS model (Arnold et al. 2013). Importantly, 
the signs of neurodegeneration were evident but slight, with grip strength deficit the 
only detected motor change and the motor neuron loss size below the threshold 
predicted to cause substantial behavioural changes. These features, alongside the lack 
of change in lifespan, suggest that the M323K model represents the early stages of 
neurodegeneration in human disease. Linked with this, perhaps the subsequent TDP-
43 mislocalisation and TDP-43 loss of function provides the ‘second hit’ to result in the 
phenotype associated with latter stages of neurodegenerative disease. Review of the 
published work documented in this thesis has led to similar conclusions (Rouaux et al. 
2018).  
If TDP-43 pathology would eventually result, plausible given the counterproductive 
functioning of the TDP-43 autoregulatory mechanism, then this may represent the late 
stage of the disease in human patients. The nuclear depletion that accompanies TDP-43 
mislocalisation and aggregation would also then cause loss of function effects of TDP-
43, giving rise to the long gene downregulation, mis-splicing, and cryptic exon 
inclusions all associated with the loss of function F210I model. This may be a ‘second 
hit’, worsening the molecular dysregulation and consequential disease phenotype. The 
effects of this loss of function may also be more severe, hence the severity of the F210I 
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model above the M323K counterpart. The suggestion from this sequence is that the 
F210I model may demonstrate the late stage effects of TDP-43 proteinopathies, 
however the vital conclusion from this data is that even in the absence of the TDP-43 
loss of function effects, TDP-43 gain of function without TDP-43 aggregation, is 
sufficient to cause a neurodegenerative, ALS-like phenotype.  
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6.6 FUTURE WORK 
The outcomes of this study have provided several insights into TDP-ALS. The 
misregulation of RNA processing upon TDP-43 mutation, the disentagling of distinct 
effects of TDP-43 loss and gain of function, and the impact of both forms of 
dysregulation in disease. However, much of the work described is preliminary, and 
requires building upon to form a more complete understanding of the specific 
mechanisms involved. 
One area of key interest is the identification of extreme splicing events in the form of 
skiptic exons, resulting from LCD mutation of TDP-43. That these events form mutant-
specific transcripts could allow them to be tested for as potential biomarkers, 
particularly as a subset of these was shown to occur in TDP-ALS patient fibroblasts. 
How these, or cryptic exon splicing events, could result in pathogenicity is unclear, it 
may be the mis-splicing of particular transcripts that is important, or the general 
pattern of splicing resulting in increased transcripts for degradation which may prove 
toxic at the cellular level. If the former is true, then in particular the E3 ubiquitin ligases 
should be studied further. Although the classification of this group is not precise, 
several transcripts coding for proteins of similar function have been identified as 
dysregulated in the LCD-mutant models. A more comprehensive study of proteins 
involved in the ubiquitination and protein degradation pathways in human tissues 
exhibiting ubiquitin pathology may show similar signs of dysregulation in many other 
ubiquitin ligase transcripts. The proteins translated from these skiptic exon transcripts 
have also thus far been poorly studied, the impact of predicted downregulation in a 
number of these transcripts at a protein level would provide further evidence 
implicating this pathway in the consequential ubiquitin pathology.  
A more conclusive subset of skiptic exon transcripts could also be formed through 
meta-analysis of the M323K model with other LCD-mutant models as was conducted 
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with the Q331K, once they become available. In the Q331K mice, a select few skiptic 
exons from the M323K model showed increased levels of inclusion rather than the 
expected skipping. These skiptic exons may not be of interest in human settings given 
their variation even at the mouse level, and this refinement would enable a more 
streamlined analysis of skiptic exons in TDP-ALS tissues. 
The meta-analysis of LCD-mutant mouse models demonstrated that both differential 
gene expression and alternative splicing changes showed substantial similarity, 
suggesting a common subset of features dysregulated regardless of the technical 
variations accompanying different studies. Currently, the identity of most of the genes 
and splicing events contributing to this correlation have not been identified, selection 
of the most well-correlated targets would present a priority set of targets to be tested 
in TDP-ALS settings in comparison to changes from the M323K or Q331K models alone. 
The meta-analysis method would also enable greater statistical power to detect small 
or variable differences, allowing the detection of several features of RNA processing 
dysregulation which would have been otherwise missed, although the importance of 
small or variable changes in the context of disease can be debated.  
One area which could be improved upon is the settings in which these analyses were 
conducted. Each model had its drawbacks, the mouse models being a different species, 
the post-mortem tissue disadvantaged by possible RNA degradation and loss of 
unstable transcripts, and the tissues available being of mixed ALS aetiology, and the 
TDP-ALS fibroblasts not being a neuronal cell type and therefore not being able to fully 
recapitulate the most important changes in ALS patients.  
The model that may to be closest to living ALS patient systems are motor neurons 
differentiated from iPSCs reprogrammed from TDP-ALS patients. These would negate 
the aforementioned drawbacks of models currently used. However, this setting too has 
flaws, with the likely use of immature motor neurons rather than the mature, aged 
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neurons of disease, and also the inconsistent presence of other cell types, such as 
astrocytes and oligodendrocytes, also thought to mediate motor neuron toxicity in ALS 
(Meyer et al. 2014; Ferraiuolo et al. 2016; Hall et al. 2017). Each of the RNA processing 
features described here could then be investigated in this setting, and if present could 
be proposed with higher confidence of occurring in TDP-ALS patients. A plan to analyse 
exactly this sequencing, using multiple differentiations from multiple clones of TDP-
ALS iPSC-derived motor neurons from four patients and grown in two different 
institutions, is currently underway. The consequences of RNA dysregulation changes 
conserved between the mouse models studied here and the heterogeneous group of 
iPSC-derived motor neurons would be at the forefront of protein changes to be tested 
for in patient tissue. It remains to be seen whether any other splicing changes show 
remarkable levels of conservation similar to the HNRNPA1 exon 7B splicing of TDP-43.  
The aims of this investigation were primarily focused on understanding the different 
roles of TDP-43 dysfunction on RNA processing, and how this may be linked to disease. 
However, the overarching aim of this work, and translational study in general, would 
be to enable some level of development of therapeutics for disease. In regards to this, 
the highlighting of RNA processing dysfunction in disease, and the burgeoning 
importance of RBPs in several diseases, have led to the founding of biotechnology start-
ups prioritising the task of correcting the RNA expression and splicing changes with 
the goal of finding possible therapeutic targets. Once such biotech founded earlier this 
year, Skyhawk Therapeutics, specifically lists correction of exon skipping dysregulation 
in neurological disorders among its aims, and has received a sizeable $8 M in seed 
funding to proceed with this. The venture of pharmaceutical companies into this field 
highlights the growing understanding of importance of RNA homeostasis disruption in 
disease. Ideally future patients unfortunate enough to develop ALS will be able to 
benefit from published research, such as the findings discussed in this thesis (Fratta et 
al. 2018; Sivakumar et al. 2018), and the investment that follows.  
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